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ABSTRACT 
 Diabetic retinopathy is a microvascular disease of the retina and a leading cause 
of vision loss worldwide. In the non-proliferative phase, diabetes-induced degradation of 
the retinal blood supply leads to edema and progressive tissue hypoxia. In response, the 
retinal tissue expresses proangiogenic growth factors (e.g. vascular endothelial growth 
factor), which drive proliferation of aberrant blood vessels within the eye. These poorly 
formed vessels leak fluid and blood cells into the eye and grow into the vitreous, which 
puts traction on the retina and leads to detachment. Given the hypoxic etiology, retinal 
oxygen tension and metabolism have received considerable attention. Dark-adapted 
conditions drive the retina to a significantly lower oxygen tension compared to light-
adapted conditions as rod cells consume more energy in order to boost sensitivity. While 
tolerable in the healthy retina, it has been hypothesized that increased nightly metabolism 
overwhelms the compromised oxygen supply in the diabetic retina, leading to hypoxia 
and pathological vascular endothelial growth factor expression.  
 This thesis develops ocular devices that shine light onto the retina to modulate rod 
metabolism, reducing oxygen demand and mitigating nightly hypoxia. The 
phototherapeutic effect is characterized through mathematical modeling of retinal 
metabolism and in vivo testing. Implantable phototherapy devices are designed, 
fabricated, and evaluated. This thesis also develops overnight phototherapeutic contact 
lenses utilizing radioluminescence, chemiluminescence, and electroluminescence 
approaches. Phototherapy holds promise as a non-invasive, preventative therapy for the 
treatment of hypoxic retinal diseases such as diabetic retinopathy. 
  
viii 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ............................................................................................ iii 
ABSTRACT ..................................................................................................................... vii 
TABLE OF CONTENTS .............................................................................................. viii 
LIST OF FIGURES ....................................................................................................... xiii 
LIST OF TABLES .......................................................................................................... xx 
CHAPTER 1 : Diabetic Retinopathy and the Human Eye ........................................... 1 
Epidemiology .................................................................................................................. 1 
Economic Burden ............................................................................................................ 3 
Classification ................................................................................................................... 3 
Risk Factors .................................................................................................................... 4 
Type 1 vs. Type 2 Diabetes Mellitus .............................................................................. 5 
Timeline of Diabetic Retinopathy Progression ............................................................... 6 
Anatomy and Physiology of the Human Eye .................................................................. 7 
Vasculature of the Retina .......................................................................................... 12 
Etiology of Diabetic Retinopathy ............................................................................. 13 
Oxygen and Diabetic Retinopathy ............................................................................ 14 
Current Treatment Options ........................................................................................... 16 
Laser Photocoagulation ............................................................................................. 16 
Anti-VEGF Injections ............................................................................................... 17 
  
ix 
Hypoxic Diseases of the Eye .................................................................................... 18 
Motivation for Preventative Therapies ..................................................................... 19 
CHAPTER 2 : Photomodulation of Rod Metabolism ................................................. 20 
Effect of Light on Retinal Metabolism ......................................................................... 20 
Human Phototransduction Cascade .......................................................................... 21 
Metabolism of Phototransduction ............................................................................. 23 
Energetics of Dark Current Suppression ................................................................... 27 
Detailed Modeling of Phototherapeutic Effect ............................................................. 28 
Coupling of 1D Model with VEGF Expression ........................................................ 32 
Absorbance Spectrum of Rod Cell, Emission Spectrum of Light Source ................ 34 
Quantum Efficiency of Eye ...................................................................................... 35 
Troland Definition and Conversion .......................................................................... 37 
Conversion of Luminance to Retinal Photon Flux Irradiance .................................. 37 
Analysis of Phototherapeutic Sleep Mask Failure ........................................................ 39 
Calculation of Approximate Retinal Irradiance from Noctura 400 .......................... 40 
Factor 1: Variability in the Transmissivity of the Eyelid and Pupil Dilation ........... 40 
Factor 2: Pupil Constriction During Sleep ................................................................ 41 
Factor 3: Bell’s Phenomenon, Upward Gaze Angle During Sleep ........................... 42 
Calculation of Retinal Irradiance Versus Gaze Angle .............................................. 44 
Compliance Challenges for Sleep Masks ................................................................. 46 
Analysis of Troxler Neural Adaptation in Phototherapy .......................................... 48 
Pros and Cons of Phototherapy Light Mask Approach ............................................ 52 
  
x 
CHAPTER 3 – Chandelier Style Phototherapy Device ............................................... 53 
Choosing Radioluminescence ....................................................................................... 53 
Mechanism of Action ................................................................................................ 56 
Source Lifetime ......................................................................................................... 56 
Safety Considerations ................................................................................................... 57 
Risk of Tritium Uptake from Broken Device ........................................................... 57 
Risk of Beta Particle Escape and Considerations of Penetration Depth ................... 59 
Irradiance vs. Distance from GTLS .......................................................................... 60 
Characterization of Irradiance from GTLS in an Eye Model ................................... 66 
Implant Site and Surgical Considerations ................................................................. 67 
Biocompatibility and Stability Considerations ......................................................... 67 
Scleral Anchoring System ......................................................................................... 68 
Implantation Procedure ................................................................................................. 70 
Leak Testing of the Anchoring Mechanism .............................................................. 71 
In Vivo Validation of GTLS Implant ............................................................................ 74 
Intrinsically Photosensitive Retinal Ganglion Cells ..................................................... 76 
CHAPTER 4 – Phototherapy Contact Lenses .............................................................. 77 
Towards Smart Lenses .............................................................................................. 77 
Choice of Light Source and Wear Considerations .................................................... 78 
Pupillary Constriction During Sleep ......................................................................... 79 
Light Emission Measurements from GTLS Contact Lens ............................................ 80 
Design & Fabrication of GTLS Lenses ........................................................................ 83 
  
xi 
2-Part Molding Process ............................................................................................. 83 
In Vivo ERG Results with GTLS Lens ......................................................................... 84 
Conversion of Flash Intensity to Photon Count ........................................................ 88 
Dry-Film Molded Lenses with Suture Anchors ........................................................ 88 
Rigid Gas Permeable Lens Development ..................................................................... 90 
Overcoming Pupil Constriction During Sleep .......................................................... 92 
Orthokeratology for Improved Compliance .................................................................. 94 
Evaluating Chemiluminescent Light Source ................................................................ 97 
Prototype Chemiluminescent Lens ......................................................................... 100 
CHAPTER 5 – Wirelessly Powered LED Contact Lens ........................................... 102 
LED Sourcing and Characterization ....................................................................... 102 
In Vivo Characterization of Rod Suppression by LED .............................................. 105 
Wireless LED Contact Lens Development ................................................................. 109 
Design Calculations and Considerations ................................................................ 109 
Feasibility of Battery Power ................................................................................... 116 
Fabrication of Circuits and Lens ................................................................................. 116 
CHAPTER 6 – Permeability of Contact Lenses ......................................................... 123 
Historical and Future Perspectives on Gas Permeable Lenses ................................... 123 
Corneal Anatomy .................................................................................................... 124 
Target Permeability to Mitigate Corneal Swelling ................................................. 126 
Gas Permeable Materials for Contact Lenses ......................................................... 130 
Permeability of PDMS and Rigid Gas Permeable Materials .................................. 131 
  
xii 
Measurement of Silicone Dk/t .................................................................................... 132 
Design of Gas Permeability Apparatus ................................................................... 132 
Cavity-Style Design for Smart Lenses ........................................................................ 134 
Simulations of Cavity-Style Lens Gas Transmissibility ......................................... 135 
Experimental Validation of Cavity-Style Lens Approach .......................................... 137 
Modeling Oxygen Profiles in Cornea ......................................................................... 139 
Effect of Embedding Impermeable Components in Lenses ................................... 142 
Rectangular Obstruction in Lenses ......................................................................... 143 
Cylindrical Obstruction in Lenses .......................................................................... 145 
CHAPTER 7 – Fabrication Techniques ..................................................................... 149 
Dry Film Photoresist Molding .................................................................................... 149 
Optimized Process for Dry Film Molds .................................................................. 151 
Electrochemical Etching ............................................................................................. 157 
Stainless Steel ......................................................................................................... 157 
Copper Etching ........................................................................................................... 159 
Flexible Copper-on-Parylene Circuit Boards .............................................................. 159 
REFERENCES .......................................................................................................... 162 
 
 
 
 
 
  
xiii 
LIST OF FIGURES 
Figure 1.1: Global prevalence of diabetic retinopathy. Reprinted from [4]. ..................... 2 
Figure 1.2: Regional incidence of diabetic retinopathy. Reprinted from [5]. .................... 2 
Figure 1.3: Stages of DR. Reprinted from [8]. ................................................................... 4 
Figure 1.4: Relative contribution of complications to lifetime direct healthcare costs. 
Reprinted from [6]. ..................................................................................................... 6 
Figure 1.5: DR onset and progression in patients diagnosed with diabetes at <30 years 
old. Reprinted from [2]. .............................................................................................. 7 
Figure 1.6: Anatomical overview of the eye. Reproduced from [19]. ............................. 10 
Figure 1.7: Regions of the retina with overlays indicating fovea, parafovea, perifovea, 
and macula. Reprinted from [21]. ............................................................................. 11 
Figure 1.8: Hypoxic etiology of diabetic retinopathy. Adapted from [16]. ..................... 13 
Figure 1.9: Interventions for diabetic retinopathy. .......................................................... 17 
Figure 2.1: Summary of phototransduction cascade. Reprinted from [56], [58]. ............ 22 
Figure 2.2: ATP expenditure in rod cell versus rhodopsin activation by light. Reprinted 
from [40]. .................................................................................................................. 24 
Figure 2.3: Simulated effect of blood flow and intervention on retinal oxygen tension. 30 
Figure 2.4: Oxygen flux through outer nuclear layer (ONL) / outer retina as a function of 
retinal blood supply and intervention. ...................................................................... 31 
Figure 2.5: Relative VEGF expression in the retina as a function of retinal vascular 
degeneration and light intensity. ............................................................................... 34 
  
xiv 
Figure 2.6: Absorbance spectrum of rhodopsin, emission spectra of green and iceblue 
phosphors, and their respective probability products with integrated average 
probability inlaid. ...................................................................................................... 35 
Figure 2.7: Noctura 400 phototherapeutic sleep mask [55]. ............................................ 39 
Figure 2.8: Range of transmittance of human eyelid over visible spectrum. Reproduced 
from [77]. .................................................................................................................. 41 
Figure 2.9: Schematic of Noctura 400 light emitting sleep mask optics and geometry of 
retinal illumination. ................................................................................................... 43 
Figure 2.10: Relative amount of light transmitted to retina as a function of gaze angle 
while sleeping. .......................................................................................................... 46 
Figure 2.11: Compliance in CLEOPATRA phototherapeutic sleep mask trial over time. 
Adapted from supplementary data of [95]. ............................................................... 47 
Figure 2.12: Perceived brightness of light from a sleep on retina versus the period of eye 
oscillation between 35 to 40°. ................................................................................... 51 
Figure 3.1: Principle of radioluminescence in a gaseous tritium light source. ................ 56 
Figure 3.2: Relative contributions of ionization versus Bremsstrahlung losses in Copper 
(Z=29). Reprinted from [125] . ................................................................................. 60 
Figure 3.3: Geometry of GTLS with respect to photodetector in setup. .......................... 61 
Figure 3.4: Photon irradiance as a function of distance from a GTLS source of 1.5 mm 
diameter, 6 mm length. ............................................................................................. 64 
Figure 3.5: Photon irradiance as a function of distance from a GTLS source of 300 µm 
diameter, 2 mm length. ............................................................................................. 64 
Figure 3.6: Setup for characterizing light output from GTLS. ........................................ 65 
  
xv 
Figure 3.7: Retinal photon irradiance measured within an in vitro eye model from a 
GTLS (1.5 mm D × 6 mm L). ................................................................................... 66 
Figure 3.8: Rendering of transcleral phototherapy implant with PDMS acnhoring system 
and GTLS light source. ............................................................................................. 68 
Figure 3.9: Component dimensions for the transcleral phototherapy implant ................. 69 
Figure 3.10: Implantation of device into porcine eye. ..................................................... 70 
Figure 3.11: Experimental setup for permeation testing of enucleated porcine eyes with 
and without implants. ................................................................................................ 72 
Figure 3.12: Permeation rates with and without implants (n=3) with overlaid standard 
deviation. ................................................................................................................... 73 
Figure 3.13: In vivo implantation of device into rabbit eye.. ........................................... 75 
Figure 3.14: Histology of retina at 4 weeks post implantation using h&e staining. ........ 75 
Figure 4.1: Photon irradiance on detector as a function of perpendicular distance from 
the GTLS lens, with (upper) and without (lower) metallic reflector. ....................... 81 
Figure 4.2: Photon irradiance on detector as a function of angular position from the 
optical axis around a 25 mm sphere produced by a GTLS lens with metallic 
reflector. .................................................................................................................... 81 
Figure 4.3: Setup to measure light intensity as a function of angle. ................................ 82 
Figure 4.4: Phototherapeutic GTLS contact lens fabrication through 2-step, 2-part 
moulding process and Images of lens under light and dark conditions. ................... 83 
Figure 4.5: ERG of rabbit wearing GTLS contact lens with reflector and control lens. . 85 
Figure 4.6: Electroretinogram with and without GTLS contact lens. .............................. 86 
  
xvi 
Figure 4.7: Quantification of ERG parameters (a-wave and b-wave amplitude and 
implicit time) as a function of flash intensity. .......................................................... 87 
Figure 4.8: GTLS contact lens (left) and control lens (right) with suture holes to secure 
lens onto the rabbit eye for overnight studies. .......................................................... 89 
Figure 4.9: Weeklong contact lens wear via suturing to rabbit eye. ................................ 89 
Figure 4.10: Optical coherence tomography of the cavity forming lens pair containing 
375 µm D× 2 mm L wire pieces to validate fit. ........................................................ 91 
Figure 4.11: GTLS illumination element. ........................................................................ 92 
Figure 4.12: Cavity-style RGP lens with GTLS concentrated near the center of vision to 
maximize light entry through a constricted pupil, shown under various levels of 
illumination. .............................................................................................................. 94 
Figure 4.13: (Left) Orthokeratology lens profile and Phototherapeutic lens built on an 
orthokeratology lens platform. .................................................................................. 96 
Figure 4.14: Chemiluminescent process in Cyalume system. Reprinted from [152]. ..... 98 
Figure 4.15: Evaluation of specific radiant power of Cyalume chemiluminescent system
................................................................................................................................... 99 
Figure 4.16: Chemiluminescent contact lens prototype. ................................................ 101 
Figure 5.1: XZBGR155W5MAV LED embedded onto ERG contact lens electrode with 
epoxy. ...................................................................................................................... 103 
Figure 5.2: Experimental setup of light intensity measurements with irradiance from 
LED embedded contact lens measured by photodetector. ...................................... 103 
Figure 5.3: Irradiance from XZBGR155W5MAV LED at a distance of 25.4 mm. ...... 104 
  
xvii 
Figure 5.4: Experimental setup with rabbit, ERG, and LED contact lens used to 
determined the relationship between retinal illumination and rod dark current 
suppression. ............................................................................................................. 105 
Figure 5.5: Representative series of ERGs with various LED irradiance at a flash 
intensity of 30 mcd·s/m2. ........................................................................................ 106 
Figure 5.6: B-wave amplitude versus LED duty cycle over all flash intensities. .......... 107 
Figure 5.7: B-wave amplitude versus retinal irradiance from LED contact lens, 
normalized by the amplitude of the b-wave with no irradiance. ............................. 108 
Figure 5.8: Circuit diagram of simple RLC model of a resonant coil with inductance L 
and resistance R1 with parallel capacitor C and load R2 in magnetic field inducing a 
voltage V. ................................................................................................................ 111 
Figure 5.9: Circuit diagram of half wave voltage doubler circuit with parallel load 
branches consisting of the LED and voltage limiting Zener. .................................. 115 
Figure 5.10: Traces for wireless LED contact lens and constituent components. ......... 117 
Figure 5.11: Assembly of FR-4 circuit. ......................................................................... 118 
Figure 5.12: Frequency response of wireless LED circuit on FR-4 board. ................... 119 
Figure 5.13: Fabrication of flexible copper on Parylene wireless LED circuit and 
integration into contact lens. ................................................................................... 121 
Figure 5.14: Completed wireless LED contact lens under illumination, in the dark, and 
on finger for scale. .................................................................................................. 122 
Figure 6.1: Samsung’s smart lens for augmented reality features a large oxygen 
impermeable chip [160]. ......................................................................................... 124 
  
xviii 
Figure 6.2: Corneal cross-section with zoom-ins of epithelium, stroma, and 
endothelium. Reprinted from [18]. ......................................................................... 125 
Figure 6.3: Effect of contact lenses on corneal hypoxia and swelling. Reprinted from 
[18]. ......................................................................................................................... 126 
Figure 6.4: Effect of hypoxia on corneal swelling in an eye adapted to overnight contact 
lens wear. Adapted from [18]. ................................................................................ 127 
Figure 6.5: EOP versus transmissibility of contact lenses. Reprinted from [173]. ........ 130 
Figure 6.6: Cavity style contact lens formed by bonding two lenses of different curvature 
along a complimentary peripheral edge. ................................................................. 135 
Figure 6.7: Model of composite contact lens on top of cornea used for simulations. ... 141 
Figure 6.8: Slices of oxygen tension throughout contact on cornea COMSOL model for a 
monolithic PDMS lens and two cavity style lenses (50 µm top/bottom RGP lenses) 
with air and PDMS filler, respectively. .................................................................. 142 
Figure 6.9: Oxygen profiles of lenses containing a 3 mm wide × 300 µm thick 
rectangular obstruction. ........................................................................................... 143 
Figure 6.10: Effect of shell permeability (air, Vycor, PDMS, water) on effective 
obstruction area for a rectangular object. ................................................................ 144 
Figure 6.11: Oxygen profiles of lenses containing a 300 µm diameter cylindrical 
obstruction. .............................................................................................................. 145 
Figure 6.12: Effect of shell permeability (air, Vycor, PDMS, water) on effective 
obstruction area of a cylindrical object. .................................................................. 146 
Figure 6.13: Effect of rectangular obstruction in contact lens on corneal oxygenation. 147 
  
xix 
Figure 6.14: Effect of rectangular obstruction in contact lens on corneal oxygen flux 
to underlying corneal tissue. ................................................................................... 148 
Figure 7.1: High-resolution dry film photoresist mold for PDMS contact lens fabrication.
................................................................................................................................. 150 
Figure 7.2: Optimization of soft baking conditions for dry film photoresist. ................ 153 
Figure 7.3: Considerations for exposure. ....................................................................... 154 
Figure 7.4: Removal of overlaying dry film resist ensures that alignment marks are 
visible. ..................................................................................................................... 155 
Figure 7.5: Electrochemical etching setup comprised of DC power supply, stainless steel 
cathode, substrate anode, and etching container. .................................................... 158 
Figure 7.6: Etched stainless steel reflectors on copper backing. ................................... 158 
Figure 7.7: Copper on Parylene flexible circuit board fabrication. ............................... 160	
 
 
 
  
xx 
LIST OF TABLES 
Table 1.1: Risk factors of diabetic retinopathy .................................................................. 5 
Table 1.2: Major corneal parameters in humans [18]. ....................................................... 8 
Table 1.3: Oxygen uptake in human retina in healthy and DR patients ........................... 16 
Table 1.4: Retinal diseases that may benefit from reduced retinal hypoxia. ................... 18 
Table 2.1: Retinal oxygen uptake differences under light and dark-adapted condition in 
macaque, rabbit, cat, bullfrog. .................................................................................. 25 
Table 2.2: Retinal oxygen model parameters adapted from [44]. .................................... 26 
Table 2.3: Response of rod current to background illumination steps. ............................ 27 
Table 2.4: Relationship between VEGF secretion and oxygen tension. .......................... 33 
Table 2.5: Parameters for quantum efficiency of the eye. ............................................... 36 
Table 2.6: Constants of light. ........................................................................................... 38 
Table 2.7: Parameters of calculation for Noctura 400 light emitting sleep mask optics and 
geometry of retinal illumination. .............................................................................. 44 
Table 2.8: Pros and cons of sleep mask phototherapy. .................................................... 52 
Table 3.1: Measured and reported parameters of GTLS [121]. ....................................... 55 
Table 4.1: Pros, cons, and use cases for GTLS, LED, and chemiluminescence lighting 
strategies in phototherapeutic contact lenses. ........................................................... 79 
Table 4.2: Cavity-style contact lens parameters. .............................................................. 91 
Table 5.1: Irradiance needed for 50% reduction in b-wave amplitude. ......................... 108 
Table 5.2: Coil parameters used for calculation of inductance. ..................................... 111 
  
xxi 
Table 5.3: Calculation of skin depth for copper. ............................................................ 113 
Table 5.4: Component specifications for wireless LED contact lens. ........................... 117 
Table 6.1: Electrical analogies of gas diffusive transport. ............................................. 128 
Table 6.2: Permeability of common contact lens materials. .......................................... 131 
Table 6.3: Measurement and calculation of silicone oxygen transport properties ......... 134 
Table 6.4: Transmissibility of cavity style lens of various lens thickness and filler 
material. .................................................................................................................. 136 
Table 6.5: Oxygen transmissibility of cavity-style contact lenses and related components.
................................................................................................................................. 137 
Table 6.6: Parameters of oxygen transport in the cornea. .............................................. 140 
Table 7.1: Standard electrode potentials of major components of stainless steel. ......... 157 
 
 
  
1 
CHAPTER 1 : Diabetic Retinopathy and the Human Eye 
 
Key Take-Aways 
 
• Diabetic retinopathy is a leading cause of blindness, which affects over 100 
million diabetics around the world. 
• Degradation of the retinal blood supply leads to oxygen deficiency within the 
retina, which drives pathological proliferation of new, poorly formed vessels. 
• Reduction of retinal metabolism through panretinal photocoagulation and/or 
interruption of the vascular endothelial growth factor signaling is therapeutic. 
 
Epidemiology 
 Diabetes Mellitus (DM) is one of the world’s fastest growing chronic diseases. 
The World Health Organization estimated that the total number of people with diabetes 
would double from 171 million in 2000 to 366 million by 2030. Alarmingly, these 
predictions have already been surpassed with more than 400 million people worldwide 
suffering from diabetes in 2015 (Figure 1.1). 
 Diabetes causes a number of complications in patients with diabetic retinopathy 
(DR) being one of the most significant. DR is a condition where damage occurs to the 
small blood vessels and neurons of the retina due to diabetes. DR is the leading cause of 
blindness in patients aged 20-74 years and affects 80-100% of people who have had 
diabetes for 20 years or more [1]–[3]. 
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Figure 1.1: Global prevalence of diabetic retinopathy. Reprinted from [4]. 
  It is estimated that over one-third of all diabetes patients worldwide have signs of 
DR, with the number of DR and vision-threatening DR (VTDR) cases expected to rise to 
224 million and 70 million respectively by 2040 (Figure 1.2). Several factors drive this 
trend, including the increasing prevalence of diabetes due to dietary and lifestyle habits, 
increasing life expectancy of those with diabetes, and aging demographics, especially in 
developed countries [1], [4], [5]. 
 
Figure 1.2: Regional incidence of diabetic retinopathy. Reprinted from [5]. 
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Economic Burden 
 Diabetic retinopathy has a surprisingly large impact on the overall costs of 
diabetes care, including direct treatment costs as well as indirect costs (due to vision loss, 
such as lost wages, disability payments, rehabilitation counseling, transportation, 
residential care and caregiver costs). It has been estimated that the indirect costs of DR 
were ~ 3-fold greater than the direct costs [6]. Research predicts that effective prevention 
and treatment of diabetic retinopathy would result in annual savings of $600 million in 
the USA [3]. The healthcare costs also increase with the severity of DR (from mild 
NPDR to severe PDR) due to the increased cost of inpatient procedures [7]. 
Encouragingly, timely diagnosis and appropriate care can prevent up to 70% of diabetes-
related visual impairment [3]. 
 
Classification 
 Diabetic retinopathy is a progressive disease. Clinicians commonly classify the 
disease according to the state of neovascularization, either non-proliferative or 
proliferative. Non-proliferative diabetic retinopathy (NPDR) characterizes the early 
stages of the disease and involves progressive alterations to blood vessels in the retina 
including occlusion, microaneurysms, and hemorrhages. Proliferative diabetic 
retinopathy (PDR) follows as hypoxia drives the ingrowth of new, often abnormally 
formed, blood vessels into the retina and vitreous of the eye. During NPDR, patients can 
still have 20/20 vision and symptoms are mild or non-existent, unless there is macular 
edema. Diabetic macular edema (DME) refers to the swelling of the region surrounding 
the center of the retina (i.e. the part of the retina that controls detailed vision). DME can 
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occur at any stage of DR, but it is more likely to happen as the disease progresses, 
ultimately causing total blindness. In contrast to NPDR, development of PDR represents 
a significant risk for blurred vision, significant vision loss (including blindness), scarring, 
retinal detachment, and the onset of glaucoma (damage to the optic nerve) [8].  
 
Figure 1.3: Stages of DR. a) Mild non-proliferative diabetic retinopathy (DR) with 
microaneurysms and hemorrhage. b) Moderate non-proliferative DR with 
microaneurysms, hemorrhage and cotton wool spots. c) Proliferative DR with new 
blood vessels at the optic disc. d) Diabetic macular edema with hard exudates at the 
fovea center. Reprinted from [8]. 
Risk Factors 
 The greatest risk factor for the development of diabetic retinopathy is the duration 
of diabetes [2]. The most important modifiable factor is glycemic control, which can 
reduce the rate of progression and incidence [9]–[11]. Table 1.1 summarizes other 
modifiable, non-modifiable and emerging risk factors [1], [12].  
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Table 1.1: Risk factors of diabetic retinopathy 
Non-modifiable Modifiable Novel/Emerging 
Duration of diabetes 
Puberty 
Pregnancy 
Cataract Surgery 
Hyperglycemia 
Hypertension 
Hyperlipidemia 
Obesity 
Smoking 
Inflammation 
Metabolic Hormones 
Oxidative Stress 
Vitamin D deficiency 
Genetic Risk Factors 
 
Type 1 vs. Type 2 Diabetes Mellitus 
 Type 1 diabetes, also known as insulin-dependent diabetes mellitus (T1DM), is an 
autoimmune condition caused by the patient’s body attacking its own pancreas and 
compromising insulin production. T1DM is associated with a genetic predisposition, and 
can also result from faulty beta-cells in the pancreas that are incapable of producing 
insulin. Another common name for T1DM, juvenile-onset diabetes, refers to the fact that 
it often begins in childhood.  
 Common names for type 2 diabetes mellitus (T2DM) include non-insulin 
dependent diabetes and adult-onset diabetes: this is the most common form of diabetes, 
accounting for roughly 90% of the cases in adults. In this condition, cells in the body 
become insulin-resistant, exceeding the capacity of the pancreas to produce insulin. 
Supplementing with exogenous insulin is effective in managing the disease. Sedentary 
lifestyle, improper diet, poor sleep habits, obesity, and stress are driving an increase of 
T2DM in teenagers [13]. 
 The prevalence and incidence of DR in T1DM is much higher than T2DM (77.3% 
vs. 25.2%), although T2DM affects more people [1], [14]. Thus the proportion of cost 
associated with retinopathy is greater in T1DM compared to T2DM (Figure 1.4). This 
difference is in part due to the duration of diabetes in these patients, and recent studies 
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have shown a decline in the incidence of DR among those with T1DM due to increased 
awareness of risk factors, better glycemic control, and regular screening [1], [12].  
 
 
Figure 1.4: Relative contribution of complications to lifetime direct healthcare costs. 
Reprinted from [6]. 
 In general, patients with T2DM in Western communities have a higher prevalence 
of DR than their Asian counterparts [1]. Many studies in Asia and the Middle East only 
include T2DM patients in their analysis due to the negligible fraction of T1DM in these 
ethnic groups. DR prevalence rate is highest in the USA followed by Europe. 
 
Timeline of Diabetic Retinopathy Progression 
 The timeline for DR progression is highly variable and case-dependent; however, 
duration of diabetes seems to be one of the biggest risk factors affecting the onset of DR. 
Figure 1.5 shows the onset of DR in insulin-taking patients with a diagnosis of diabetes at 
age <30 years, as a function of duration of diabetes [15]. The probability of developing 
diabetic retinopathy reaches 80-100% within 10-15 years for patients, explaining the 
incidence in D1DM patients, who become insulin-dependent significantly younger [2]. 
Trends for patients diagnosed with diabetes at >30 years are similar [16].  
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Figure 1.5: DR onset and progression in patients diagnosed with diabetes at <30 years 
old. Reprinted from [2]. 
 
Anatomy and Physiology of the Human Eye  
 Given that the eye is the organ that diabetic retinopathy affects, it is important to 
have a sense of its basic anatomy, physiology, and nomenclature (Figure 1.6) in order to 
understand the etiology of the disease as well as considerations for potential therapies. In 
humans, the eye is approximately 24 mm in diameter [17] with a spherical shape. A 
tough fibrous envelope, termed the sclera, surrounds the eye. The centrally located 
corneal tissue is transparent for light collection and protrudes slightly with a radius of 
curvature of approximately 8 mm. Three pairs of muscles, inserted into the sclera, allow 
for movement of the eye within its socket. Light entering the eye passes through several 
regions: cornea, aqueous humor, iris, lens, vitreous humor, and finally retina. 
 The cornea is an avascular tissue consisting of intricately arranged collagen fibers, 
which a sparse population of keratocytes maintains. It provides a clear optical opening 
into the rest of the eye. An outer layer of epithelial cells provides a barrier to bacteria 
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while an inner layer of endothelial cells maintains the hydration balance of the tissue. 
Lacrimal glands provide tears and mucus that is spread over the cornea through blinking. 
The cornea transitions continuously into the sclera. Table 1.2 summarizes key parameters 
of the cornea. 
Table 1.2: Major corneal parameters in humans [18]. 
Area 1.1cm2 
Diameter 11.8mm (Horizontal) 10.6mm (Vertical) 
Radius of  
Curvature 
7.8mm (Anterior, Central) 
6.5mm (Posterior, Central) 
Thickness 0.54mm (Central) 0.67mm (Peripheral) 
Refractive Index 1.376 
Power 42D 
 
 The anterior chamber is the region below the cornea filled with aqueous humor, a 
transparent liquid that provides nutrients to the cornea and regulates intraocular pressure. 
The anterior chamber houses the iris, which is a thin, circular, and highly pigmented 
tissue that forms the pupil of the eye. A set of dilator muscles can pull on the iris radially 
to enlarge the pupil. The outer edge of pupil attaches to the anterior ciliary body and 
sclera. Just anterior of the iris is the important trabecular meshwork, which is responsible 
for drainage of aqueous humor back into the blood stream via the canal of Schlemm. 
 The lens of the eye is a biconvex structure consisting of a collagen lens capsule 
filled with high-refractive index crystallin proteins. Suspensory ligaments between the 
ciliary body and periphery of the lens capsule hold it just behind the iris and can change 
the shape of the lens and hence decrease or increase optical power through contraction or 
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relaxation of the ciliary muscles. The lens along with all anterior regions comprises the 
anterior segment of the eye. 
 The vitreous humor, retina, choroid, and optic nerve compose the posterior 
segment of the eye. The vitreous humor is a transparent collagen jelly composed mainly 
of water (98-99%) and surrounded by vitreous membrane.  
 The retina is a delicate and intricately layered tissue that is responsible for the 
transduction of light into electrical signals for the visual system. Moving inward from the 
sclera, the functional layers include [17]: 
• the choroid, a dense vascular network that provides oxygen and nutrients to the 
outer retina; 
• the pigmented epithelium, a layer of cells that contain high levels of melanin to 
absorb any photons that manage to pass through the photoreceptors; 
• the photoreceptors, composed of rods (scotopic vision) and cones (photopic 
vision). Outer segments contain light-sensitive pigments and molecules involved 
in the phototransduction cascade; inner segments contain mitochondria, nuclei, 
and synapses to intermediate neurons; 
• the intermediate neurons, composed of bipolar cells, horizontal cells, and 
amacrine cells responsible for processing signals from the photoreceptors and 
passing on to ganglion cells; 
• the ganglion cell layer, neurons that transmit the electrical signals through the 
optic nerve fibre into the brain; 
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Figure 1.6: Anatomical overview of the eye. “1. Lens, 2. Zonule of Zinn or Ciliary 
zonule, 3. Posterior chamber and 4. Anterior chamber with 5. Aqueous humour flow; 
6. Pupil, 7. Corneosclera or Fibrous tunic with 8. Cornea, 9. Trabecular meshwork and 
Schlemm's canal. 10. Corneal limbus and 11. Sclera; 12. Conjunctiva, 13. Uvea with 
14. Iris, 15. Ciliary body (with a: pars plicata and b: pars plana) and 16. Choroid); 17. 
Ora serrata, 18. Vitreous humor with 19. Hyaloid canal/(old artery), 20. Retina with 
21. Macula or macula lutea, 22. Fovea and 23 Optic disc → blind spot. 24. Optical axis 
of the eye. 25. Axis of eye. 26. Optic nerve with 27. Dural sheath, 28. Tenon's capsule 
or bulbar sheath, 29. Tendon. 30. Anterior segment, 31. Posterior segment. 32. 
Ophthalmic artery, 33. Artery and central retinal vein → 36. Blood vessels of the 
retina; Ciliary arteries (34. Short posterior ones, 35. Long posterior ones and 37. 
Anterior ones). 38. Lacrimal artery, 39. Ophthalmic vein, 40. Vorticose vein. 41. 
Ethmoid bone, 42. Medial rectus muscle, 43. Lateral rectus muscle, 44. Sphenoid 
bone.” Reproduced from [19]. 
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Macroscopically, the retina encompasses several regions (Figure 1.7) [17], [20]: 
• the optic disc, the light-insensitive portion of the retina where the optic nerve pass 
through; 
• the fovea, a small depressed area near the visual pole of highest visual acuity and 
cone density; the central region termed the faveola contains no blood vessels or 
rod cells; 
• the parafovea, a region over which the photoreceptor layer thins to thicknesses 
observed around the rest of the retina; 
• the perifovea, a region over which the ganglion layer thins from 4 cells to 1 cell; 
• the peripheral area, the region between the parafovea and ora serrata; 
• the ora serrata, the scalloped boundary of the retina near the front of the eye. 
 
Figure 1.7: Regions of the retina with overlays indicating fovea, parafovea, perifovea, 
and macula. Reprinted from [21].   
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Vasculature of the Retina 
As one of the most metabolically active tissues in the body, the retina has two 
distinct blood supplies [14]. Photoreceptors and pigmented epithelium (outer retina) sit 
on top of the non-autoregulated choroidal vasculature. Choroidal capillaries are broad, 
flat, and fenestrated, which allows for the passage of small molecules out of the vessels. 
A bi-layered retinal vasculature, composed of autoregulated superficial and deep 
capillaries, supplies the inner retina. Recent mapping of the retinal vessels using optical 
coherence tomography has improved understanding of vascular distribution [22]. The 
vessels have a very high ratio of pericyte to endothelial cells and form the blood-retinal 
barrier, which prevents non-transported molecules from reaching the retina. 
In response to vascular insult, the retinal tissue can become hypoxic. The 
activation of a classic hypoxia inducible factor (HIF) pathway leads to angiogenic growth 
factor secretion, as well as the expression of survival factors and glycolytic enzymes. The 
prolyl hydroxylases involved in the cascade have a KM for oxygen that is above 
atmospheric levels, so all changes in oxygen tension are transduced [23]. Key expressed 
proangiogenic growth factors include vascular endothelial growth factor (VEGF), 
erythropoietin (EPO), and stromal-derived growth factor 1 (SDF-1), along with many 
others of interest. VEGF in particular plays a role in the maintenance of the retinal 
vascular supply by stimulating growth and repair of blood vessels as well as increasing 
vascular permeability to enable cell extravasation. However, many diseases arise due to 
excessive production of VEGF, which can trigger pathological capillary growth and 
excessive permeability that can lead to tissue edema.  
  
13 
Etiology of Diabetic Retinopathy 
In the non-proliferative phase of diabetic retinopathy there is progressive 
destruction of the retinal vasculature (e.g. occlusion of vessels, microaneurisms, 
nonperfusion), which leads to hypoxia (Figure 1.8). Other cells involved in maintaining 
the vasculature are also damaged and lost including pericytes, endothelial cells, Müller 
cells, and neurons. Inflammation of the tissue due to oxidative stress and hyperglycemia 
contribute to vessel loss, although the exact details are still under investigation.  
 
Figure 1.8: Hypoxic etiology of diabetic retinopathy. Adapted from [16]. 
After sufficient retinal vasculature degradation, the extensive hypoxia in the 
neurons and supporting astrocytes begins to drive aberrant neovascularization in the 
tissue. While other molecules are undoubtedly involved, VEGF represents a critical 
signalling molecule in diabetic retinopathy. Pharmacological blocking of VEGF provides 
immediate clinical benefits. Neovascularization of the superficial capillaries results in 
tortuous, leaky, and fragile vessels, which are prone to bleeding and fibrosis. Resulting 
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scarring can place traction on the retina, which lead to detachment. Furthermore, elevated 
VEGF can cause excessive vascular permeability resulting in retinal edema.  
Oxygen and Diabetic Retinopathy 
 Capillary nonperfusion is a hallmark of diabetic retinopathy and results in 
ischemia and hypoxia that drive expression of proangiogenic growth factors, and lead to 
the proliferative phase of the disease [24]. Understanding the oxygen needs and 
characteristics of the retina is important for understanding how diabetic retinopathy 
progresses and what could be useful in stopping progression.  
 Under normal conditions, the oxygen tension in the inner retina is roughly 10-20 
mmHg, while in the outer retina oxygen levels can drop from around 70 mmHg at the 
choroid to 0 mmHg in the photoreceptor inner segments in the dark [25], [26]. Thus in 
the dark, when photoreceptors are most metabolically active, oxygen may be siphoned 
from the inner retina to the photoreceptors with estimates of 7-15% [27]–[29] (Note: [27], 
[29] were carried out in macaque, which has been established as a good model for human 
retinal vasculature [30]). The oxygen uptake rate of the retina has been measured in 
humans to be “2.33 µl (O2)/min or 1.42 ml (O2)/min/100 g tissue blood” [31], which 
works out to 1.7 nmol/s/retina. 
 Interestingly, oxygen saturation has been found to be elevated in the vessels of the 
retina of patients with diabetic retinopathy:  
• “control 63 ± 5%, mild non-proliferative DR 69 ± 7%, moderate non-proliferative 
DR 70 ± 5%, severe non-proliferative DR, 75 ± 5%, and proliferative DR 75 ± 
8%” [32].  
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• “Oxygen saturation in the retinal arterioles of healthy volunteers was 93 ± 4% and 
58 ± 6% in venules (mean ± SD, n=31). The corresponding values for all diabetic 
patients (n=20) were 101 ± 5% and 68 ± 7%” [33]. 
• “Increasing severity of retinal changes from no retinopathy to diabetic 
maculopathy was accompanied with increasing oxygen saturation in retinal 
venules and decreasing oxygen extraction, whereas proliferative diabetic 
retinopathy showed increased oxygen saturation in both retinal arterioles and 
venules to result in a normal oxygen extraction” [34]. 
These results suggest reduction in the efficiency of oxygen extraction by the retinal 
tissue, since metabolic needs are not expected to change in diabetes. Paired 
measurements of retinal blood flow and blood oxygenation in humans [35] enables the 
calculation of retinal oxygen uptake (Table 1.3). Retinal oxygen uptake is reduced by 
around 33% in patients with NPDR, amounting to a deficit of 0.62 nmol/s. Possible 
explanations for these results [32] are that occlusion or obliteration of capillaries reduces 
opportunity for gas exchange and formation of arterio-venous shunts shortens transport 
time [36]. There is also evidence that glycosylated hemoglobin (HbA1c) has significantly 
higher oxygen affinity (10×) compared to its unmodified form and could lead to reduced 
oxygen delivery. However, HbA1c only ranges from 6.4-12% in diabetics compared to 4-
5.6% in healthy patients so differential oxygen affinity will not be a primary factor [37]. 
Furthermore, thickening of the capillary basement membrane reduces oxygen transfer 
efficiency to tissue [38]–[40]. Consistently, clinical trials have shown that vitreal oxygen 
tension is reduced in diabetic retinopathy (5.7 ± 0.7 mmHg) compared to healthy 
individuals (8.5 ± 0.6 mmHg) [41]. 
  
16 
Table 1.3: Oxygen uptake in human retina in healthy and DR patients 
 SO2, venule 
(%) 
SO2, arteriole 
(%) 
Total RBF 
(µL/min) 
Retinal O2 
Uptake (nmol/s) 
Difference 
(%)  
Control 56.29 ± 4.7 92.9 ± 1.6 42.66 ± 7.5 1.87 N/A 
NPDR 62.55 ± 5.7 94.74 ± 2.4 32.97 ± 9.2 1.25 33 
 
Current Treatment Options 
Given the hypoxic etiology of diabetic retinopathy, treatments seek to either 
reduce the hypoxia or block the pathological signalling cascade that it drives. 
Laser Photocoagulation 
 Panretinal photocoagulation has been a mainstay in the treatment of diabetic 
retinopathy since its introduction in the 1950s [42]. Originally, clinicians used laser burns 
to seal leaky vessels in the peripheral retina to reduce macular edema; however, 
researchers soon realized that it is the reduction in retinal metabolism, as a result of the 
laser burns destroying tissue, that is therapeutic. Modern therapy therefore involves an 
array of laser burns across the peripheral retina (1200-1500 burns of 0.5 mm diameter) 
(Figure 1.9), which reduce metabolic demands in the outer retina by approximately 20% 
[43]. The macula is carefully avoided due to its role in high acuity vision. The cell-free 
burned regions provide pathways for oxygen to diffuse from the outer choroidal 
vasculature through to the inner retina where it can help compensate for reduced oxygen 
supply from the inner retinal blood vessels. VEGF levels decrease in patients after laser 
photocoagulation, highlighting how hypoxia drives disease progression via VEGF [44]. 
 While panretinal photocoagulation generally leads to the arresting of the disease, 
it causes permanent reduction in peripheral vision acuity and contrast sensitivity.  For this 
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reason, patients often put it off until they have begun to suffer central vision problems, 
many of which are irreversible. A major benefit of the therapy is that it is an effective and 
permanent solution, which makes it particularly attractive for patient groups with high 
compliance risk or accessibility challenges. Given the long history and extensive data on 
panretinal photocoagulation, it offers a tried and tested therapy for clinicians. 
 
Figure 1.9: Interventions for diabetic retinopathy. (Left) Panretinal photocoagulation 
involves sacrificing a portion of the retina with an array of laser burns to reduce 
metabolic demand. (Right) Intravitreal injections of anti-VEGF drugs suppress 
neovascularization in the hypoxic retina and are given monthly to bi-monthly. 
Anti-VEGF Injections 
 The emergence of VEGF as a driver of diabetic retinopathy led to design of anti-
VEGF pharmaceuticals including ranibizumab (Lucentis) and aflibercept (Eylea) [45]. 
Monthly to bimonthly injection of these compounds into the vitreous of the eye causes 
regression of proliferative diabetic retinopathy and resolution of macular edema (Figure 
1.9). Patient compliance however is often poor due to the discomfort associated with 
injections into the eye. The ongoing development of sustained release formulations aims 
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to reduce the frequency of injections. While effective managing diabetic retinopathy, 
chronic VEGF inhibition can result in loss of ganglion cells [46]. 
Hypoxic Diseases of the Eye 
 Beyond diabetic retinopathy, a number of retinal diseases with a hypoxic or 
VEGF-implicated etiology [14] exists and may benefit from similar treatments to diabetic 
retinopathy. Table 1.4 summarizes these benefits and highlights the magnitude of the 
problem. 
Table 1.4: Retinal diseases that may benefit from reduced retinal hypoxia. 
Disease Market Size Rationale 
Diabetic 
Macular Edema 
$3.71B 
globally 
(2017) [47] 
Increased permeability due to VEGF expression in 
the retina leads to accumulation of fluid in the 
retina and swelling; increased thickness of the 
retina makes diffusion of oxygen less efficient 
leading to hypoxia 
Glaucoma $2.4B globally (2013) [48] 
Increased capillary permeability due to VEGF 
expression in the retina leads to increased fluid 
entering the eye and increased pressure 
Age-associated 
macular 
degeneration 
$4B globally 
(2017) [49] 
Drusen/plaque build-up between the outer blood 
supply and photoreceptors reduces oxygen 
diffusion 
Retinal vein 
occlusion 
$1.4B globally 
(2017) [50] 
Blockage of blood flow leads to hypoxia in the 
retina 
 
Retinal 
detachment 
$2.6B globally 
(2023 
estimate) [51] 
When the retina detaches from the eye the 
photoreceptors lose blood supply so reducing their 
metabolism would be valuable while a tamponade 
is used to reattach the retina in proximity to the 
choroidal blood supply 
Sickle-cell 
disease 
No Data 
Available 
Poor oxygen supply and increased likelihood of 
capillary occlusion leads to hypoxia in retina 
Choroidal 
ischemia 
No Data 
Available 
Low oxygen delivery from the choroid leads to 
photoreceptor hypoxia 
Retinopathy of 
Prematurity 
No Data 
Available 
Retinal hypoxia due to poorly developed 
Vasculature drives aberrant neovascularization [52] 
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Motivation for Preventative Therapies 
 Diabetic retinopathy represents a major and growing burden on the healthcare 
system. There is a desperate need for the development of preventative therapies to slow, 
stop, or even reverse disease progression. The following chapters outline the 
development of a new phototherapeutic technology that may be useful in conjunction 
with existing therapies to improve the outlook of diabetic retinopathy.   
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CHAPTER 2 : Photomodulation of Rod Metabolism  
 
Key Take-Aways 
 
• Rod metabolism is dominated by the circulating Na+ (dark) current in the rod 
outer segment, which is reduced in light. 
• Photon absorption in rods reduces oxygen consumption by ~6000 O2 per photon 
over the scotopic range of light intensity. 
• Phototherapy can improve retinal oxygenation similar to panretinal laser therapy. 
 
Effect of Light on Retinal Metabolism 
 The transduction of photons into electrical signals enables human vision. The 
approximately 100 million rod cells of the retina [53] provide the high sensitivity 
phototransduction necessary for vision under low-light conditions. Due to the 
biochemistry of human vision, higher sensitivity requires greater energy expenditure. In 
the dark, rod cells burn considerably more energy to boost their sensitivity and allow us 
to perceive the faint scene. Unfortunately, the same expenditure occurs while sleeping in 
the dark, wastefully consuming oxygen and exacerbating retinal hypoxia.  
 The hypothesis that nightly rod-driven retinal hypoxia can be pathological was 
made by Dr Geoffrey Arden at least as early as 1998 [54]. As the retinal capillaries that 
oxygenate the inner retina are lost in diabetic retinopathy, the neural tissue becomes 
reliant on diffusion of oxygen from the (outer) choroidal vessels. During periods of 
illumination rod oxygen consumption is relatively low, allowing choroidal oxygen to 
reach the inner retina; however, during darkness (e.g. sleep) the increased rod metabolism 
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consumes virtually all of the choroidal oxygen causing the inner retina to become 
severely hypoxic. In response to oxygen deprivation, cells secrete proangiogenic growth 
factors, including VEGF, which initiates the proliferative phase of the disease by spurring 
the ingrowth of poorly formed, aberrant vessels that leak, bleed, and scar the tissue. The 
concept of phototherapy has been proposed wherein a nightly illumination on the retina 
tempers rod metabolism thereby saving choroidal oxygen for the de-vascularized inner 
retina. 
 The phototherapy approach is similar to panretinal photocoagulation in that it 
reduces the metabolism of the retina by around 20% and thus is likely to be similarly 
efficacious; however, it does so non-destructively and hence reversibly. While the 
concept of shining light onto the retina during sleep seems like it would be highly 
disturbing, the levels of light needed are quite low to suppress rod metabolism and 
because the illumination is constant the visual system quickly ignores it (Troxler effect). 
Mask-style phototherapeutic devices are under development in the UK by Polyphotonix 
and are undergoing evaluation [55]. This chapter explores aspects relevant to 
photomodulation of rod metabolism, laying the foundation for design of phototherapy 
devices. 
Human Phototransduction Cascade 
 The rod outer segment is filled with lipid membrane discs packed with the 
components of the phototransduction cascade, providing a high probability of photon 
absorption. Several amplifying steps comprise the cascade, which enables the 
transduction of a single photon absorption event into a measurable electrical signal [56], 
[57]. Figure 2.1 summarizes the phototransduction cascade. 
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Figure 2.1: Summary of phototransduction cascade.  Photon absorption by rhodopsin 
leads to protein activation, catalyzing the exchange of GDP for GTP in G-protein 
transducin. Consequently, the heterotrimer dissociates with its alpha subunit activating 
phosphodiesterase, which in turn hydrolyzes cGMP. Reduced cytoplasmic levels of 
cGMP cause the closure of gated sodium channels, reducing the influx of Na+. 
Consequently, the cell hyperpolarizes leading to calcium channel closure, reduced 
intracellular Ca2+, and reduced glutamate secretion. Reprinted from [56], [58]. 
 Rhodopsin (R) is a key photosensitive protein composed of the membrane-bound 
protein scotopsin and covalently bound chromophore, retinal, responsible for the 
absorption of photons. The absorption of an incident photon causes the isomerization of 
retinal into all-trans-retinal, which results in the conformational change of rhodopsin to 
its active form metarhodopsin II (R*). This opsin interacts with transducins (G), a type of 
G protein, activating them by catalyzing the exchange of GDP for GTP. As a result, the 
heterotrimeric transducin dissociates, with its α subunit activating phosphodiesterase 
(PDE). Phosphodiesterase causes the breakdown of cGMP into 5’-GMP, leading to a 
drop in cGMP levels. cGMP-gated sodium channels then close leading to a reduction in 
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the sodium influx into the rod outer segment. However, since Na-K+ ATPase in the rod 
inner segment continues to extrude Na+, the cell hyperpolarizes. Voltage-gated calcium 
channels within the rod close in response to the hyperpolarization causing intracellular 
Ca2+ to drop. Neurotransmitter release from the rod slows, as the fusion of the glutamate 
containing vesicles to the cell membrane requires calcium. Reduced glutamate release 
causes depolarization of rod bipolar cells. 
Metabolism of Phototransduction 
 In the dark, the rod cell supports a circulating sodium current that enters the outer 
segment via Na+ channels and exits the inner segment via active extrusion by Na+-K+ 
ATPase [59]. Measurements of the current magnitude are on the order of 30 pA per rod 
cell [57], which requires an enormous energy expenditure to maintain, and accounts for 
the majority of overall rod metabolism [60], [61]. Given that a Na+-K+ ATPase requires 1 
ATP to transport 3 Na+ across the cell membrane, the energy expenditure per pA is: 
6.24×10!" Na!/sA ∙ 10!!"A/pA ∙ 1ATP3Na! = 2.08×10! ATP/spA  
Oxidative metabolism supplies most of the rod energy [62], requiring 1 O2 molecule for 
every 6 ATP produced or 0.35×10! !!/!!" . The literature provides a full accounting of rod 
metabolism and energy expenditure [60]. Figure 2.2 shows the total metabolic expenses 
amount to roughly 9×10! !"#/!!"#  under dark adaptation and 2×10! !"#/!!"#  under light 
adaptation. In practice, the presence of non-photoresponsive cells within the retina 
attenuates the stark contrast between light and dark-adapted retinal metabolism and 
oxygen levels. 
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Figure 2.2: ATP expenditure in rod cell versus rhodopsin activation by light. “ATP 
required for extrusion of Na+ entering through ih channels (□), extrusion of Ca2+ 
entering voltage-gated channels at synaptic terminal (○), sum of ATP for Na+ and Ca2+ 
extrusion (△), and sum of ATP turnover in whole rod (●).” Reprinted from [40]. 
 Retinal oxygen profiles from a variety of non-primate and primate models have 
shown a significant reduction in retinal oxygen tension under dark adaptation and have 
quantified light-adapted and dark-adapted retinal metabolism (Table 2.1). Generally, it is 
only the outer retinal metabolism that changes significantly, while the inner retinal 
metabolism remains indifferent to illumination level [63]. 
 Given that there are 100 million rod cells in the average human eye [53], the 
suppression of the rod dark current can provide considerable oxygen savings:  
ΔO!retina = 7×10! ATPsrod 1 O!6 ATP 10! rodretina  
ΔO!retina = 1.1×10!" O!retina = 1.9 nmol O!s ∙ retina 
Therefore light can reduce retinal oxygen consumption by around 1.9 nmol/s.  
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Table 2.1: Retinal oxygen uptake differences under light and dark-adapted condition in 
macaque, rabbit, cat, bullfrog. 
Species Light Adapted Dark Adapted D / L Ratio Reference 
Macaque Outer Retina:  
4.6 ± 2.3 ml O2 / 
100g retina / 
min 
Outer Retina:  
6.4 ± 0.7 ml O2 
/ 100g retina / 
min 
1.4 [27] 
Macaque 
 
Macaca 
fascicularis 
 
Macaca 
nemestrina 
 
Outer Retina:  
M. fasc. 
2.2 ± 1 ml O2 / 
100g retina / 
min 
 
M. nem. 
2.6 ± 0.4 ml O2 / 
100g retina / 
min 
Outer Retina:  
M. fasc. 
3.1 ± 1 ml O2 / 
100g retina / 
min 
 
M. nem. 
3.7 ± 0.6 ml O2 / 
100g retina / 
min 
M. fasc. 
 
1.4 
 
 
 
M. nem. 
 
1.4 
[29] 
Rabbit 93 ± 6 nmols / 
min 
 
129±8 nmols / 
min 
 
1.38 [62] 
Cat 2 ml O2 / 100g 
retina / min 
 
1.4 ± 0.9 ml O2 / 
100g retina / 
min 
 
6 ml O2 / 100g 
retina / min 
 
3.7 ± 1.5 ml O2 / 
100g retina / 
min 
 
3 
 
 
2.6 
[64] 
 
 
[63] 
Bullfrog 4.67 nmol/s/g 4.85 nmol/s/g 1.04 [65] 
 
 For comparison, consider the amount of oxygen being delivered to the retina 
through the retinal vasculature. Parameters from Table 2.2 enable calculation of oxygen 
supplied from the blood [66]: 
s!"α! = bf ∙m!"#,!" p!"##$ − β!"p α! + p!"##$!p!"##$! + K!"#! − β!"p !β!"p ! + K!"#! Hb ∙ δ  
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s!"α! = 0.0066 mLg ∙ s 0.137g/retina 80− 20mmHg 1.5 × 10!! MmmHg  
+ 80!.!80!.! + 26!.! − 20!.!20!.! + 26!.! 0.140 gmL ∙ 0.0616mmolg  
s!"α! = 5 nmol O!s ∙ retina 
Therefore, the 1.9 !"#$ !!!∙!"#$%& oxygen savings through suppression of the circulating dark 
current is comparable to 38% of the retinal blood supply.  
Table 2.2: Retinal oxygen model parameters adapted from [44].  
α1 The solubility of oxygen in blood, a constant set to 1.5 × 10-3 
(mM/mmHg)  
[67] 
α2 The solubility of oxygen in retina, a constant set to 2.4 × 10-5 
(ml O2/ml tissue/mmHg) 
[64] 
βox The ratio of the partial pressures of oxygen in venous blood 
and retina (at steady state), set to 1  
 
bf Local blood flow in the inner retina , 0.0066 ml/g/s [68] 
Dox Diffusivity of oxygen in retina, 2 × 10-9 m2/s [69] 
δ The oxygen carrying capacity of hemoglobin, set to 0.0616 
mmol/g 
[70] 
Hb The hemoglobin concentration in blood, set to 140 g/L [70] 
Khem A constant which equals the partial pressure of oxygen at 
which hemoglobin is 50% saturated with oxygen, set to 26 
mmHg 
[71] 
Kox The partial pressure of oxygen, at which the consumption 
runs at half maximal speed, set to 2 mmHg  
[72] 
n Hill coefficient, set to 2.7  [71] 
p Local partial pressure of oxygen in retina 20 mmHg  [25] 
pblood Partial pressure of oxygen in arterial blood 80 mmHg [63] 
qox,max Maximal consumption rate of oxygen. Inner retina (26 
mmHg/s independent of illumination) and inner segments 
(90 mmHg/s in light and 170 mmHg/s in darkness)  
[63] 
sox The amount of oxygen per unit time transferred locally from 
the blood to retina mmHg/s 
 
mret,in Inner retinal mass, 137 mg (from 1,094 mm2 × 0.125 mm 
thick inner retina × 1 mg/mm3) 
[53][66] 
Pchoroid Choroidal oxygen tension 55 mmHg [25] 
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Energetics of Dark Current Suppression 
 In an individual rod, it takes around 600 photons/µm2/s to achieve this 
suppression. Table 2.3 summarizes the relationship between light intensity and rod dark 
current suppression.   
Table 2.3: Response of rod current to background illumination steps. 
Species Relationship with Illumination Reference 
Guinea pig rod cell; response to 5 s 
step in background light R I = II+ I!" 
I50 = 325 photon/µm2 
[61] 
Guinea pig rod cell; response to 5 s 
step in background light R I = R!"#(1− e! !!!) 
Ks = 387 photon/µm2/s 
[61] 
Mouse I50 = 120 photon/µm2 (converted 
from 200 Rh*/rod/s) 
[60] 
Human, response to 4-6 s steps R I = R!"#(1− e! !!!) K! = !!(!)∙! = 214 to 
739photon/µm2/s 
τ(t) = 123 to 424 ms 
k = 0.011 µm2/photon 
Rmax= 13 pA 
[73] 
 
Then the oxygen savings per photon is: 
ΔO!photon =  7×10! ATProd ∙ s 1 O!6 ATP600photonsµm! ∙ s 3.1  µm!rod = 6000 O!photon  
This calculation highlights the effectiveness by which light can modulate rod metabolism.  
 We can also compare the energy efficiency of photomodulation of rod oxygen 
consumption compared to the electrolysis of water to produce oxygen. O!(g)+ 4H! + 4e! !.!"#  2H!O E!"!#$%&"'()( = 4e! 1.23V  per O! = 4.92eV per O!  
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E!"#$#% = 1.2398e V ∙ µm0.500 µm  per 6000 O! = 413 µeV per O! E!"#$%&"'('E!"#$#% = 11900× 
Therefore, the use of light to modulate oxygen consumption is 104× more efficient than 
electrolysis and provides major benefits with respect to design since power 
considerations become minimal.  
 For suppression of rod circulating current the entire retina requires: 
W!"#$#%,!"# = ϕA!"# = 600 photonsµm! ∙ s 1,094,000,000 µm! = 7×10!!  photonss ∙ retina 
W!"#$#%,!"# = 7×10!!  photonss ∙ retina 1.2398 eV ∙ µm0.500 µm 1.6×10!!" JeV = 280 nW 
An 8-hour period (i.e. duration of sleep) requires a total of 8 mJ for this illumination. 
Numerous powering strategies are suitable for providing such small amounts of energy. 
 
Detailed Modeling of Phototherapeutic Effect 
 Modeling of retinal oxygen tension utilizing a four-layered, 1D model of the 
retina, modified from [63], [66], [74], aided in determining the therapeutic effect that 
phototherapy could have in alleviating hypoxia in diabetic retinopathy patients. The 
simulation (COMSOL Multiphysics) solves the diffusion equation: dPdt = ∇ D!"∇P − q!" + s!" 
where q!" = q!",!"# !!!!!" follows Michaelis-Menten kinetics for oxygen consumption 
and 𝑠!" accounts for vascular oxygen supply as previously defined, included for inner 
retina only. 
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 The retina subdivides into the following compartments from vitreous to choroid: 
Inner retina: Accounts for 50% of retinal thickness. It contains the retinal vasculature 
providing a blood supply term sox that can be varied to account for vessel non-perfusion 
due to disease. Oxygen consumption is distributed over the inner retina, independent of 
illumination, and is due to ganglion cells, bipolar cells, Müller cells, and amacrine cells. 
Outer nuclear layer: Accounts for 25% of retinal thickness. Contains the rod cell bodies 
but consumes little oxygen as energy is produced in the inner rod segments. 
Inner rod segments: Accounts for 10% of retinal thickness. Contains most of the 
mitochondria supplying energy to the rod cell and therefore accounts for the vast majority 
of oxygen consumption. Oxygen consumption is dependent on illumination of the retina. 
Outer rod segments: Accounts for 15% of retinal thickness. Responsible for the 
phototransduction cascade but consume little oxygen as energy is produced in the inner 
rod segments. 
 Regarding boundary conditions, the model assumes zero flux into the vitreous, 
justified by minimal oxygen gradient within vitreous, and a constant 55 mmHg at the 
choroid, since choroidal blood supply is robust and greatly exceeds retinal consumption. 
 A parameter sweep varying the retinal blood supply from 0.4 to 0 mL/g retina/min 
simulates the loss of blood flow due to diabetic retinopathy. Additionally, reducing 
oxygen consumption of the rod inner segments from 170 to 90 mmHg/s accounts for 
reduced metabolism under light/phototherapy/panretinal laser photocoagulation. Inner 
retinal metabolism  remains constant at 26 mmHg/s. Panretinal laser photocoagulation 
involves 1200-1500 burns of 500 µm diameter (i.e. 20% of retinal area) and will reduce 
photoreceptors numbers and oxygen consumption accordingly [75],[76]. The model 
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postulates a 32% suppression of rod metabolism under phototherapy based on earlier 
estimates, though this can vary significantly depending on illumination intensity as 
reported by [60]. Further, since the mechanisms of action of the therapies are independent 
the model treats combination therapies as multiplicative. Figure 2.3 depicts how blood 
flow and intervention affect the retinal oxygen profile. 
 
Figure 2.3: Simulated effect of blood flow and intervention on retinal oxygen tension. 
Inner segment metabolism: dark adaptation (qmax = 170 mmHg/s), panretinal laser 
(qmax = 136 mmHg), phototherapy lens (qmax = 116mmHg), phototherapy + panretinal 
laser (qmax = 92 mmHg), and light adaptation (qmax = 90 mmHg). Inner retinal 
metabolism: qmax = 26 mmHg/s. Michaelis-Menten constant for cellular oxygen 
uptake: KM = 2 mmHg. No flux assumed at vitreous while choroid held at 55 mmHg.  
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 Since the choroid is relatively resistant to degradation in diabetic retinopathy, 
most of the hypoxia driving the disease likely arises in the inner retina, which suffers 
from a progressively degraded blood supply. Given that the inner retina is supplied from 
the retinal vasculature while the outer retina is supplied by the choroid, it may not be 
initially obvious how the suppression of photoreceptor metabolism can improve inner 
retinal oxygenation. Researchers hypothesize that, analogous to the mechanism of action 
of panretinal photocoagulation, reducing rod metabolism can mitigate siphoning of 
oxygen from the inner retina or allow choroidal oxygen to reach the inner retina [75]. To 
this end, Figure 2.4 plots the oxygen flux through the outer nuclear layer of the retina.  
 
Figure 2.4: Oxygen flux through outer nuclear layer (ONL) / outer retina as a function 
of retinal blood supply and intervention. Positive values indicate that photoreceptors 
are siphoning inner retinal oxygen while negative values indicate choroidal oxygen is 
reaching the inner retina. 
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 Based on these simulations, it becomes apparent that both mechanisms of action 
are possible depending on the degree of retinal blood flow and the metabolic state of the 
rod cells. The difference in oxygen flux between light and dark conditions is 
approximately 0.15 nmol/s, which is relatively small compared to total inner retinal blood 
supply in a healthy retina (~5 nmol/s in this model) but comparable to the clinically 
measured oxygen deficit in diabetics of 0.62 nmol/s [35]. Alternatively, consider that 
panretinal laser photocoagulation is therapeutically effective and it improves oxygen flux 
by only 0.03 nmol/s in this model; thus, the 0.07 nmol/s savings from a phototherapy lens 
is relatively significant. 
 
Coupling of 1D Model with VEGF Expression 
 There is strong evidence in the literature that VEGF mediates the transition to 
proliferative diabetic retinopathy by driving the aberrant growth of blood vessels, 
primarily in the inner retina [77], [78]. The prolyl hydroxylase of the HIF signaling 
cascade, which is responsible for the transduction of oxygen tension to angiogenic gene 
expression, has a Michaelis constant for oxygen greater than atmosphere (KM > PO2) so 
there is a monotonically increasing relationship between physiological oxygen and HIF 
signaling [23]. The rate of VEGF secretion, driven by HIF, roughly follows a power law 
in humans dependent on the local oxygen tension (Table 2.4). 
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Table 2.4: Relationship between VEGF secretion and oxygen tension. 
Model Relationship Comment Reference 
Human 
lymphocytes 𝑉!"#$ = 40𝑚𝑚𝐻𝑔𝑃!! !.!" 
Used in 
simulations. Low 
exponent value 
makes this most 
conservative. 
[79] 
HeLa cells 𝑉!"#$ = 50𝑚𝑚𝐻𝑔𝑃!! !.!" None. [80] 
Glial (Müller) 
cells from ex 
vivo rabbit 
retina 
𝑉!"#$
=
1.25𝑚𝑚𝑜𝑙 𝐺𝑙𝑢, 206𝑚𝑚𝐻𝑔𝑃!! !.!"5𝑚𝑚𝑜𝑙 𝐺𝑙𝑢, 76𝑚𝑚𝐻𝑔𝑃!! !.!!10𝑚𝑚𝑜𝑙 𝐺𝑙𝑢, 188𝑚𝑚𝐻𝑔𝑃!! !.!!
 
 
Values extracted 
from paper by 
curve fitting; each 
glucose 
concentration only 
had 2 oxygen data 
points. 
[81] 
 
 The weighting of retinal oxygen profiles by their likelihood to induce VEGF 
secretion allows for comparisons between interventions. Figure 2.5 plots the relative 
amount of total VEGF production expected as a function of light conditions and disease 
progression.  Loss of blood flow in the inner retina functions as a proxy of disease 
progression in this model. 
 From the plot, it can be seen that with phototherapy a patient could sustain nearly 
20% loss of retinal vasculature before VEGF levels reached levels experienced by 
healthy individuals during sleep (which are known to be safe). This result gives an 
indication of the therapeutic value of the light in modulating oxygen consumption, 
hypoxia, and VEGF secretion. 
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Figure 2.5: Relative VEGF expression in the retina as a function of retinal vascular 
degeneration and light intensity. Overlaid dashed arrows indicate that a patient treated 
with phototherapy can sustain nearly 20% retinal vascular loss, while maintaining 
tolerable VEGF levels (i.e. equal to those seen in a healthy individual at night). 
 It should be noted that this model is a first approximation and does not account 
for different hypoxia thresholds among cell types in the retina. Retinal staining for VEGF 
in enucleated eyes suffering from proliferative diabetic retinopathy found localization of 
VEGF expression primarily within the inner retina [82].  
Absorbance Spectrum of Rod Cell, Emission Spectrum of Light Source  
 Rod and cone absorbance vary as a function of incident light wavelength [83]. For 
rod cells, the key pigment is rhodopsin, which has a peak absorbance of 491 to 505nm 
with a mean of 498 ± 3 nm (S.D) and a full-width half maximal of 104 nm. The 
probability of absorbance of a photon of a given wavelength is then the product of the 
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relative absorbance at the given wavelength and the quantum efficiency of the 
chromophore or overall rod cell. Since light sources and phosphors emit with a 
distribution of wavelength, integrating the product of the relative emission curve E(λ) and 
the chromophore absorbance curve A(λ) provides the average absorbance probability P: 
P = A(λ) ∙ E λ dλ 
Example plots for a green and iceblue emitting phosphor are depicted in Figure 2.6, 
highlighting the efficiency loss due to emission with off-peak absorbance wavelength. 
 
Figure 2.6: Absorbance spectrum of rhodopsin, emission spectra of green and iceblue 
phosphors, and their respective probability products with integrated average probability 
inlaid. 
Quantum Efficiency of Eye 
 An important parameter in calculating the necessary photon flux density for the 
suppression of rod metabolism is the quantum efficiency of the rod. It accounts for the 
fact that rhodopsin does not absorb each photon incident on the retina. The mean number 
of photon absorptions, m [Rh*/rod] is proportional to the light intensity, I [photons/µm2], 
and the effective collection area, Aeff [µm2] of the outer segment [84]: m = A!"" ∙ I 
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For light incident parallel to the rod outer segment, the effective collection area is the 
cross-sectional area of the rod (including a focusing factor F, which accounts for a larger 
collection aperture of the inner segments compared to the outer segments) times the 
probability of photon absorption, which is the product of the quantum efficiency of 
isomerization Qisom, a factor f that accounts for the relative efficiency of absorption for 
axial light (f=1) versus transverse light (f ≈ 0.5) with respect to the rod (and 
chromophores) [85], and absorbed photons fraction based on a specific axial pigment 
density α [µm-2]: A!"" = πr!F Q!"#$V(λ) 1− 10!!!!  
A!"",!""#$ = π 1µm ! 2 0.67 (0.98) 1− 10!!∙!.!"#∙!" = 2.5 µm!rod  
Thus at a photon flux density of 1 photon/µm2/s isomerization will occur at 2.5 Rh*/rod/s. 
Note that this analysis assumes photon flux density at photoreceptors and therefore does 
not include the pre-retinal transmittance. 
Table 2.5: Parameters for quantum efficiency of the eye. 
r Rod radius, human, 1 µm 0.65 µm 
[73] 
[14] 
L Rod outer segment length, 20-25 µm 25-45 µm 
[73] 
[14] 
F Focusing factor, approximately 2 [73], [86] 
Qisom Quantum efficiency of isomerization, 0.67 [87] 
α Specific axial pigment density, 0.016 µm-1 [85] 
f Light orientation factor, axial = 1, transverse ≈ 0.5 [85] 
V(λ) Scotopic luminosity function, 0.98 @ 500 nm [88] 
Tpre-ret 
Pre-retinal transmittance, 0.69 
0.75 
[89] 
[90].  
 
A similar process as above can be carried out for transverse light (i.e. perpendicular to the 
rod) without the focus factor F; however, the absorbed fraction needs to be integrated due 
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to the varying path lengths across the circular body. The calculation can be simplified 
using a Taylor expansion so long as 𝑓𝛼𝑑 ≪ 1 (i.e. negligible self-screening): A!"",!"#$%&'"%' = πr!lQ!"#$V(λ)ln(10)fα 
Troland Definition and Conversion 
 For a given scene, the amount of light entering the eye is proportional to the area 
of the pupil. The troland unit, T, accounts for this proportionality: T = L! ∙ p 
Lv is the luminance [lm/sr/m2 = cd/m2] of the scene and p is the area of the pupil [mm2]. 
Conversion of Luminance to Retinal Photon Flux Irradiance 
 In many instances, it is useful to convert an object of a given luminance into a 
photon flux irradiance on the retina. Starting from the luminance L!  !"!"∙!! , convert to 
radiance L! !!"∙!! : L! = !!!!!∙!!(!),  K!! = 1700 !"!  is the scotopic luminous efficacy (507nm). Then convert to photon flux 
radiance L! !"#$#%&/!!"∙!!  by dividing through by the energy per photon: 
E!"#$#% = hcλ = 1.986×10!!" J ∙mλ [m] ∙ photon   
L! = L!E!"#$#% = 5.03×10!" ∙ λ m ∙ L! = 2.96×10!" ∙ λ m  L!V!(λ) 
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Table 2.6: Constants of light. 
h Planck constant 6.626×10−34 [J·s] [91] 
c Speed of light 299792458 [m/s] [92] 
 
The photon flux at the pupil P! !"#$#%&! , given the area of the source A! m! , area of the 
pupil A! m! , and distance from the source D! m  is: 
P! = L!A!A!D!!  
Using a simplified model of the eye optics with a posterior nodal distance, Dr, of 16.67 
mm [93], the area of the object image on the retina is: 
A! = D!!A!D!!  
For a complete treatment of the theoretical eye see [94]. Then the retinal flux irradiance E!  !"#$#%&!∙!!  is: E! = T P!A! = T L!A!D!!  
T is the pre-retinal transmittance. 
 For a screen of luminance L, the ratio of retinal flux irradiance when the subject 
views the screen at a distance (i.e. through normal eye optics) versus through a closed 
eyelid at close proximity is: 
E!"#$%&'(E!"!#$% = T!"!
L!A!D!!T!"# ∙ T!"! ∙ L! ∙ A!D!"!! =  
D!"!!T!"# ∙ D!! = 24mm !0.01 ∙ 16.67mm ! ≅ 200 
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This formula is useful for converting between luminance values under typical 
experimental conditions versus the less common situation of light emitting sleep masks. 
 
Analysis of Phototherapeutic Sleep Mask Failure  
 The only preventive phototherapy-based device currently reported in the literature 
is the Noctura 400 sleep mask, which Polyphotonix (UK) produces and has recently 
completed Phase III clinical trials [95]. The mask features organic LED patches over each 
eye with onboard battery and circuitry to monitor wear. The device is intended to deliver 
light through the eyelid and onto the retina. While previous smaller studies with the mask 
showed some promise (e.g. reduced retinal edema, improved visual acuity, reduced 
bleeding) [45], [54], [96]–[100] the larger Phase III ultimately showed no therapeutic 
effect. Furthermore, patient compliance with the light emitting sleep mask was reported 
as only 19.5% after 2 years (39.5% at 4 months). The analysis in this section will look at 
probable reasons the sleep mask style device failed and suggest ways of overcoming 
those challenges. 
 
Figure 2.7: Noctura 400 phototherapeutic sleep mask [55]. 
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Calculation of Approximate Retinal Irradiance from Noctura 400 
 According to the manufacturer of the Noctura 400 sleep mask, it emits 186 
scotopic cd/m2 at 505 nm with the aim to achieve a 40% reduction in rod-circulating 
current (retinal irradiance of 100 photons/µm2/s). Knowing these parameters, it is 
possible to infer the other assumptions they made about the optics of the eye during sleep. 
The retinal irradiance resulting from light emitted from a mask, that passes through an 
attenuating eyelid, a forward gazing pupil, and absorbing media of the eye is: 
E! = T!"# ∙ T!"! ∙ L! ∙ A!D!"!! = T!"# ∙ T!"! 5.03×10!" ∙ λ ∙ L!K!! ∙ V! λ ∙ A!D!"!!  
If we assume Deye = 24 mm, Tlid = 10-2 [99], Teye = 0.69 [89],  Ap = 28 mm2 (a 6 mm 
diameter pupil) we find: 
E! = 0.01 ∙ 0.69 ∙ 5.03×10!" ∙ 505×10!! ∙ 1861700 ∙ 0.99 ∙ 28(24)! = 94 photonss ∙ µm!  
This finding suggests that the designers of the Noctura 400 assumed a dilated pupil and 
relatively high eyelid transmittance. However, these assumptions are not valid as 
discussed below and may be the reason the sleep mask failed to be efficacious in trials.  
Factor 1: Variability in the Transmissivity of the Eyelid and Pupil Dilation 
 The transmissivity of the human eyelid is varies over an order of magnitude 
across the population from about 10-2 to 10-3 at 505 nm (Figure 2.8) [101]. This variation 
means that if the mask was designed assuming an eyelid transmissivity of 10-2, then it 
will be significantly less efficacious for patients with eyelid transmissivity below this. 
The large range of eyelid transmissivity would require personalized testing and 
calibration for each patient but this was not done.  
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 A second source of variability arises due to differences in the diameter of the 
dark-adapted pupil across the population. It is known to vary by a factor of 4 in area from 
12.5 to 50 mm2 [102]. However, the assumption of a dilated pupil during sleep is likely 
incorrect altogether as explained below. 
 
Figure 2.8: Range of transmittance of human eyelid over visible spectrum. Reproduced 
from [77]. 
Factor 2: Pupil Constriction During Sleep 
 Though not common knowledge even among ophthalmologists, the pupil actually 
constricts progressively the deeper the sleep [103], including during REM [104]. This 
process restricts the aperture for light to enter the eye even during forward gaze. In the 
limited studies that have looked at pupil size during sleep, one monitoring children ages 1 
to 5 found that the average pupil diameter during deep sleep was 2.1 ± 0.5 mm while 
under dark-adapted awake conditions it was 6.1 ± 0.9 mm [103]. This reduction in pupil 
area during deep sleep would result in a retinal flux reduction to 11% of the dilated state.   
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 The pupil in older (61 ± 4.4 y) patients tends to be more constricted compared to 
younger (22.8 ± 4 y) individuals under both conditions of light-adaptation (65% relative 
area) and dark-adaptation (73% relative area) [105]. Therefore, the effect of pupillary 
constriction in an elderly population is expected to be comparable or worse. 
Factor 3: Bell’s Phenomenon, Upward Gaze Angle During Sleep 
 A compounding factor is that during sleep, the eye has a tendency to roll upwards 
in the socket and therefore away from the light emitting sources. During drowsiness and 
Stage 1 of sleep the eyes deviates upwards from a forward gaze significantly (up to 40°), 
during Stage 2, 3, 4 the gaze is elevated 55-85% of the time (0-20°: ~1/4, 20-40°: ~1/2, 
>40°: ~1/4), and during REM a forward or below forward gaze is typical [106]. Thus 
photon flux density at the retina will reduce accordingly. 
 The transmittance will decrease significantly due to the additional thickness of 
eyelid that the light must pass through. Anatomically, the eyelid narrows towards the 
lashes and thickens towards the brow. As a conservative first approximation, assume that 
the path length through the eyelid is t θ = t!/cos (θ). The transmissivity is then: 
T θ = 10!"# !!!! ∙ !!!"# (!) = 10!"# !!!"# (!) = T! !!"# (!) 
For T0 = 0.01: 
T 40° = 10!"# !.!"!"# (!"°) = 0.0024 
 The amount of light reaching the pupil will also decrease due to the geometry of 
the system. The governing equation for radiative transfer is: 
dΦ = L ∙ dA! ∙ cos (θ!) ∙ dA! ∙ cos (θ!)ρ!  
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A is an area, θ is the angle between surface normal and the line-of-sight between surfaces, 
and L is the radiance of the emitting surface [107]. As the gaze angle increases both the 
effective surface area of the emitter and the solid angle of the receiving pupil decrease. 
Furthermore, the thickness of eyelid that light must transmit through increases. Utilizing 
a simplified 2D geometry for the eye and Noctura 400 phototherapy sleep mask, shown 
in Figure 2.9, the relative amount of light transmitted as a function of gaze angle was 
calculated and plotted in Figure 2.10. 
 
Figure 2.9: Schematic of Noctura 400 light emitting sleep mask optics and geometry of 
retinal illumination. Overlays on anatomical cross section of human eye indicate 
simplified eyelid of thickness t (red, dash), pupil of arc length p (blue, bold), eyeball of 
radius r and gaze angle θ (black circle), OLED of height h at a distance d away from 
the eye, and primary optical path P1 to P2 with eyelid transmission through P3 to P2. 
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Calculation of Retinal Irradiance Versus Gaze Angle 
 Table 2.7 summarizes the relevant parameters used in the calculation of retinal 
irradiance versus gaze angle. 
Table 2.7: Parameters of calculation for Noctura 400 light emitting sleep mask optics 
and geometry of retinal illumination. 
Symbol Description Value 
Pi 0: Point at center of eye 
1: Point on OLED 
2: Point on pupil 
3: Intersection point on eyelid 
 
θ Gaze angle 0 to 50° 
p0 Arc length of pupil  6mm 
h0 Height of OLED  12.7mm 
w0 Width of OLED 19mm 
d0 Nearest distance of OLED to eyelid  5mm 
t0 Thickness of eyelid 0.5mm 
r0 Radius of eye 12mm 
T0 Transmissivity of eyelid 0.01 at 0.5mm thick 
 
Briefly, the point of illumination was parameterized by h and defined as: 
P!: x! = 0y! = h 
The point of the pupil receiving light was parameterized by arc length p and defined as: θ! = pr! 
P!: x! = d! + t! + r! 1− cos θ+ θ!y! = r! ∙ sin θ+ θ!  
From points P1 and P2, the angle and length of the line-of-sight was calculated as: θ! : tan!! y! − y!x! − x!  ρ =  x! − x! ! + y! − y! ! 
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The point of entry into the eyelid P3 was calculated at the intersection of the line-of-sight 
and arc of the eyelid:  
P!: x!y! at intersection of y = y! − y!x! − x! ∙ x+ hx− d! − t! − r! ! +  y! =  t! + r! !  
The distance of transmission through the eyelid was then calculated as the distance 
between P2 and P3: t! = x! − x! ! + y! − y! ! 
Since a 2D calculation was performed, the differential areas of the OLED and pupil were 
defined as: dA! = w! ∙ dh dA! = p!4 π ∙ dp 
The equation for radiative transfer was then integrated to provide the amount of light 
exiting the eyelid just above the pupil and is plotted in Figure 2.10: 
Φ(θ) = L!w!p!π4 cos (θ!) ∙ cos (θ+ θ! + θ!)ρ!
!!!
!!!!
∙!!!!!!! T
!!!! ∙ dp ∙ dh 
Weighting the transmissivity by the gaze angle during sleep, the average transmissivity 
can be estimated as: 
T!"# = 14T!"° + 12 ∙ T!"° + 14T!"° = 14 0.86+ 12 ∙ 0.23+ 14 0.05 = 0.34 
Thus the intensity of light on the retina is likely 1/3 of what the designers intended due to 
this effect. 
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Figure 2.10: Relative amount of light transmitted to retina as a function of gaze angle 
while sleeping. Results of gaze angle only (blue) and combined gaze angle with eyelid 
absorbance (red) highlights the compounding of these loss mechanisms. Logarithmic 
y-axis. 
Compliance Challenges for Sleep Masks 
 All phototherapy sleep mask trials to date report compliance as a major challenge. 
After an initial drop in compliance (defined as wearing the mask ≥6 hour/night) down to 
30-45% following start of the trial, compliance continued to drop off exponentially with a 
time constant of 3 years [95] (paper appendix). Given that diabetic retinopathy is a slow 
progressing disease on the order of 10 years, it is unlikely that any meaningful number of 
patients would comply long enough to improve outcomes. Furthermore, the actual 
compliance in a real world setting compared to a clinical trial setting has historically been 
less than 50% [108], [109] (private correspondence with Tony Kuo, Director of Research 
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& Evaluation in the Division of Chronic Disease and Injury Prevention at the Los 
Angeles County Department of Public Health). 
 
Figure 2.11: Compliance in CLEOPATRA phototherapeutic sleep mask trial over time. 
Level of compliance defined as wearing the mask for ≥6hours/night at least 70% 
(blue), 60% (red), or 50% (green) of the time. Adapted from supplementary data of 
[95]. 
 The literature [109], [110] describes several factors that affect compliance to a 
therapy, including: cognitive (literacy, comprehension), interpersonal (physician-patient 
trust), cultural (socioeconomic), complexity of regimen, burden of regimen, immediacy 
of therapy results, among many others. In the case of preventative therapies like 
phototherapy, the two major challenges are the burden of the therapy and the lack of 
immediacy between therapy and results. What follows is an analysis of the impact these 
challenges have on sleep mask phototherapy and a proposed solution to overcome them. 
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Analysis of Troxler Neural Adaptation in Phototherapy 
 The idea of shining light onto the retina to suppress retinal metabolism and 
prevent tissue hypoxia makes good physiological sense but faces the immediate objection 
that it will negatively impact the ability of the patient to sleep. However, the visual 
system like many sensory systems responds to changes in stimuli rather than absolute 
stimuli magnitude. This gives rise to the well known phenomenon whereby a stabilized 
image on the retina quickly disappears from conscious vision, known eponymously as 
Troxler fading [26], [111]–[114]. Studies with contact lenses and suction cups have 
demonstrated that when illumination is stabilized on the retina, complete perceptual loss 
occurs within a few minutes [115].  
 Using data on time to fading versus luminance difference [111], the time constant 
of Troxler fading was estimated. The data was plotted as time to fading versus the ratio of 
maximum to minimum/background scene luminance. A logarithmic fit was used due the 
logarithmic nature of vision and need for only a single parameter k; it also returns a time 
to fading of 0 for a ratio of 1, as expected: 
Time to Fading =  k ∙ ln B!"#B!"#  
A further assumption was made that the fading is exponential in nature. Humans are able 
to perceive contrast differences !!"#!!!"#!!"#!!!"# on the order of 8% [116][117]. Given that an 
exponential will decay within 2.5 time constants τ to 8%, the time to fading was 
approximated as 2.5τ. The resulting fit had a constant of k = 12: 
2.5 ∙ τ =  12 ∙ ln B!"#B!"# s  with an R! = 0.88 
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τ =  4.8 ∙ ln B!"#B!"# s  
Then, a retinal image of initial brightness B will fade as follows: 
B!"#$"%&"'  =  B! ∙ e!!! 
Consider that changes in perceived brightness can occur as a combination of temporal 
changes (e.g. neural adaptation) and changes due to eye motion across a scene of varying 
brightness. The material derivative can be used to combine these contributions:  DBDt  =  ∂B∂t + 𝒖 ∙ ∇B 
Where B is the brightness and u is the velocity of gaze parameters (e.g. angle, pupil area), 
ł is the gradient. Consider a simplified case where only gaze angle varies at a rate !"!"  (i.e. 
assume pupil area is constant). Then the perceived brightness is governed by: DBDt  =  −Bτ + dθdt dBdθ 
To solve the differential equation, consider a specific example where the eye is 
oscillating between two gaze angles within a period of time T. θ(t) = !!"#!!!"#! + !!"#!!!"#! sin 2π !!  
From the previous analysis of retinal irradiance from Noctura 400 versus gaze angle, the 
orientation of the eye can be mapped to an actual brightness. For simplicity of analysis, 
assume a linear mapping θmax →Bmax and θmin →Bmin, then:  B!"#$# t = !!"#!!!"#! + !!"#!!!"#! sin 2π !!   dBdt = B!"# − B!"#2 2πT cos(2π tT) 
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Solving the differential equation: 
B!"#$ t = 2π τT ! B!"# − B!"#2 sin 2π tT2π τT ! +  1 + 2π
τTB!"# − B!"#2 cos 2π tT2π τT ! +  1 + k!e!!!  
The term k!e!!! in the solution of the equation is ignored because it quickly decays away.  
 
For !! ≫ !!" ≅ 0.16 (i.e. changes in brightness are fast with respect to neural adaptation): 
B!"#$ t = B!"# − B!"#2 sin 2π tT + B!"# − B!"#2  cos 2π tT2π τT  B!"#$ t ≅ B!"# − B!"#2 sin 2π tT  
 
For !! ≪ !!" ≅ 0.16 (i.e. changes in brightness are slow with respect to neural adaptation): B!"#$ t = 2π τTB!"# − B!"#2 2π τT sin 2π tT + cos 2π tT  B!"#$ t ≅ 2π τTB!"# − B!"#2 cos 2π tT  
 
In general, the range (max-min) of perceived brightness is: 
B!"#$,!"#$% = 2π τT B!"# − B!"#2π τT ! +  1 
 
 From studies on human sleep, room light levels of 5-10 lux (lm/m2) have been 
shown to cause sleep disturbance and depression [118]. This amounts to approximately 
0.5-1 photons/µm2/s on the retina. As an example, consider the eye deviating from 35° to 
40°, which will cause a change in brightness of !!"°!!"° = 2.5 and an expected Troxler fading 
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time constant of 4.4 s. Assuming 100 photons/µm2/s is provided by the Noctura 400, then 
the perceived brightness is: 
B!"#$,!"#$% = 2π 11T 100− 1002.52π 11T ! +  1 
Figure 2.12 plots the perceived brightness of light on the retina as a function of the period 
of eye oscillation between 35° to 40°. It can be observed that even relatively small and 
slow eye movements are expected to produce a flicker in light intensity above levels (1 
photon/µm2/s) known to cause sleep disturbance.  
 
Figure 2.12: Perceived brightness of light from a sleep on retina versus the period of 
eye oscillation between 35 to 40°. 
 This analysis shows that Troxler neural adaptation is generally too slow to 
eliminate perception of light from a sleep mask. Even addition of a feedback control 
system is unlikely to provide much improvement given that different regions of the retina 
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experience different levels of light attenuation as a function of gaze angle. Compensation 
of total retinal light dose not overcome this problem. One viable solution is to affix the 
light source to the eye such that it maintains a constant path despite eye movement. This 
can be accomplished through an implant or a contact lens. Psychophysical studies using 
light sources suction cupped onto the cornea to stabilize retinal illumination have shown 
elimination of perceived light (to levels comparable with Eigengrau) well into the 
photopic range, highlighting the viability of such an approach [115]. 
Pros and Cons of Phototherapy Light Mask Approach  
 The concept of phototherapy is promising for the treatment of diabetic 
retinopathy; however, a sleep mask is likely not the best means of delivering the therapy. 
The following chapters explore the development of new phototherapy devices that 
overcome the limitations of sleep masks. 
Table 2.8: Pros and cons of sleep mask phototherapy. 
Pros Cons 
• No irreversible eye damage or 
side-effects due to treatment 
(compared to traditional 
therapies like laser and 
repeated anti-VEGF injections 
• A preventive therapy  
• Agnostic of phenotype (e.g. 
genetic factors) 
• Validated clinical safety [95], 
[119] 
• Illumination occurs through the eyelid and is not 
uniform across patients  
• Eye rolls back towards the skull during sleep 
(Bell’s phenomena), leading to variation of light 
dosage on the retina and affecting sleep quality 
• Requires regular nightly use for therapeutic 
efficacy 
• Bulky device on face while sleeping, thus 
leading to compliance issues 
• Phototherapy is yet to obtain regulatory approval 
• Phase III trials [95] refuted efficacy claims of 
previous trials [119] 
• Troxler neural adaptation is incomplete 
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CHAPTER 3 – Chandelier Style Phototherapy Device  
 
Key Take-Aways 
 
• Radioluminescence provides long-term retinal illumination and a small size. 
• Skirt-style anchoring system allows for rapid and leak-free implantation of a 
chandelier device through the pars plana. 
• 4-week animal tests demonstrate safety of implantation and phototherapy 
 
 The delivery mode of phototherapy is critical to the success of the therapy for 
anatomical/physiological reasons (e.g. external light is attenuated by the eyelid and pupil; 
varying eye gaze during sleep causes light intensity variation) as well as human factors 
(e.g. low long-term patient compliance in preventative therapies). One strategy for 
delivering light to the retina at a constant, predictable, and therapeutic dose is to implant 
the light source within the eye. Clinical success in glaucoma drainage devices and retinal 
prostheses has demonstrated that long-term implantation is feasible. The additional 
benefit of implantation is that patient compliance can be greatly improved so long as the 
device does not require patient input (e.g. recharging device). This chapter develops and 
describes an implantable phototherapy device powered via radioluminescence. 
 
Choosing Radioluminescence  
 There are numerous means of producing light such as electrical discharge, 
incandescence, and luminescence. Each method has distinct benefits, limitation, and 
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constraints that restrict suitability for a given application. For the purposes of an ocular 
implant, it is desirable that the method: 
• require minimal power 
• occupy minimal volume 
• have maximal lifetime 
• generate minimal byproducts (e.g. heat, waste, sound, radiation) 
• is safe (product of probability of failure and severity of failure) 
• maintain performance in the body (i.e. does not degrade) 
• be controllable 
• provide sufficient light output 
After analyzing the available means of light generation, radioluminescence stood out as a 
viable candidate. Radioluminescence is the production of light through the interaction of 
ionizing radiation (e.g. alpha particle, beta particle, gamma ray) with a phosphor material. 
Several radioluminescent systems have been developed: 
• Radium-based: Radium-226 emits alpha particles with an average energy of 4.6 
MeV to excite a combined phosphor. The high-energy alpha particles can damage 
the phosphor leading to degradation of luminosity over several years, significantly 
faster than the half-life of 1600 years. Furthermore, gamma rays of 0.7 MeV are 
also produced and can escape encapsulating layers, thus posing a safety risk.  
• Promethium-based: Promethium-147 emits beta particles with a maximum energy 
of 0.23 MeV to excite a combined phosphor. However, the half-life is only 2.62 
years and the high energy beta particles can penetrate up to 5mm of tissue, water, 
or plastic thus posing a safety risk. 
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• Strontium-based: Strontium-90 emits beta particles with a maximum energy of 
0.546 MeV to excite a combined phosphor. It has a half-life of 28.8 years but the 
penetration depth of its beta particle and its long biological half-life of 18 years 
make it a safety risk. 
• Tritium-based: Hydrogen-3 is a gas that emits beta particles with an energy of 
around 5keV (maximum 18.6 keV) to excite a phosphor within a hermetically 
sealed compartment. It has a half-life of 12.3 years. The low energy beta particle 
and short biological half-life of 8.2 days make it relatively safe. 
Gaseous tritium light source (GTLS) provided the best combination of luminous lifetime 
and safety profile and were selected to move forward with. Extensive safety and testing 
data on tritium light sources is compiled in [120].  
 The activity of tritium commonly appears in units of Bequeral (Bq = [decays / s]). 
The molar content of tritium can be calculated, knowing the half-life of tritium as: 
N! = BqN! ln2τ!/!  
The parameters for the utilized GTLS (mb-microtec, CH) are summarized in Table 3.1. 
Table 3.1: Measured and reported parameters of GTLS [121]. 
Model T-6915 T-5666 
Outer Diameter 300 µm 1.5 mm 
Inner Diameter 250 µm 1 mm 
Length 2 mm 6 mm 
Wall Thickness 25 µm 250 µm 
Tritium Activity 0.016 GBq 0.91 GBq 
Tritium Content 15 nmol 850 nmol 
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Mechanism of Action 
 A gaseous tritium light source is constructed by filling a phosphor-lined glass 
capillary with tritium and then hermetically sealing it, often by use of a carbon diode 
laser. The tritium undergoes beta decay with a half-life of 12.3 years emitting high-
energy electrons with an average energy of 5.7 keV that strike the phosphor. As the 
electron penetrates the phosphor, its kinetic energy converts to electrical energy through 
ionization of the phosphor atoms. The excited electrons diffuse within the phosphor until 
they are captured by luminescent/impurity centers where they de-excite, emitting a 
photon in the process. The phosphor and dopant are chosen to produce emission centered 
at particular wavelength, usually in the visible spectrum. 
 
Figure 3.1: Principle of radioluminescence in a gaseous tritium light source. Tritium 
undergoes beta decay, emitting a high-energy electron, which strikes and ionizes 
phosphor, leading to light emission. 
Source Lifetime 
 The brightness of GTLS decreases over time due primarily to an exponential 
decay in the tritium content, the degradation of the phosphor, and pressure buildup (T2 → 
2 He) [121]. Reports from the manufacturer indicate that brightness will decrease to 
about 60-80% over 2 years and 10-50% over 10 years.  
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Safety Considerations 
 There are 3 major safety considerations in utilizing gaseous tritium light sources: 
the uptake of tritium from a fractured capillary, the escape of beta particles, and 
bremsstrahlung radiation. For implanted devices, the risk of fracture is minimal; however, 
the risk must be managed in the case of worn devices like contact lenses or sleep masks. 
Each of these aspects is covered in detail below. 
Risk of Tritium Uptake from Broken Device 
 The radioluminescent light sources are themselves composed of a green emitting 
phosphor encapsulated in a glass capillary, which is filled with pure tritium gas. Tritium 
is considered one of the safest radioisotopes, having a half-life of 12.3 years and emitting 
a very low energy beta particle (<18.6 keV, average of 5.7 keV), unable to penetrate 
through the glass capillary. 
 From a radiation safety perspective, the worst hypothetical scenario would 
involve the breakage of the tritium capillary, oxidation of all the tritium to form tritiated 
water, followed by retention of the tritiated water within the body with a biological half-
life of 10 days. The effective dose that would result is 20 mSievert per µmol tritium. For 
reference, a full body CT-scan is around 20 mSv. The calculation of dose is as follows. 
Tritium has a radioactive half-life, τR, of 12.3yrs and therefore beginning with an initial 
amount of tritium N0, the remaining tritium if lost purely by radioactive decay is: 
N! t = N! ∙ 2!!!! =  N! ∙ e!!∙!" !!!  
The rate constant for decay is then: 
k! = ln (2)τ!  
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In the body, tritium can oxidize to form tritiated water. Water has a biological half-life τB 
of less than 10 days or a rate constant of elimination of: 
k! = ln (2)τ!  
Tritium within the body can therefore be eliminated by one of two mechanisms: 
radioactive decay or biological elimination. The rate of tritium loss is the sum of the two: dNdt = −k! ∙ N− k! ∙ N = −N ∙ (k! + k!)  
So starting from an initial dose of tritium N0 the amount left in the body is: N(t) = N!e!(!!!!!)∙! 
The instantaneous dose D of radiation the body absorbs is: D = k! ∙ N(t) 
The total dose T of radiation is the integration of the instantaneous dose over time: 
T = D dt!! = k! ∙ N! ∙ e!(!!!!!)∙!
!
! = N! ∙ k!k! + k! = N! ∙ τ!τ! + τ! TN! = 10 days12.3 yrs ∙ 365daysyr + 10 days = 0.22% decay in body 
The dosage can be then converted to standard units by assuming the beta particles 
(average energy of 5.7 keV/decay = 9.13×10-16 J/decay) are emitted uniformly over the 
entire body of a 60kg individual: 
DosageN! =  0.0022  9.13×10!!" Jdecay 6.022×10!"  decaymol60 kg = 20 mGrayµmol  
When converting from dose (Gray) to effective dose (Sieverts), both the weighting 
factors for particle type and anatomical distribution are 1, so there is no weighting. 
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Risk of Beta Particle Escape and Considerations of Penetration Depth 
 The high-energy beta particle emitted during the radioactive decay of tritium is 
supposed to deposit its energy in the phosphor coating through ionization ultimately 
produce light. However, suppose the electron passes through a crack in the phosphor and 
strikes the glass capillary instead. It is worthwhile to consider the maximal penetration 
depth that would be expected to ensure the construction of the capillary is suitable to 
avoid radiation escaping the device.  
 The continuous slowing down approximation range ∆x is found by integrating the 
reciprocal of the stopping power of the substrate, S E = − !"!", from the initial/maximal 
energy of the particle to rest [122]. Stopping power is often reported as mass stopping 
power Sm by dividing the stopping power by density. Using data for Pyrex glass [123] 
and a maximal beta electron energy of 18.6 keV, the continuous slowing down 
approximation range is then: 
∆x = 1S! E ∙ ρ!"#$% dE!!! = 1S! E ∙ 2.32 𝑔/𝑐𝑚! dE =!".! !"#! 4.5 µm 
 Thus as long as the capillary is greater than 5 µm thick, negligible beta particles 
will escape the device. For a phosphor like zinc sulfide, CSDAZnS(20 keV) = 2.8 µm, 
which gives a ballpark estimate for the maximal thickness of this layer. 
 
Risk of Bremsstrahlung Radiation 
 Electron energy loss by ionization increases approximately logarithmically with 
energy where as bremsstrahlung losses increase approximately linearly with energy. The 
critical energy Ec is defined as the energy at which both loss rates are equal. For 
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borosilicate glass the critical energy is around 50 MeV [124], so the fraction of energy 
lost to bremsstrahlung for an the relatively low energy, 18.2 keV  tritium beta electron is 
negligible. The same is true for the low atomic weight phosphor [125]. Figure 3.2 plots 
the relative contributions of ionization and bremsstrahlung radiation loss mechanisms for 
copper, which has an Ec of around 20 MeV and Z=29, so it provides an upper bound on 
expected bremsstrahlung from lower atomic weight materials like glass and phosphor. 
 
Figure 3.2: Relative contributions of ionization versus Bremsstrahlung losses in 
Copper (Z=29). Reprinted from [125] . 
Irradiance vs. Distance from GTLS 
 According to the geometry in Figure 3.3, the radiant flux expected from a vertical 
cylindrical source on a surface below was calculated as a function of perpendicular 
distance away from the source axis, r. This calculation allows for the determination of 
source radiance.  
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Figure 3.3: Geometry of GTLS with respect to photodetector in setup. 
The calculation is as follows: P! = r! ∙ cos θ , r! ∙ sin θ , z  P! = (r, 0,0) P! = (0,0, d) 
 n! = (cos θ , sin θ , 0) n! = (0,0,1) n! = (0,0,−1) 
 ρ!,! = P! − P!  ρ!,! = P! − P!  
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m!,! = P! − P!ρ!,! = −m!,! 
m!,! = P! − P!ρ!,! = −m!,! 
 cos θ! =  n! ∙m!,! cos θ! =  n! ∙m!,! cos θ! =  n! ∙m!,! cos θ! =  n! ∙m!,! θ!"# = cos!! r!r  dA! = r! ∙ dθ ∙ dz A! = π ∙ r!! 
 
Then the radiant flux due to the sidewall of the cylinder is: 
dΦ!"#$dA! = L ∙ cos (θ!) ∙ cos (θ!)ρ!,!! ∙ dA!!!  
dΦ!"#$dA! = L ∙ r0 ∙ (−r0+ r ∙ cos (θ)) ∙ z(r! − 2 ∙ cos (θ) ∙ r ∙ r0+ r0! + z!)! dθdz!!"#!!!"#
!!!!
!  
The radiant flux due to the bottom of the cylinder is: dΦ!"##"$dA! = L ∙ cos (θ!) ∙ cos (θ!)ρ!,!! ∙ A! dΦ!"##"$dA! = L ∙ π ∙ d! ∙ r0!d! + r! ! 
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The total radiant flux on the sensor A2 is then found by integrating total radiant flux over 
surface, noting that: r = x! + y! 
Φ!"#!$% = dΦ!"##"$ + dΦ!"#$!!  
 In order to extract the radiance of the GTLS, the theoretical radiant power 
incident on the sensor was plotted as a function of distance and compared to the 
experimentally collected measurements. The best fit of the model occurred for a radiance 
of L = 2.56 mW/sr/m2. This value is within the range the manufacturer reported [121]. 
The experimental details follow. 
 The photon irradiance as a function of distance from several GTLSs was 
measured using a Newport Power Meter (Model 1936-R) with photosensor wand (918D-
ST-UV). Characterization enabled the selection of the smallest source capable of 
providing sufficient dosage for phototherapy. The photosensor was placed directly 
underneath the GTLS, which was affixed to a linear micrometer stage, allowing for 
precise control of the distance (Figure 3.6). The work was carried out in a dark room and 
the setup was further covered with a dark box between measurements. Using this setup, 
ambient light levels were below 1 pW/cm2  (0.027 photons/s/µm2) over the experiment. 
The GTLSs were measured in both a vertical (perpendicular) and horizontal (parallel) 
orientation with respect to the photosensor. Results for 1.5 mm D × 6 mm L and 300 µm 
D × 2 mm L GTLS with green phosphor (532 nm peak emission, 74 nm FWHM) are 
displayed in Figure 3.4 and Figure 3.5, respectively. 
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Figure 3.4: Photon irradiance as a function of distance from a GTLS source of 1.5 mm 
diameter, 6 mm length. Orientation of the source was either horizontal (parallel) or 
vertical (perpendicular) with respect to the photodetector. Shortest distances between 
GTLS and photodetector reported. 
 
Figure 3.5: Photon irradiance as a function of distance from a GTLS source of 300 µm 
diameter, 2 mm length.  
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The 1.5 mm D×6 mm L GTLS provides a light output of: P = 2π ∙ L!! ∙ A!"#$ = 2π ∙ L!! ∙ 2 ∙ πr! + 2πrl = 4π! ∙ L!! ∙ r! + rl  P = 4π! ∙ 2.56 mWsr ∙m! ∙ 7.5×10!!m ! + 7.5×10!!m 6×10!!m  
P = 510 nW = 1.37×10!" photonss (532 nm) 
This light output is suitable for suppression of rod cell metabolism based on the range of 
irradiances explored in Chapter 2, which estimated 7×10!!  !"#$#%&!∙!"#$%& . 
 
Figure 3.6: Setup for characterizing light output from GTLS. (A, B) Irradiance versus 
distance was measured by moving the GTLS known distances away from the 
photodetector in horizontal and vertical orientations, respectively. (C, D) Ocular model 
setup used measure the expected irradiance at various locations on retina. Isolated 
through-ports are sequentially positioned over the photodetector and measured. 
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Characterization of Irradiance from GTLS in an Eye Model 
 The candidate light source (1.5 mm D × 6 mm L) was then tested in an ocular 
model to map photon irradiance uniformity on the retina. The setup consisted of a hollow 
blackened polypropylene 25 mm diameter sphere with sampling ports drilled in three 
circumferential bands for taking irradiance measurements. The GTLS was inserted 
through a closely sized hole and secured (Figure 3.6). 
 Retinal photon irradiance was observed to be within the range of predicted 
therapeutic value over the eye, varying by a factor of 3× over the entire retina but by only 
a factor of 1.6× over the mid-periphery. Given that vision is logarithmic in nature, the 
variation in photon irradiance is acceptable. 
  
Figure 3.7: Retinal photon irradiance measured within an in vitro eye model from a 
GTLS (1.5 mm D × 6 mm L). Sampling ports are spaced evenly in circumferential 
bands as indicated. The absolute photon irradiance measured at each port is indicated 
(left), while the % of maximum is overlaid on the schematic (right). Position of the 
GTLS was at the pars plana and the device was affixed in a radial alignment. 
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Implant Site and Surgical Considerations 
 The pars plana was selected as a site for implantation given that it serves no major 
function in adult eyes and provides access into the posterior chamber of the eye with 
direct line-of-sight to the retina. Ophthalmological procedures commonly use the pars 
plana as an entry site for glaucoma drainage devices [126], [127]. The pars plana is 
approximately 4 mm wide and located around 3 mm from the corneal limbus, between 
the pars plicata and ora serrata. 
Biocompatibility and Stability Considerations 
 There are major challenges in designing long term implants, especially with 
respect to: 1) biocompatibility, 2) degradation of active components, and 3) interfacial 
bond failure. The proposed design overcomes these challenges by utilizing borosilicate 
glass encapsulation of the active lighting system and a medical grade silicone anchoring 
system. Borosilicate glass encapsulation provides the highest level of protection to the 
internal components, as it is impermeable to all chemicals found in a biological system. 
Furthermore, it provides a hermetic package to maintain the tritium gas and phosphor 
inside the implant. Borosilicate glass also has the highest level of bioinertness [128], 
[129] and is frequently used as the negative control in biocompatibility testing. It 
provokes minimal if any host response. The medical grade silicone used was MED4-4210 
(NuSil, CA), which is designed for long-term implantation in humans and already is in 
use in ocular implants [130]. Silicones can form irreversible bonds with glass, providing 
durable interfaces. 
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Scleral Anchoring System 
 Implantable devices were fabricated by securing a GTLS (mb-microtec ag, 
Switzerland) to a medical grade silicone anchoring system (MED4-4210 PDMS), Figure 
3.8. The purpose of the anchoring system is to easily and reliably secure the device in the 
sclera while preventing leakage of vitreous humor transclerally around the implant.  
 
Figure 3.8: Rendering of transcleral phototherapy implant with PDMS acnhoring 
system and GTLS light source. 
 The anchoring system has a back-plate that sits on the surface of the sclera, 
preventing the device from falling into the eye, and a hemispherical skirt structure that 
creates a seal against the inside of the eye (ciliary body) to prevent the device from being 
pushed out of the eye and to block fluid leakage. The back-plate of the anchoring system 
was formed by casting PDMS in a 240 µm deep dry-film photoresist mold.  It consists of 
6 arms that provide a place for the surgeon to grip the device, which can be trimmed 
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following implantation. It is bonded to the bottom of the GTLS cylinder via PDMS 
gluing. The hemispherical skirt has a 2 mm radius to fit the pars plana and was created by 
spin coating PDMS (2.5 krpm, 1 min results in approximately 240 µm thickness) onto a 
hemispherical mold and trimming with a 5 mm diameter biopsy punch. A central 1.5 mm 
hole punched into the center of the skirt allows it to encircle the GTLS and a small bead 
of PDMS glues it securely. Upon implantation of the device, the hemispherical skirt 
compresses to accommodate the thickness of the sclera (approximately 0.5 mm at the 
pars plana [131]), ensuring a tight seal. Figure 3.9 summarizes the dimensions of the 
device components. 
 
Figure 3.9: Component dimensions for the transcleral phototherapy implant: (left) 
Back-plate, (middle) hemispherical skirt, (right) GTLS. The back-plate is glued to the 
bottom of the GTLS with PDMS while the skirt encircles the GTLS and is bonded with 
a bead of PDMS around the interface. 
 
  
70 
Implantation Procedure 
 Development of the implantation procedure used an excised porcine eye model. 
Sierra Medical, Whittier, CA supplied fresh unscalded eyes, which were used 
immediately. Figure 3.10 summarizes this process. 
 
Figure 3.10: Implantation of device into porcine eye. A partial peritomy provides 
access through the conjunctiva to the sclera. A scleral incision of 2.5mm is made at the 
pars plana. The implant is inserted through the incision. The deployment of the skirt 
locks the device in place. The seal of the skirt prevents leakage of fluid from the eye. 
The tight seal of skirt against the inside of the eye can be visualized in a cut away of 
the eye. 
 The developed procedure involves an incision in the conjunctiva at the pars plana 
to provide access to the underlying sclera (i.e. partial peritomy). A 2.5mm linear incision 
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in the sclera made with a scalpel provides an entry that can expand to a diameter of 
1.6mm – sufficient to accommodate the outer diameter of the GTLS (1.5mm) and skirt. 
The implant is then gripped firmly with forceps and inserted through the incision. To 
ensure the deployment of the skirt against the ciliary body, the arms of the device can be 
grasped with forceps and the device can be pushed further in. The successful deployment 
of the skirt is quite apparent with a tactile clicking sensation and robust anchoring of the 
device in place. The arms of the device can be trimmed down using surgical scissors if 
desired and covered with the conjunctiva to prevent infection of the implant site.  
Leak Testing of the Anchoring Mechanism 
 The quality of the seal of the implant against the ciliary body is important since 
excessive transcleral leakage of fluid from the vitreous can cause conjunctival blebbing 
and hypotony. Leakage was evaluated by measuring the permeation rate of fluid from 
freshly enucleated porcine eyes (Sierra Medical, USA; used within 12 hrs of receipt) 
when subject to physiologic pressure (10-21 mmHg) with (n=3) and without an implant 
(n=3).  
 A syringe was inserted into each eyeball and connected to an elevated column of 
water, enabling pressure and flow rate to be monitored over time (Figure 3.11). The 
resultant plots of column height versus time were converted into an average permeability 
according to the following equations: P = ρgh 
P is eye pressure [cmH2O], ρis density of water [1 g/cm3], g is gravitational acceleration 
[9.8 m/s2], and h is the height of the water column [cm].  
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Figure 3.11: Experimental setup for permeation testing of enucleated porcine eyes with 
and without implants. Water columns of up to 28 cmH2O were inserted via syringe into 
the eyeballs and monitored over time to simultaneously record pressure and flow rate. 
By geometry, the height of the water column relates to the volume of water: 
h = Vπ ∙ r! 
Where r is the inner radius of the column tube. The loss of water from the eye is assumed 
to be a linear function of permeability K and pressure P, giving the relations:  dVdt = −K ∙ P = −K ∙ ρg Vπ ∙ r! 
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Or alternatively, in terms of the column height: 
π ∙ r! dhdt = −K ∙ ρgh 
This can be solved for the column height over time: 
h(t) = h!e!!∙!!!∙!! ! 
By fitting the data with the model, the value of the permeation constant K can be 
obtained with respect to the time constant τ: 
K = πr!τρg 
 Error! Reference source not found. plots the measured permeation for eyes with 
and without implants. No significant difference was observed, suggesting a sufficiently 
robust seal. For comparison, human eyes have a permeation of 9.6 µl/hr/mmHg [132].  
 
Figure 3.12: Permeation rates with and without implants (n=3) with overlaid standard 
deviation. The difference of 0.7 µl/hr/mmHg between the groups was not statistically 
significant by T-test (P > 0.05). 
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 The enucleated porcine eye, with a measured permeation of 5.4 µl/hr/mmHg, 
provides a reasonable model. Specifically, the contribution of leakage around the device 
of 0.7 µl/hr/mmHg (i.e. the difference in permeation with and without the implant) is 
probably quite accurate since this permeation route is mechanical in nature and not 
dependent on cellular or physiological processes. Another factor that may have 
contributed to the differences in permeation rates is that the porcine model eliminated 
evaporative mechanisms of fluid loss, where as the human measurements would have had 
these occurring. 
 
In Vivo Validation of GTLS Implant 
 In order to validate the safety of the implantation process, the efficacy of the skirt 
sealing in preventing leakage, stability of implant anchoring, and safety of constant 
phototherapy, in vivo testing was carried out. Devices were implanted into the eyes of 
young albino New Zealand rabbits (n=2). Animals were anesthetized by an intramuscular 
injection of Ketamine/Xylazine in conjunction with 1-2 eye drops of 0.5% Tetracaine to 
numb the ocular region. Eye drops of Tropicamide/Phenylephrine dilated the pupil. 
Partial peritomy was done on the temporal side of the conjunctiva before a 2.5mm 
sclerotomy was made at the pars plana (2.5mm away from the limbus); the tritium device 
was inserted into the incision. Once in position, the device was pressed gently to lock it in 
place via skirt deployment. The conjunctiva was subsequently used to cover the implant 
and closed with a 6-0 vicryl suture (Figure 3.13). All wounds were coated with antibiotic 
ointment. Surgery times were between 10-15min. The animals were monitored until they 
awoke and then returned back to their cages for recovery.  
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Figure 3.13: In vivo implantation of device into rabbit eye. A) Device back-plate arms 
have been trimmed and covered with the conjunctival flap then sutured closed. B) Side 
view of GTLS within the rabbit eye with lights on C) and with lights off to visualize the 
radioluminescence. 
 
Figure 3.14: Histology of retina at 4 weeks post implantation using hematoxylin and 
eosin staining. Layers of the retina are observed to be normal and show no adverse 
changes to the retina. 
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 A weekly follow-up revealed no adverse effects or changes in animal behavior. At 
4 weeks post implantation the animals were euthanized by IV injection of pentobarbital. 
Histological examination of eyeballs stained with H&E found no adverse changes to the 
retina (Figure 3.14). 
  
Intrinsically Photosensitive Retinal Ganglion Cells 
 Intrinsically photosensitive retinal ganglion cells (ipRGCs) signal ambient light 
levels and represent a third class of photoreceptors, distinct from rods and cones. These 
neural cells contain melanopsin, a light sensitive protein with a peak absorbance of 480 
nm, which allows them to detect light. The role of ipRGCs includes: reporting length of 
day-night cycles for circadian rhythm, controlling pupillary state, and regulating 
melatonin production [133]. Irradiance response curves for ipRGCs have an IR50 of 3.25 
× 1012 photons/cm2/s for M1-phenotype and an IR50 of 3.44 × 10
13 photons/cm2/s) for 
M2-phenotype [134]. Given that phototherapy is on the order of 1010 to 1011 
photons/cm2/s, well below even the IR10, it is unlikely that low-level phototherapy will 
have adverse effects on ipRGCs and their respective functions.  
 The shedding of photoreceptor outer segments is a critical process for maintaining 
vision that dependent on the circadian rhythm [135]. Shedding of rod cells peaks at onset 
of light, where as cone outer segments are shed at onset of darkness. Given that ipRGCs 
entrain circadian rhythm, the shedding of photoreceptors should proceed normally.  
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CHAPTER 4 – Phototherapy Contact Lenses 
 
Key Take-Aways 
 
• Phototherapeutic overnight contact lenses provide a non-invasive option for 
hypoxic retinal diseases like diabetic retinopathy. 
• Pupil constriction during sleep requires centering light sources on the optical axis 
• Radioluminescent contact lenses offer a long-term, reusable solution; 
chemiluminescent contact lenses offer a short-term, disposable solution  
 
Towards Smart Lenses 
 Contact lenses have had a long history in medicine with the first glass lenses 
being fitted in the 1880s in Germany for the treatment of keratoconus and later myopia 
with the introduction of optically powered lenses [18]. The development of PMMA and 
discovery of its biocompatibility led to its use in contact lenses around the 1940s. Soft 
lenses first appeared in the 1960s based on poly-HEMA and silicone elastomers, 
providing improved comfort. Rigid gas permeable lenses developed in the 1970s marked 
a significant improvement over PMMA by providing oxygenation to the cornea, thereby 
enabling overnight orthokeratology lenses in the 1980s-1990s. Disposable lenses began 
to be market in the 1990s followed by the introduction of silicone hydrogel lenses around 
2000. Myopia control lenses appeared in the 2010s. Since then researchers and 
companies have been experimenting with integrating diagnostic sensors (e.g. glucose 
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monitoring) and drug delivery into contact lenses in a push towards multifunctional smart 
lenses.  
 Contact lenses provide an excellent platform for phototherapy in that they are 
relatively non-invasive, well accepted, and can localize the light emitting elements 
directly into the optical path of the eye. This chapter summarizes the development of 
phototherapeutic contact lens options. 
Choice of Light Source and Wear Considerations 
 There are several aspect that should be consider regarding the light source used in 
a phototherapeutic contact lens: 
• Disposable or re-usable contact lens platform 
• Passive or active lighting system 
• Range and tunability of light intensity 
• Risk of failure and safety 
• Size of light source 
• Impact on user routine 
• Cost 
From the available means of light production, three options were identified as feasible, 
namely gaseous tritium light sources (GTLS), chemiluminescence, and light emitting 
diodes. Table 4.1 describes the pros/cons and target application for each. Note that 
contact lenses based on light emitting diodes are developed in Chapter 5. 
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Table 4.1: Pros, cons, and use cases for GTLS, LED, and chemiluminescence lighting 
strategies in phototherapeutic contact lenses. 
Radioluminescence / GTLS 
Pro Provides constant light output for several years, obviating the need for recharging 
over the life of the lens. Manufacturers can produce sources in sizes down to 300 
µm diameter, making them feasible for integration into a contact lens. The glass 
encapsulation provides optimal biocompatibility.  
Con The sources emit moderate light intensity and may require multiple elements to 
achieve sufficient retinal irradiance. The glass encapsulation is rigid and fragile at 
only 100 µm thick. The tritium is a radiation hazard if the sources are broken and 
requires proper disposal. 
Use May find application in a re-usable, rigid contact lens.  
 
Chemiluminescence 
Pro Provides medium light output for periods of hours, depending on geometry. Often 
in a two-component liquid system allowing flexibility in geometry.   
Con Chemicals are irritants. Irreversible reaction.  
Use May find application in disposable soft lenses.   
 
Light Emitting Diode 
Pro Provides variable and controllable light output in terms of both intensity and 
frequency with appropriate circuitry. Available in package sizes down to 0.65 mm 
× 0.35 mm × 0.2 mm, making them feasible for integration into a contact lens. 
Single LED can provide ample light output. Mechanically robust. 
Con Require electrical circuitry, which is susceptible to degradation. May contain toxic 
materials (e.g. heavy metals). 
Use May find application in disposable or short-term re-usable soft or hard lenses. 
 
Pupillary Constriction During Sleep 
 The pupil constricts during sleep and with age. Since light entering the eye must 
pass through the pupil, a larger diameter is preferable for treatment with phototherapy. 
Two muscles control the size of the pupil: the iris sphincter muscle (constricts pupil 
under parasympathetic tone) and the iris dilator muscle (dilates pupil under sympathetic 
tone). The combination of reduced inhibition of the oculomotor nucleus 
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(parasympathetic) and reduced sympathetic tone during sleep and drowsiness leads to 
pupil constriction [103].  
 Through pharmacological intervention it is possible to overcome the sleep-
induced miosis [136], [137].  Anticholinergic mydriatics (e.g. atropine, tropicamide) are a 
class of compounds that block parasympathetic activity and prevent constriction of the 
ciliary muscle leading to pupil dilation. Sympathomimetics (e.g. phenylephrine, 4-
hydroxyamphetamine) are compounds that act as agonists to the sympathetic nervous 
system, inducing contraction of the iris dilator muscle and thereby pupil dilation. The use 
of these compounds separately or in conjunction provides a means of dilating the pupil to 
improve the phototherapeutic dose transmitted through the pupil unto the retina.  Care 
should be taken to ensure complications are managed appropriately (e.g. elevated 
intraocular pressure is a known side-effect). Mydriatics are contraindicated for some 
patients [138]. 
 
Light Emission Measurements from GTLS Contact Lens 
 All measurements of light emission were carried out with a Newport Power Meter 
(Model 1936-R) with photosensor wand (918D-ST-UV). A contact lens containing 24× 
T-6915 GTLS (300 µm diameter, 2 mm length) with green phosphor arranged in a spoke 
pattern around a 3 mm central pupil was prepared as described subsequently in section, 
“2-Part Mold”. Measurements of light intensity were made with and without a metallic 
reflector (aluminum foil) placed on the front of the lens both as a function of distance 
from the lens and as a function of angle. 
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Figure 4.1: Photon irradiance on detector as a function of perpendicular distance from 
the GTLS lens, with (upper) and without (lower) metallic reflector. Ratio of intensity 
with and without reflector is approximately twice. 
 
 
Figure 4.2: Photon irradiance on detector as a function of angular position from the 
optical axis around a 25 mm sphere produced by a GTLS lens with metallic reflector. 
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 Measurement of irradiance versus distance was carried out in a similar setup as 
described in section, “Irradiance vs. Distance from GTLS”. To measure irradiance as a 
function of angle, the setup was modified slightly by affixing the lens to a pivot arm in 
such a way that its orientation angle could be adjusted. Utilizing a micrometer stage, and 
a 25 mm sphere centered over the photodetector, the lens was positioned tangentially 
around the sphere, the sphere was removed, and measurements were made (Figure 4.3).  
 
Figure 4.3: Setup to measure light intensity as a function of angle. (Left) The lens is 
positioned via a micrometer stage onto a 25mm sphere at various positions. (Right) The 
sphere is removed and the measurement is made with the photodetector. 
 Results indicate that the use of a metallic reflector effectively doubles the light 
directed towards the retina from the GTLSs. The design and geometry of the reflector is 
important though. In a separate set of experiments, titanium was deposited via electron-
beam physical vapour deposition directly onto the back half of cylindrical GTLSs (Figure 
4.8) to act as a reflector but no measureable improvement in light output was observed. In 
such geometry, most reflected light is directed back into the light source itself and may be 
lost due to absorbance within the phosphor. Generally, the irradiance as a function of 
angular retinal position is relatively constant, with proximity effects approximately 
balancing projected area effects. 
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Design & Fabrication of GTLS Lenses 
2-Part Molding Process 
 A preliminary version of a phototherapeutic contact lens was fabricated by 
embedding 24 GTLS sources into medical grade PDMS (MED4-4210) through a two-
step, two-part molding process (Figure 4.4). In the first step, the front face of the lens is 
cast with PDMS in mold B, with mold A imprinting alignment grooves, and partially 
cured (5 min, 100 °C). In the second step, the GTLS are positioned in alignment grooves 
and tacked in place with a dab of PDMS and partial cure (5 min, 100 °C). In the third 
step, with lens remaining in mold B, the back face of the lens is cast with PDMS by mold 
C and fully cured (12 hr, 100 °C). The lens in then removed from the mold and subject to 
acetone leaching (3×12 hr, 55 °C) to remove any unreacted monomer.  
 
Figure 4.4: (Top) Phototherapeutic GTLS contact lens fabrication through 2-step, 2-
part moulding process. (Bottom) Images of lens under light and dark conditions. Scale 
bar 5 mm. 
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 The design places the GTLS in an evenly spaced radial pattern starting at r =1.5 
mm and ending at r = 3.5 mm. This annular arrangement of light sources in the lens was 
intended to provide an unobstructed view during photopic vision when the pupil is 
contracted (<3 mm D), while directing the complete phototherapeutic dose through the 
dilated pupil (>7 mm D) under scotopic vision (Figure 4). The lens was 500 µm thick.  
 
In Vivo ERG Results with GTLS Lens 
 The bioactivity of the GTLS lens was investigated through electroretinogram 
(ERG) flash response recordings in New Zealand rabbits. Animals were anesthetized by 
intramuscular injection of Ketamine/Xylazine and dark-adapted for 20 min prior to 
measurements. The ERG setup (HMsERG system, OcuScience LLC, USA) utilized DLT 
Plus ElectrodesTM (LKC Technologies, USA) and was designed for rabbit use. Scotopic 
ERG was performed with flash intensities of 0.1, 0.3, 1, 3, 10, and 25 cd⋅s/m2, with no 
background illumination. The phototherapeutic contact lens was put in the eye of the 
rabbit with a control contact lens (no GTLS but otherwise identical) placed in the 
contralateral eye. Following the first set of recordings, the lenses were removed and 
swapped from each eye to the other, and then a second set of identical recordings was 
taken. This procedure ensured that observed differences between ERGs were genuine and 
not artifacts of system setup or animal. 
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Figure 4.5: ERG of rabbit wearing GTLS contact lens with reflector and control lens. 
 The dark adapted ERG response arises from the closure of sodium channels in the 
rod outer segment in response to a flash of light [139]. Closure of channels reduces the 
circulating dark current and hence results in a negative deflection in the recording. For a 
given flash intensity, the magnitude of the a-wave is proportional to the dark-adapted 
state of the rod, since a less dark-adapted rod has a smaller circulating current to begin 
with. Thus comparison of the a-waves of ERGs gives information as to the magnitude of 
the circulating dark current and hence metabolic state of the rod. The hyperpolarization of 
the rod is transmitted downstream to the bipolar cells, which are mostly responsible for 
the b-wave due to the extrusion of potassium. The magnitude of the b-wave is generally 
much greater than that of the a-wave, which makes it more prominent and easier to 
measure. Not surprisingly, the magnitudes of the two waves are approximately 
proportional to one another (∆!∆! =0.8-1.2) [140] and so the b-wave can also be used as a 
proxy for rod metabolism. 
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Figure 4.6: Electroretinogram with and without GTLS contact lens. (Left) Schematic 
of ERG origin. The circulating Na+ current in rod outer segment is suppressed when 
incident photons cause the closure of ion channels in the outer segment. A negative 
deflecting a-wave is measured, which has a magnitude proportional to the number of 
channels closed in response to the flash. The hyperpolarization of the rod in response 
to light flash causes downstream signaling, which results in the positive deflecting b-
wave, partly due to K+ release from the rod bipolar cell.  (Right) Pair of representative 
ERGs at a flash intensity of 1 cd·s/m2 with GTLS contact lens and control lens in 
alternate eyes. 
 The ERG recordings were observed to be symmetrical across eyes, with notably 
suppressed b-wave amplitude in the eye treated with the phototherapeutic contact lens 
(Figure 4.6). The recordings were analyzed to extract salient features: both the amplitude 
and implicit time of the b-wave in the treated eye was found to be significantly shorter 
than in the untreated eye, a noted characteristic of suppressed dark adaptation [141]. 
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Specifically looking at the difference in b-wave amplitude, the phototherapeutic contact 
lens induces an average suppression of rod cell dark adaptation to 32 ± 2 % of full dark 
adaptation. 
 
Figure 4.7: Quantification of ERG parameters (a-wave and b-wave amplitude and 
implicit time) as a function of flash intensity. 
 The expectation is for the degree of rod suppression to be larger in a rabbit model 
given the smaller size of the rabbit eye (18 mm axial length [142]) compared to a human 
eye (24 mm axial length [143]). Accounting for the anatomical differences, rabbit retinal 
irradiance from the phototherapeutic contact lens is approximately 2× that expected in a 
human. Given the logarithmic nature of vision, the expected rod cell suppression in 
human use would be approximately 50%, which exceeds the design specification but is 
well within a tunable range. Human ERG data will need to be collected in the future to 
validate these estimates.  
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Conversion of Flash Intensity to Photon Count 
 The electroretinogram is initiated through a flash of light, commonly reported in 
!"∙!!! . To make these numbers more meaningful in comparison to the background 
illumination provided by the light emitting contact lens, the flash intensity F! !"∙!!!  can be 
converted to units of  !"#$#%&!!!  according to the following equations: 
F! photonsm! =  1.02×10!" A!F! cd ∙ sm!D!!  
F! photonsµm! =  1.02 A!F! mcd ∙ sm!D!!  
For a 7 mm diameter pupil, eyeball diameter Dr = 9.9mm for rabbit [142], and 
unobstructed area fraction of lens 0.9: 
F! photonsµm! ≅  0.36 ∙ F! mcd ∙ sm!  
Dry-Film Molded Lenses with Suture Anchors 
 A modification to the previous phototherapeutic contact lens was made to 
maintain lens centration in overnight rabbit experiments. The PDMS lens was created in 
two parts that were bonded together with PDMS glue. Dry film photoresist molds of the 
top and bottom PDMS lens were made containing GTLS alignment grooves as well as 4 
suture anchors spaced around the lens. Given the dry film thickness of 120 µm per layer, 
the grooves in the top lens were made 120 µm deep and the grooves in the top lens were 
made 240 µm deep, thereby accommodating the 300 µm diameter GTLS. The top and 
bottom of the lens each have a 120 µm thick PDMS outer surface, producing a lens 600 
µm thick.  
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Figure 4.8: GTLS contact lens (left) and control lens (right) with suture holes to secure 
lens onto the rabbit eye for overnight studies. 
 To evaluate long-term wear, the lens was affixed to the cornea of a rabbit via 
suturing to the conjunctiva and left for 1 week (Figure 4.9). No problems with the contact 
lens were found following removal; however, tearing of the conjunctiva due to the 
sutures was observed. Additionally, the cornea was observed to have become cloudy and 
had significant loss of epithelium. 
 
Figure 4.9: Weeklong contact lens wear via suturing to rabbit eye. (Bottom right) 
Corneal cloudiness observed underneath lens following removal. 
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 The results of this study highlight the drawbacks of silicone-based contact lenses, 
which have a tendency to grip and cause traction on the cornea due to their innate 
hydrophobicity and compliance. These characteristics may have been the cause of the 
corneal cloudiness. While some of the challenges of long-term contact lens studies are 
unique to animal models (e.g. need to suture, unpredictable rubbing, lens hygiene), it is 
worthwhile investigating alternatives to silicone-based lenses. 
 
Rigid Gas Permeable Lens Development 
 One of the concerns with PDMS-based lenses is that they are soft, which could 
lead to fracture of the encapsulated GTLSs. Furthermore, PDMS has a tendency to grip 
the eye due to its hydrophobic nature and this can lead to traction on the cornea. To 
overcome these drawbacks, rigid gas permeable (RGP) lens material was investigated, 
specifically HDS 100. RGP makes a trade-off in terms of oxygen permeability and 
compliance compared to silicone in order to achieve hydrophilicity. The material is 
relatively rigid compared to the compliance of the cornea but its innate hydrophilicity 
prevent it from gripping and therefore make it suitable for long term use. 
 A cavity-style hard contact lens, details of which are discussed in section “Cavity-
Style Design for Smart Lens”, was designed to be able to encase GTLSs and maintain a 
hydrophilic surface. Briefly, a pair of rigid-gas permeable lenses were designed such that 
they would form a cavity when stacked on top of each other. A 600 µm central cavity 
thickness was targeted to accommodate the 300 µm diameter cylindrical GTLSs within 
the curved lens geometry plus additional reflector and GTLS holder. 
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 Table 4.2 summarizes the parameters of the lenses, which were turned by a 
certified lens manufacturer out of FDA approved RGP material. Optical coherence 
tomography scans of the stacked lenses with test wire (375 µm D × 2 mm L) verify the 
cavity geometry and fit (Figure 4.10). The cavity is >400 µm wide over a diameter of 7 
mm, with a central width of 641 µm. 
Table 4.2: Cavity-style contact lens parameters. 
 Bottom Lens Top Lens 
Base Curvature Radius (BC) 8.39 6 
Power (PWR) +0.75 0 
Diameter (DIA) 11.3 11.4 
Back Optical Zone (BOZ) 6.2 7.3 
Front Optical Zone (FOZ) 7.1 N/A 
Central Thickness (CT) 0.18 0.18 
Edge Thickness (ET) 0.15 0.15 
Lens Material (MAT) HDS 100 HDS 100 
 
 
Figure 4.10: Optical coherence tomography of the cavity forming lens pair containing 
375 µm D× 2 mm L wire pieces to validate fit. (Left) Optical image of top view of lens 
with overlaid OCT scan lines. (Center) Corresponding OCT scans with relevant 
dimensions overlaid. (Right) Images of paired lenses containing GTLS. 
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Overcoming Pupil Constriction During Sleep 
 Recent evidence that pupils constrict during sleep may undermine the 
effectiveness of the previous spoke-patterned GTLS design. To overcome this limitation, 
a new lighting arrangement was produced that concentrated the sources at the center of 
the lens with a small 500 µm pupil for vision. 
 In the limited studies that have looked at pupil size during sleep, one monitoring 
children ages 1 to 5 found that the average pupil diameter during deep sleep was 2.1 ± 0.5 
mm while under dark-adapted awake conditions it was 6.1 ± 0.9 mm [103]. The pupil in 
older (61 ± 4.4 y) patients tends to be more constricted compared to younger (22.8 ± 4 y) 
individuals under both conditions of light-adaptation (65% relative area) and dark-
adaptation (73% relative area) [105]. 
 
Figure 4.11: GTLS illumination element. (left) Microfabricated PDMS holder and 
spacer (right) with GTLS installed and overlaid average maximal (6 mm) and minimal 
(2 mm) pupil diameter during sleep. 
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 The GTLS illumination element repositions light sources nearer the center of the 
lens so that the constricted pupil encircles a larger percentage of them. A 500 µm 
artificial pupil in the structure and corresponding reflector enables vision while wearing 
the lens. Under pupil dilation (6 mm D), almost all 32 sources are able to transmit light 
through the pupil, under partial dilation (4 mm D) the equivalent of 13 are able to, and 
under pupil constriction (2 mm D) the equivalent of 4 are able to.  
 The illumination element is composed of a PDMS aligner, which features spacing 
grooves to seat the GTLS evenly and ensure there is a path for gas diffusion between the 
sources. The aligner also has a 500 µm diameter hole in the center to maintain an optical 
path for vision and allow transmission of oxygen. GTLS are glued to the aligner on their 
inside end only, enabling the illumination element to be bent to fit the curved surface of 
the lens. 
 A reflector was electrochemically etched (detailed in section 
“Electrochemical Etching  
Stainless Steel”) out of stainless steel (0.001” thickness, 7 mm diameter) and shaped to 
match the curvature of the lens by forming over a stainless sphere (15 mm diameter). 
Tabs around the reflector pupil allow for it to be mechanically secured and centered on 
the PDMS aligner. Ruffles in the reflector prevent it from sealing off a portion of the lens 
cavity, thereby allowing gas to diffuse around it.  
 To form the completed cavity-lens, the light source assembly was first centered 
on the bottom lens. A bead of cyanoacrylate was applied along the inner surface of the 
top lens before bring the two lenses in contact, forming a peripheral bond between them 
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and a hollow gas cavity housing the GTLS lighting system. Figure 4.12 shows the 
completed lens under various illumination conditions. 
 
Figure 4.12: Cavity-style RGP lens with GTLS concentrated near the center of vision to 
maximize light entry through a constricted pupil, shown under various levels of 
illumination. 
  
Orthokeratology for Improved Compliance 
 A major barrier to the success of preventative therapies is long-term patient 
compliance, which has plagued phototherapeutic sleep mask trials [95]. The same is 
likely to occur with phototherapeutic contact lenses without further modification. Patients 
may understand the long-term consequences of their disease and how nightly 
phototherapy can help treat it, but the disconnect between future benefits (e.g. preserved 
sight, reduced numbers of injections or rounds of laser treatment) and the nightly 
inconvenience they face putting in the lenses will gradually erode their compliance. 
Maintenance of such routines can be quickly jeopardized by even short-lived externalities 
(e.g. sickness, late-nights, travel), when it may be justified to stop utilizing the lenses 
temporarily, due to the slippery slope of procrastination. Generally, what is needed to 
sustain therapy is immediate feedback. There are three main types that play a role in 
medicine: 
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• External: A doctor, specialist, parent, or spouse monitors compliance with the 
therapy (e.g. a trainer motivating a patient to do exercises).  
• Vitamins: Complying with the therapy provides an improvement to the quality of 
life of the patient. (e.g. feeling energized after a healthy meal) 
• Painkillers: Complying with the therapy alleviates a negative symptom of the 
patient. (e.g. taking an anti-inflammatory pill for a sprain) 
Studies have shown that compliance is almost always higher with the “painkiller” class of 
feedback [109], [110]. Therefore, I hypothesize what is needed to improve the 
compliance of phototherapy is the coupling of its preventive function to a painkilling 
function.  
 For contact lenses, the ability to correct vision (e.g. myopia) is an obvious 
painkilling function and the reason people tolerate the discomfort of putting in the lenses 
daily. However, phototherapy lenses provide no therapeutic benefit during the day when 
vision correction would be valued, and conversely vision-correcting lenses provide no 
benefit during sleep when phototherapy is valued. The coupling of preventative and 
painkilling functions requires that the vision-correcting feature occur during the night and 
last through the day. Miraculously, a little known means of vision correction known as 
orthokeratology does just that by utilizing specialized nightly contact lenses to reshape 
the cornea, providing patients with corrected vision daily even after lens removal [144]. 
Building on top of this platform could provide much improved patient compliance. 
 Orthokeratology has been around since the 1960s as a means of treating myopia, 
although only recent advances in lens materials and designs have seen it grow in 
popularity [145]. A practitioner prescribes the patient a pair of lenses with a central 
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curvature that is flatter than their corneal curvature such that some of the epithelial tissue 
is displaced peripherally, resulting in reduced corneal optical power (Figure 4.13). 
Reverse-curve geometry, with steeper mid-periphery secondary curve, allows the lens to 
come back into contact with the cornea and maintain centration of the lens. Modern 
orthokeratology lenses are worn during sleep to provide a sufficiently long period for 
corneal reshaping and are removed each morning. The corneal reshaping is transient and 
will revert back over 24 to 48 hours; however, with regular use corrected vision can be 
achieved.  
 
Figure 4.13: (Left) Orthokeratology lens profile, highlighting the relatively flat base 
curve and steep secondary curve. (Right) Phototherapeutic lens built on an 
orthokeratology lens platform. 
 The benefits (e.g. correct vision, no need for daily contacts/glasses) provided by 
orthokeratology provide strong incentive for patients to utilize them daily. In fact, 
orthokeratology has a >95% compliance rate among users [146]. By integrating 
phototherapy into an orthokeratology lens, it is likely that similar levels of compliance 
can be achieved within the sub-population of diabetics who are myopic (8.4 million in the 
USA, 1.4 million of which already wear contact lenses) [147]. As proof-of-concept, a 
prototype phototherapeutic orthokeratology lens was fabricated (Figure 4.13) by 
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encapsulating lighting elements and reflector in PDMS on a standard orthokeratology 
lens. 
Evaluating Chemiluminescent Light Source 
 For short term and disposable applications, a chemiluminescent contact lens could 
be useful. This section presents a feasibility analysis and proof-of-concept. 
 A widely used chemiluminescent system involves (Figure 4.14) the oxidation of a 
phenyl oxalate ester with hydrogen peroxide under basic conditions to produce 1,2-
dioxetanedione, which spontaneously decomposes to carbon dioxide, releasing energy 
that can excite a dye and thereby cause the emission of a photon [148]. Cyalume is the 
trade name of one such chemiluminescent system that is widely available and well 
characterized. Cyalume is composed of [149]: 
• Phenyl oxalate ester (e.g. TCPO, CPPO) 
• Dye (e.g. 9,10-Bis(phenylethynyl)anthracene) 
• Solvent (e.g. alkyl phthalates, acetyl citrate esters, and alkyl benzoates) 
• Base (e.g. sodium salicylate) 
• Hydrogen peroxide 
 The safety of Cyalume has been evaluated in rabbits both by direct exposure of 
the nasolacrimal system and subcutaneous implantation for 30-40 days without toxic 
effects observed; however, subconjunctival, subtarsorrhaphic, and intra-aqueous exposure 
caused complications, although not at greater rates than commonly used contrast agents 
such as iophendylate [150]. Human response to Cyalume exposure has generally been 
found to be asymptomatic or transiently irritating [151]. Given the small volumes of 
chemiluminescent material anticipated, its isolation in a lens, and the low risk if exposure 
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does occur, it seems that a chemiluminescent lens could be feasible from a safety 
perspective.  
 For the present application, it is of interest to maintain a sufficient glow for a 
period of 8-10 hours. There are a couple of parameters that can be adjusted to tune the 
light intensity and duration: 
• pH – Since the reaction involves base-catalyzed nucleophilic attack of the oxalate 
ester by hydrogen peroxide [149], making the solution more basic can accelerate 
the reaction while making the solution more acidic can retard the reaction. 
• Mass Transport – Since the chemical components are separated into two parts, 
controlling the mixing of these components can be used to control the progression 
of the reaction. 
 
Figure 4.14: Chemiluminescent process in Cyalume system. Reprinted from [152]. 
 The light output kinetics of a Cyalume chemiluminescent system was investigated 
at 37 °C under different mixing ratios of Part A (fluorophore mixture) and Part B 
(peroxide mixture). Two different volumes were tested to evaluate the effect of self-
absorbance on light output.  
 The components were measured, mixed, and added to a 6 well plate (15.3 mm 
diameter) as follows: 100 µL:100 µL, 67 µL:133 µL, 133 µL:67 µL, 200 µL:200 µL, 133 
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µL:267 µL, 267 µL:267 µL. The well plate was incubated at 37 °C between 
measurements. Measurements of light output were made using a Newport Power Meter 
(Model 1936-R) with photosensor wand (918D-ST-UV) by sequentially aligning each 
well over the detector area and recording the power at 498 nm. Figure 4.15 plots specific 
radiant power, which was converted from the raw data (in µW/cm2), to compare the 
effectiveness of each mixture. 
 
Figure 4.15: Evaluation of specific radiant power of Cyalume chemiluminescent 
system over time at 37°C. Legend indicates the volume ratio tested, µL Part A 
(fluorophore mixture) : µL Part B (peroxide mixture ).  
 From a design perspective, an emission of 7×1011 photons/s/retina (600 
photons/s/µm2) is required to suppress rod dark current and maximally reduce 
metabolism. The 1:1 ratio is observed to provide the most uniform light output over time 
at approximately 5.6×1010 photons/s/µL over a 6 hour period. This puts the volume 
requirements of chemiluminescent components at around 12.5 µL, achievable within a 
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contact lens. One can also integrate the light output to calculate the photon energy 
emitted from the chemiluminescent components. For a 1:1 ratio, this is 600 µJ/µL. 
 The effect of self-absorbance on light output was found to be negligible, 
evidenced by the near overlap of curves (Figure 4.15) with the same ratio but different 
volumes (and hence thicknesses in the wells, 1.1 mm and 2.2 mm). Given that most 
contact lenses are <1 mm thick, self-absorbance will not constrain design even in the case 
of a reflector where path length could be doubled.   
Prototype Chemiluminescent Lens 
 A prototype lens was fabricated to demonstrate proof-of-concept (Figure 4.16). 
The lens was composed of two PDMS halves, each with an annular reservoir, bonded to a 
circular thin (100 µm) glass septum. Part A (10 µL) and Part B (10 µL) of a Cyalume 
chemiluminescent system were separately loaded via syringe into the top and bottom 
reservoirs, respectively. Compression of the lens fractured the septum allowing the 
chemicals to mix and start the chemiluminescent reaction, which persisted over a 6hr 
period.  
 While this prototype provides proof-of-concept of the chemiluminescent lens, 
several additional aspects need to be addressed. Firstly, the septum preventing the 
mixture of chemiluminescent components should be fabricated out of a safer material 
than glass or utilize a different mechanism to reduce the hazard of a shard puncturing the 
lens. Secondly, the reservoirs should be made impermeable to the chemiluminescent 
chemicals. Thirdly, the kinetics of the light emission should be tuned to provide a more 
uniform emission over time. This could be accomplished using a diffusion-limited 
approach whereby the reservoirs are separated by a channel to slow mixing of the parts. 
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Figure 4.16: Chemiluminescent contact lens prototype. (A) Empty lens showing 
stainless reflector. (B) Reservoirs filled with chemiluminescent components. (C) Glass 
septum is broken allowing mixing and activation. (D) Activated lens on finger for 
scale. (E) Activated lens after 15min. (F) Activated lens after 6 hours.  
 
  
  
102 
CHAPTER 5 – Wirelessly Powered LED Contact Lens  
 The use of a light emitting diode as an illumination source could provide 
advantages over other schemes by allowing for active on/off/dimming control, reducing 
hazardous compounds, and having the benefits of an established ecosystem (e.g. 
manufacturing, hardware, software). Previous estimates of the operational power 
requirements (e.g. 280 nW of light divided by luminous efficiency) for the LED suggest 
that wireless powering, and optional onboard energy storage, would be appropriate. To 
this end, a prototype wirelessly powered contact lens was designed and built from stand-
alone components as proof-of-concept. An application-specific integrated circuit (ASIC) 
could eventually be produced, miniaturizing, optimizing, and incorporating additional 
functionality. 
LED Sourcing and Characterization 
 A 0201 green emitting LED, specifically the XZBGR155W5MAV LED 
(SunLED, CA, USA), was identified as a candidate light source due to its small profile 
(0.65×0.35×0.2 mm), peak wavelength (518 nm), wide viewing angle (2θ1/2 = 140°), 
luminous intensity (79 mcd @ IF = 5 mA), and low toxicity profile (lead-free, InGaN 
emitter) [153]. The LED was soldered to 30 AWG tin-plated copper wire and embedded 
onto an ERG-Jet Contact Lens Electrode (Fabrinal Eye Care, Switzerland) using a 2-part 
epoxy (Figure 5.1).  
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Figure 5.1: (left) XZBGR155W5MAV LED soldered to wire leads and (right) 
embedded onto ERG contact lens electrode with epoxy. 
 The light output from the LED was measured (Figure 5.2) at a distance of 25.4 
mm from the photodetector under pulse width modulation driven at 5 V with a 27.39 kΩ 
current-limiting resistance in series (27 kΩ+390 Ω).  
 
Figure 5.2: Experimental setup of light intensity measurements with irradiance from 
LED embedded contact lens measured by photodetector. 
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 An Arduino Uno (Sain Smart, USA) was used to drive the LED with frequency 
60 Hz and duty cycles ranging from 1 to 1/32768 = 0.515. The linearity of the response is 
observed in Figure 5.3, demonstrating control of photon irradiance over three orders of 
magnitude from 10 to 10,000 photons/µm2/s. For a rabbit with a smaller eye diameter 
than the distance used in the measurements, the irradiance should be scaled by 
approximately !!"#$%&"!!"##$% ! =  !".! !!!" !! ! ≅ 2. 
 
 
Figure 5.3: Irradiance from XZBGR155W5MAV LED at a distance of 25.4 mm. The 
LED is powered at 5 V with a 27.39 kΩ current-limiting resistance in series and driven 
via pulse width modulation using a microcrontroller.  
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In Vivo Characterization of Rod Suppression by LED 
 Similar ERG measurements were made using the LED contact lens setup to 
further understand the relationship between retinal irradiance and rod ERG, particularly 
b-wave suppression. The LED light intensity was varied using pulse width modulation 
with duty cycle of 0, 1/4096, 1/1024, 1/512, 1/256, 1/128, 1/32, 1/4, corresponding to 
approximate retinal irradiance of 0, 27, 59, 108, 198, 378, 1470, and 11446 
photons/µm2/s, respectively. The rabbit was dark adapted for 20 min prior to the start of 
the experiment. An unmodified ERG-Jet contact lens electrode served as a control in the 
right eye of the animal, while the LED modified ERG-Jet contact lens electrode was 
placed in the left eye (Figure 5.4).  
 
Figure 5.4: Experimental setup with rabbit, ERG, and LED contact lens used to 
determined the relationship between retinal illumination and rod dark current 
suppression. 
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 A series of flash intensities were used over the experiment: 100, 30, 10, 3, and 1 
mcd·s/m2. Starting with the lowest flash intensity, a baseline ERG was taken (i.e. duty 
cycle = 0) with a pulse train of 5 flashes spaced 10 s apart. The LED duty cycle was 
increased to the next level and the pulse train was repeated. This was done for each level 
of LED intensity/duty cycle. Following a set of measurements, the animal was dark 
adapted for an additional 15min, the electrodes were repositioned if necessary, and the 
experiment was repeated with the next flash intensity. A representative series is depicted 
in Figure 5.5. This protocol was developed to ensure that steps in LED intensity could be 
compared. Previous protocols where flash intensity was stepped up within a series, while 
LED intensity was varied across series had too much variability due to animal motion, 
drift, and the need to reseat electrodes to allow for comparisons of LED intensity.   
 
Figure 5.5: Representative series of ERGs with various LED irradiance at a flash 
intensity of 30 mcd·s/m2. 
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 From the series of ERG measurements, the b-wave amplitude was extracted and 
plotted as a function of LED duty cycle. On a semi-log plot the amplitude linearly 
decreases with duty cycle (Figure 5.6). For dim flash intensities of 1 or 3 mcd·s/m2 the b-
wave disappears at duty cycles of 1/1024 and 1/256, respectively as the flash is not 
sufficiently above noise. 
 
Figure 5.6: B-wave amplitude versus LED duty cycle over all flash intensities. 
 The retinal irradiance was estimated by converting the duty cycle from Figure 5.6 
using data from Figure 5.3 and assuming an 18 mm rabbit eye diameter. Figure 5.7 plots 
the b-wave amplitudes, which were normalized by the amplitude of the b-wave with no 
irradiance. The calculated retinal irradiance for half-suppression of the b-wave was found 
by fitting a logarithmic curve to the data and calculating the y = 0.5 intercept, 
summarized in Table 5.1. 
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Table 5.1: Irradiance needed for 50% reduction in b-wave amplitude. 
Flash Intensity 
[mcd·s/m2] 
Irradiance for 
50% B-Wave [photons/µm2/s] 
100 26 
30 60 
10 144 
3 44 
1 24 
Mean 60 
Std. Dev. 50 
SEM 20 
 
 
Figure 5.7: B-wave amplitude versus retinal irradiance from LED contact lens, 
normalized by the amplitude of the b-wave with no irradiance. Half-suppression of b-
wave (dashed-line). 
 The necessary retinal irradiance for suppression of b-wave amplitude by 50% is 
therefore around 60 ± 20 (SEM) photons/µm2/s in rabbit.  
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Wireless LED Contact Lens Development 
 For wireless power, there are specific frequency bands that are allowed/intended 
for industrial, scientific and medical (ISM) use. For example, a common band is 13.56 
MHz, used often in near-field communication and radiofrequency identification. The 
band is attractive for wireless contact lens applications due to the simplicity of designing 
circuits to operate at this frequency, the availability of existing components and 
hardware, and the reasonable power that can be transferred. 
 For biological safety considerations, there are limits to the intensity of magnetic 
fields that humans can be continuously exposed to. The Federal Communications 
Commission regulations (47 CFR 1.13101.1310, radiofrequency radiation exposure 
limits) impose a limit of 4.89 [A/m] / f [MHz] for controlled exposure, specifically at 
13.56 MHz: 0.36 [A/m] or 0.45 [µT].  
 Wireless power transfer systems commonly use inductive coupling between two 
resonant coils. Generally speaking, the design constraints on the primary, power-
providing coil are minimal as it is external to the body. Primary coil design is well 
understood and summarized elsewhere [154], [155]. It is therefore assumed that such a 
coil system can be designed, built, and driven to achieve the maximum allowable 
magnetic field for powering the secondary coil.  
Design Calculations and Considerations 
 On the secondary coil side, the goal is to produce a design able to develop the 
maximal voltage (or at least up to 3-4 V to power an LED) within the limits of a safe 
magnetic field strength. Faraday’s Law states the voltage induced on a coil is 
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geometrically dependent on the number and cross sectional area of loops through which a 
time varying magnetic flux passes: 
V!" =  −n ∙ d(B ∙ A)dt  
Clearly, maximizing number and size of loops will maximize induced voltage; however, 
there are geometrical, practical, and processing constraints that need to be considered. 
Firstly, the size of the coil needs to fit within a contact lens, limiting the coil geometry to 
a diameter around 6-10 mm diameter. Practically, single layer planar geometries are 
easiest to fabricate and preferable if they can satisfy the design requirements. From a 
process perspective, 100 µm features are robustly achievable, though smaller features 
could be made if necessary. Within these constraints, it is possible to produce a 10 mm 
outer diameter spiral coil with 10 turns composed of 100 µm wide traces with 100 µm 
spacing. A simple model for the inductance of a single-layer helical coil has been 
developed: 
L = a!n!9a+ 10c  µH  
where a is the average coil radius in inches, c is the span of the coil in inches, and n is the 
number of turns in the coil [156]. With these parameters, the resulting inductance is 
calculated to be 0.84 μH (Table 5.2) and the coil has a loop area of 5.25×10-4  m2. At a 
frequency of 13.56 MHz, such a coil will generate a voltage of:  V! =  −n ∙ A ∙ 2π ∙ f ∙ B! V! = 5.25×10!! m! 2π 13.56 MHz 0.45  µT = 20 mV  
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Table 5.2: Coil parameters used for calculation of inductance. 
Parameter Value 
a 4mm (0.157”) 
c 4mm (0.157”) 
n 10.1 
L 0.843μH 
 
 By combining the inductive coil in parallel with a suitable capacitor and the load, 
an RLC circuit is produced with a characteristic resonant frequency that is able to amplify 
this voltage significantly. The properties of this circuit (Figure 5.8) can be evaluated by 
nodal analysis. 
 
Figure 5.8: Circuit diagram of simple RLC model of a resonant coil with inductance L 
and resistance R1 with parallel capacitor C and load R2 in magnetic field inducing a 
voltage V. 
Consider Kirchoff’s current law at each node: Node A: V! = −n ∙ A ∙ω ∙ B! ∙ Re{e!!!} Node B: V! − V!jωL + V! − V!R! = 0 Node C: V! − V!R! − V!1jωC − V!R! = 0 
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Solving for VB and VC: V!V!  = jωCR!R! + R! + R!R! + R! − CR!Lω! + j ωCR!R! +ωL  V!V!  = R!R! + R! − CR!Lω! + j ωCR!R! +ωL  
If we look at the voltage gain !!!!  we have: V!V! = R!C!L!R!!ω! + C!R!!R!!ω! − 2CLR!!ω! + L!ω! + R!! + 2R!R! + R!!  
 
Which is maximized at 𝜔 for minimum denominator: ddω C!L!R!!ω! + C!R!!R!!ω! − 2CLR!!ω! + L!ω! + R!! + 2R!R! + R!! = 0 
ω!"#$%&%'" = 4CLR!! − 2C!R!!R!! − 2L!2CLR!  
In the limit that R1 is small and the circuit is not loaded (i.e. R2 = ∞), the resonance 
condition simplifies to: 
ω!"#$%&%'" = 1LC 
Given an inductance of 0.83 µH for the coil as previously estimated, in order to achieve a 
resonant frequency of 13.56 MHz, a capacitor of the following value is required: 
C = 12πf !L = 12π ∙ 13.56 MHz !(0.843 µH) = 163 pF 
Furthermore, the gain !!!!  simplifies to: V!V! = 1R! LC = ω!"#$%&%'"LR  
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 The assumption that R2 is large so that loading is minimal is evaluated as follows. 
From earlier evaluation of the LED, we know that 1000 photons/µm2/s is produced at 3.6 
µA and consumes approximately 20 µW. For R2 to consume a similar amount of power at 
3 V, it would require a resistance of: 
R! = V2 !P = 3V2
!
20 µW = 225 kΩ 
Therefore, the anticipated loading effect of an LED is minimal. 
 Regarding assumptions on R1 being small it is important to consider the impact 
the skin effect has on trace resistance. Under alternating current conditions, current 
density skews towards the surface of a conductor due to opposing eddy currents arising 
from the alternating magnetic field induced by the alternating current. Current density 
drops off exponentially by a characteristic constant known as the skin depth, which is 
dependent on frequency [157]. The skin depth for copper at 13.56 MHz is around 17 μm 
(Table 5.3). For conductor dimensions greater than the skin depth, there are diminished 
returns with respect to conductance.  
 
Table 5.3: Calculation of skin depth for copper. 
Description Symbol Value 
Resistivity of the conductor ρ 16.78×10!! Ω ∙m 20℃  
Frequency f 13.56×10! Hz 
Absolute magnetic permeability of the conductor µ = µ!µ! 1.26×10!! H/m 
Skin Depth δ = ρπ ∙ f ∙ µ 17.7 µm 
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The resistance R1 of the coil due to skin effect under ac operation can be estimated from 
the equation [158]: 
R!" f = 2.16 ∙ 10!! fρ!2 w+ d  
Here, f is frequency [Hz], w and d are trace width and thickness [inch], and 𝜌! is the 
relative resistance of the material compared to copper (i.e. Cu = 1). Given a coil length of 
roughly 250 [mm] (9.9”), and trace width of 100µm (0.0039”) and thickness of 35.5µm 
(0.0014” or 1oz Cu/ft2), the resistance of the coil at 13.56 MHz can be estimated as: 
R!"#$ 13.56 MHz = 2.16 ∙ 10!! 13,560,0002 0.0039"+ 0.0014" ∙ (9.9") = 0.74 Ω 
Therefore, the assumption that R1 is small is reasonable. It follows that such a secondary 
coil, when operated under resonance will produce a voltage across the load of: 
V! = V!V! ∙ V! = ω!"#$%&%'"LR! ∙ n ∙ A ∙ω!"#$%&%'" ∙ B!  
V! = 2π ∙ 13,560,000 Hz (0.84 [µH])0.74 [Ω] ∙ 20 mV = 96 ∙ 20 mV =  1.9 [V] 
  
 In order to support an LED, the ac voltage can be rectified and boosted using a 
simple half-wave voltage doubling circuit (Figure 5.9). Under unloaded conditions, the 
output voltage is nominally 2×(Vpk-Vd). Under intended operation the LED is expected to 
consume around 3.6 µA. The Shockley current equation for the diode states: 
I = I! e !!!!"! − 1  
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Assuming I! = 3 ∙ 10!! A,n = 2.2, !"! = 0.026 V, the expected voltage drop across the 
diodes can be calculated [159]:  
V! = n kTq ln II! + 1 = 2.2 0.026 V ln 3.60.3+ 1 = 0.15 [V] 
An output voltage of 2×(1.9 V-0.15 V) = 3.5 V is expected from the rectifier. 
 
Figure 5.9: Circuit diagram of half wave voltage doubler circuit with parallel load 
branches consisting of the LED and voltage limiting Zener. During the negative 
voltage cycle, current flows through the diodes charging capacitors C1 and C2. During 
the subsequent positive cycle, charge on capacitor C1 is boosted up to nearly 2×Vpk and 
flows through diode D2 to equilibrate voltage with C2. With minimal loading, and over 
several cycles, a DC voltage of nearly 2×Vpk (minus voltage drop over diodes) is 
established across capacitor C2. 
 Additionally, in order to keep the output supply relatively stable, the time constant 
of capacitor discharge through the LED branch should greatly exceed the period of the 
circuit operation: f!! = 73 nsec ≪ RC 
C ≫ 1fR = 113.56 MHz 225 kΩ = 327 fF 
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This condition is easily met given the small load imposed by the LED. 
 As a safety measure, a reverse-biased Zener diode can be put in parallel with the 
LED branch to limit the possible voltage developed in the circuit. Above VZener, 
breakdown causes the branch to act effectively as a short, drastically reducing the load 
resistance of the circuit and detuning it from resonance, thereby preventing additional 
power transfer.  
Feasibility of Battery Power  
 Given the nightly energy requirements (8 hour @ 280 nW) for rod dark current 
suppression over the retina of 8 mJ, detailed in section “Energetics of Dark Current 
Suppression”, it is possible to evaluate the feasibility of using a battery to power the 
LED. Assuming an LED luminous efficiency of 10%, this puts the LED power 
requirements at around 80mJ. Cymbet Corporation produces two rechargeable, solid-
state, bare die batteries in their EnerChipTM series that closely meet this requirement both 
in terms of energy and physical size: CBC005 (72 mJ, 5 uAhr, 4 V, 1.7×2.25×0.200 mm) 
and CBC050 (720 mJ, 50 uAhr, 4 V, 5.7×6.1×0.200 mm). Combined with a low-power 
ASIC it appears feasible to battery power the contact lens from a rechargeable battery, 
obviating the need for continuous nightly powering.  
 
Fabrication of Circuits and Lens 
 Based on the calculations in section “Design Calculations and Considerations”, a 
single-sided circuit board layout was produced to accommodate the necessary circuit 
components (Figure 5.10). The boards were first produced out of FR-4 to facilitate testing 
and subsequently reproduced using a flexible copper on Parylene C approach to enable 
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integration into a contact lens. Further details of the circuit board fabrication are given in 
Chapter 7. Components were sourced from Digi-key (Minnesota, USA) unless otherwise 
noted and are summarized in Table 5.4. 
 
Figure 5.10: Traces for wireless LED contact lens and constituent components. 
Table 5.4: Component specifications for wireless LED contact lens. 
Name Type Value Part # Package Purpose 
C1 Ceramic 
Capacitor 
100±1pF GRM0335C1
E101FA01D 
0201 LC-tank primary 
C2 Ceramic 
Capacitor 
1-25 pF 
 
Varies 0201 LC-tank tuning 
C3, C4 Ceramic 
Capacitor 
1 µF GRM033R60
J105ME11E 
0201 Rectifier and 
Voltage Doubler 
D1, D2 Schottky 
Diode 
0.28 V @ IF 
=1.0 mA 
NSR0140P2T
5G 
SOD923 Rectifier and 
Voltage Doubler 
DZ Zener 
Diode 
4.1V 
200 mW 
DZ9F4V1S9
2-7 
SOD923 Voltage 
Regulation 
LED Green 
LED 
518nm, 79mcd 
@ IF = 5.0 mA 
XZBGR155
W5MAV 
0201 Light Emission 
R1 Resistor 20-100 kΩ 
1/20 W 
RC0603F104
CS 
0201 Current Limiting 
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 Traces were produced by photolithographic patterning, etching, and photoresist 
removal. Solder paste (SMDLTLFP, Sn42 / Bi57.6 / Ag0.4, from Chipquik, NY) was 
applied to electrical pads and components were placed by hand under a microscope. Re-
flow soldering (140 °C for 1 min, 190 °C for 30 s) was used to form electrical 
connections between components and the traces and carried out on a Voltera V-One PCB 
Printer (Voltera, ON, CA). The operation of the circuit was subsequently evaluated by 
application of a 13.56 MHz magnetic field, which was observed to induce LED emission. 
 
Figure 5.11: Assembly of FR-4 circuit. A) Solder paste was applied to electrical pads 
and components were placed by hand under a microscope. B) Re-flow soldering forms 
electrical connections between components and traces. C) Application of a 13.56 MHz 
magnetic field induces LED emission. 
 The properties of the circuit were further characterized by performing a frequency 
sweep. An Agilent 33120A Function Generator (50 Ω output impedance) was used to 
drive a primary coil (1.85 µH, 11 turns, 11 mm diameter, 3 mm height, 291 µm diameter 
wire) to produce a magnetic field. The wireless LED circuit was placed directly 
underneath the primary coil. The voltage and frequency of the function generator were 
  
119 
swept to see the relative behaviour of the wireless LED circuit, which was probed by an 
oscilloscope across the resonant capacitor and at the DC output (Figure 5.12).  
 
Figure 5.12: Frequency response of wireless LED circuit on FR-4 board. (Top) RMS 
voltage across the capacitor of the LC-tank. (Bottom) DC voltage at the circuit output 
available to drive the LED. Sweep of primary coil driving voltage indicated in legend. A 
20 kΩ current-limiting resistor used in series with LED. 
 A Tektronix TBS 1064 oscilloscope was used to probe the frequency response of 
the circuit. This model of oscilloscope features an input impedance of 1 MΩ ±2% in 
parallel with 20 pF ± 3 pF and can therefore de-tune the circuit it is measuring due to the 
relatively small capacitance of the LC-tank (100 pF). To mitigate this, a 10× probe was 
used to reduce both de-tuning and loading. Loading of the LC circuit is effectively 
reduced by 10× to only 2 pF and thus the frequency deviation is expected to be 
maintained to 1%. 
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f!"#$%&'&f!"#$%$ = C!"#$%$C!"#$%&'& < 102pF100pF = 1.01 
The resonant frequency was measured to be 13.8 MHz, though accounting for the 
oscilloscope loading this is likely closer to 13.9 MHz. The value was deemed close 
enough to proceed with flexible circuit fabrication as slight variances due to curved coil 
geometry were anticipated to modify coil inductance and therefore shift the resonant 
frequency anyways.  
 The half wave voltage doubling circuit is shown to also function as intended, 
providing a rectified DC output of approximately double the tank RMS voltage. The 
effect of the reverse-biased Zener diode is observed once the rectified DC voltage 
approaches 4.1 V and results in a widening of the frequency response. It also effectively 
functions to limit the maximum rectified voltage.  
 Utilizing a copper-on-Parylene process, detailed in Chapter 7, flexible wireless 
LED circuits were produced suitable for integration into a curved geometry contact lens. 
Using photolithography, the copper-on-Parylene substrate (25.4 µm copper on 2.5 µm 
Parylene C) was patterned and etched to produce the desired traces. The trace geometry 
was modified slightly to position the LED within the center of the lens in order to ensure 
that light was transmitted through the pupil, despite constriction. The consequences of 
this are subsequently discussed in more detail. The circuit was then cut out and the jump 
wire was wrapped with Parylene to insulate it before being bent over and soldered to 
complete the loop. The circuit was then molded to a 20 mm diameter spherical cap in 
order to fit the geometry of the contact lens. Electrical components were soldered to the 
circuit via re-flow and the circuit resonance was measured and tuned by adding additional 
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capacitors as necessary to reach 13.56 MHz. The completed circuit was then encapsulated 
in silicone (Sylgaurd 184, Dow Chemical) via a 20 mm diameter mold. 
 
Figure 5.13: Fabrication of flexible copper on Parylene wireless LED circuit and 
integration into contact lens. (A) Copper traces etched from copper on 2.5 µm Parylene 
C substrate. (B) Copper trace is cut out, jump wire is soldered to complete loop, and the 
circuit is molded to a 20 mm diameter spherical cap. (C) Electrical components are 
soldered to the circuit via re-flow. (D) The completed circuit is encapsulated in a 
silicone contact lens. 
 The tuning of the contact lens was carried out using a similar setup to the FR-4 
board, featuring a primary coil driven by a signal generator. The resonant frequency was 
measured by sweeping the field frequency and monitoring the LED light output. This 
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avoided concerns with oscilloscope loading. The peak frequency response of the 
complete circuit was measured to be 14.1 MHz with the 100 pF capacitor. This is slightly 
higher than the 13.9 MHz for the FR-4 circuit as expected due to the reduced inductance 
of the coil as a result of shaping it to a spherical curvature. The necessary capacitor value 
to achieve 13.56 MHz is calculated as: 
C!"#$% = f!"#$%&"' !f!"#$%"! ! C!"!#!$% = 14.43 MHz !13.56 MHz ! 100 pF = 113 pF 
Therefore, additional capacitance of 12.5 pF (closest achievable with available 
components) was added to the circuit, shifting the resonant frequency to 13.6 MHz. The 
circuit was then encapsulated in silicone as described. Operation of the contact lens was 
demonstrated using a 13.56 MHz RFID reader (Figure 5.14). 
 
Figure 5.14: Completed wireless LED contact lens (A) under illumination and (B) in 
the dark. (C) Lens on finger for scale. 
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CHAPTER 6 – Permeability of Contact Lenses 
 
Key Take-Aways 
 
• Lens oxygen transmissivity is critical for corneal health. 
• Cavity-style lenses with high permeability filler allow for encapsulation of active 
components while maintaining high oxygen transmissivity. 
• Shelling impermeable components in highly permeable material allows oxygen to 
shunt around them, preventing localized corneal hypoxia. 
 
Historical and Future Perspectives on Gas Permeable Lenses 
 As we have learned from the historical development of contact lenses a major 
impediment to their adoption has been comfort and safety. In these regards, the 
importance of oxygen delivery to the cornea cannot be overstated. While today’s lens 
materials (rigid gas permeable and silicone hydrogel) have overcome the problem of 
oxygen delivery in conventional lenses, next generation “smart lens” concepts will 
introduce new challenges. Most active components are based on silicon and metal, both 
gas impermeable materials, and so embedding them into lenses poses a challenge with 
respect to oxygen delivery. This chapter will explore the importance of oxygen transport 
to the cornea through the contact lens and methods of incorporating active components 
into the lens while maintaining sufficient oxygen delivery. 
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Figure 6.1: Samsung’s smart lens for augmented reality features a large oxygen 
impermeable chip [160]. 
Corneal Anatomy 
 The cornea is the clear, central, fibrous tissue on which the contact lens sits. 
Consideration of key anatomical features of the cornea is important for safe contact lens 
design. Significantly, the cornea is avascular receiving much of its oxygen supply from 
atmospheric gas exchange through the tear film and relying on diffusion through its 
500µm thickness. The cornea is composed of 3 primary layers (and 2 interfacial boundary 
layers), from anterior to posterior: epithelium, (Bowman’s layer), stroma, (Descemet’s 
layer), and endothelium [18]. The epithelium is a non-keratinized, stratified squamous 
layer of 5-6 cells undergoing constant shedding/replacement to act as a permeability 
barrier to water and infection, and presenting an extensive glycocalyx to interact with the 
tear film. The stroma is composed of intricately arranged layers of collagen for optical 
clarity that is maintained by dispersed keratocytes (3-5% by volume) and provides the 
mechanical integrity of the cornea. The endothelium is a single layer of squamous cells 
important in the maintenance of corneal transparency and is located on the posterior side 
of the stroma. 
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Figure 6.2: Corneal cross-section with zoom-ins of epithelium (top), stroma (mid), and 
endothelium (bottom). Reprinted from [18]. 
 From a metabolic perspective, oxidative metabolism of glucose is the primary 
source of energy for the cornea [161]. While 85% of glucose is consumed through 
anaerobic glycolysis, only 2 ATP molecules are produced (along with 2 lactate 
molecules) compared to the 36 ATP from the Kreb cycle. Thus energy is produced 
roughly in a ratio of 1 anaerobic : 3 aerobic. Under normal conditions, the excess lactate 
diffuses across the endothelium into the anterior chamber. However, under hypoxic 
conditions significantly more lactate must be produced to maintain energy demands and 
this increases the tonicity of the fluid, leading to swelling [162]. Total oxygen flux into 
the cornea under normal conditions measures 6 µL/hr/cm2 and is distributed 40% 
epithelial, 39% stromal, 21% endothelial [163]. The aqueous humor, while the primary 
source of nutrients to the cornea, is only moderately oxygenated at roughly 55mmHg 
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(range of 24-72mmHg reported) [164]. Thus most corneal oxygen is derived from the 
atmosphere or palpebral vasculature. During sleep the tear film is in equilibrium with the 
palpebral vasculature (55 mmHg) and while eyes are open with atmosphere (155 mmHg). 
 
Figure 6.3: Contact lenses can induce corneal hypoxia by retarding oxygen transport 
from the atmosphere. Lactic acid produced under anaerobic metabolism draws water 
into the tissue contributing to corneal swelling. Reprinted from [18]. 
Target Permeability to Mitigate Corneal Swelling 
 The introduction of a contact lens over the cornea reduces the diffusional 
transport of oxygen from the atmosphere/eyelid to the anterior corneal tissue, which can 
result in hypoxia and swelling. Even when a patient sleeps without contact lenses the 
reduced oxygen available under the closed eyelid (palpebral conjunctiva: 55 mmHg) 
versus open eyelid (atmosphere: 155 mmHg) [165] results in central corneal swelling of 
around 4% [166]–[169]. This provides a physiological baseline from which to compare 
contact lenses of varying degrees of oxygen permeability. 
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Figure 6.4: Effect of hypoxia on corneal swelling in an eye adapted to overnight 
contact lens wear. Adapted from [18]. 
 The most commonly used metric to compare contact lenses is the oxygen 
transmissibility Dk/t, where D is the diffusion coefficient of oxygen in the contact lens, k 
is the solubility of oxygen in the contact lens, and t is the thickness of the contact lens. 
This comes from the solution of Fick’s Law (in combination with Henry’s Law) when 
applied to a slab of permeable material with a pressure gradient across it. Consider a slab 
of thickness t, with a solubility k and diffusivity D for a given gas in the slab material, 
that has a partial pressure difference of ΔP across it. Henry’s law of gas solubility states: C =  k ∙ P 
The concentration of gas at the interfaces of the material are then: C 0 =  k ∙ P 0  C t =  k ∙ P t  
By conservation of mass, the flux of gas through the slab must be constant. Fick’s law of 
diffusion states: 
J =  −DdCdx 
y = 14.629e-0.031x 
R² = 0.99674 
0 
2 
4 
6 
8 
10 
12 
14 
16 
0 10 20 30 40 50 
%
 C
or
ne
al
 S
w
el
lin
g 
Anterior Corneal Oxygen Tension (mmHg) 
  
128 
This can be integrated and solved using boundary condition from Henry’s Law to give: 
C x = C 0 − JxD C 0 − C t = k ∙ ∆P = JtD J = Dkt ∙ ∆P 
Higher transmissibility means the lens imposes a lower barrier to oxygen diffusion and 
therefore has less effect on the oxygenation of the cornea. The utility of this metric can be 
appreciated by analogy to electrical circuits in Table 6.1.  
Table 6.1: Electrical analogies of gas diffusive transport. 
Parameter Oxygen System Electrical System 
Potential ΔP, Partial Pressure ΔV, Voltage 
Sheet 
Conductance 
Dk/t, D is the diffusion 
coefficient of oxygen in the 
contact lens, k is the solubility of 
oxygen in the contact lens, and t 
is the thickness of the contact lens 
G/A = σ/L, where L is the length of 
the conductor, A is the cross-
sectional area of the conductor, σ is 
the electrical conductivity, G is the 
conductance 
Flux/Current 
density 
J, the molar flux of oxygen J = I/A, where I is the current, A is 
the cross-sectional area of the 
conductor, J is the current density 
Ohm’s Law J = (Dk/t)ΔP J = (σ/L) ΔV 
 
 Since diffusional oxygen transport has an analogous form to Ohm’s law, the 
treatment and interpretation of transmissibility is straightforward. As a first 
approximation, the contact lens can be considered as an additional diffusional resistance 
in series with the corneal tissue resistance to oxygen (Rcornea):  
R!"!#$ = R!"#$%& ∙ (Dk/t)!!R!"#$%& + (Dk/t)!! 
In the case that (Dk/t)-1 >> Rcornea, oxygen flux is limited by the lens; in the case that 
(Dk/t)-1<< Rcornea, oxygen flux is limited by the tissue. Historically, Dk/t was used as a 
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metric for comparison of lenses because early lenses operated in the lens-limiting regime 
and hence a lens of 20 Fatt would be twice as good as a lens of 10 Fatt; however, as lens 
transmissibility has improved, the regime is closer to cornea-limiting and hence a 200 
Fatt lens is not twice as good as a 100 Fatt lens [170]. With respect to corneal hypoxia, 
higher transmissibility lenses are superior but the therapeutic benefit diminishes as the 
lens transmissibility exceeds that of the corneal tissue. 
 The transmissibility at which corneal swelling is kept within acceptable ranges 
(4%, i.e. same levels as without lens under closed eye conditions) was determined to be 
87 Barrer/cm [166] and little to no additional benefit has been demonstrated for lenses 
beyond this transmissibility. For prevention of anoxia throughout the entire corneal 
thickness under closed eye conditions, a slightly higher transmissibility of 125 Barrer/cm 
is needed [171]. Another concept commonly used in the discussion of contact lens 
transmissibility is the equivalent oxygen percentage (EOP), which is the resulting oxygen 
level at the anterior surface of the cornea when a lens is worn. For a completely 
permeable lens, an EOP of 20.9% is expected in an open eye [166], [172]; empirically, 
EOP (%) = 6.195 ln (Dk/L×109) - 9.778. Figure 6.5 plots the relationship between EOP 
and Dk/L. 
 The consequences of corneal swelling depend on the degree and duration of 
hypoxia. In the acute situation, visible striations and folds begin to form on the cornea at 
4-6% corneal swelling; at around 13% corneal swelling visual disturbances occur. The 
recommended limit for swelling has been proposed as 8%, which allows for rapid 
deswelling of the open eye following sleep [166]. In the chronic situation, hypoxia 
induced by overnight contact wear causes a number of physiological changes, including: 
  
130 
epithelial microcysts, corneal neovascularization, endothelial polymegethism (higher than 
normal variation in cell size), slowed epithelial healing, increased bacterial binding and 
corneal infection, among others.  
 
Figure 6.5: EOP versus transmissibility of contact lenses. Reprinted from [173]. 
 
Gas Permeable Materials for Contact Lenses 
 In the 1960’s, the importance of oxygen transmissibility in contact lenses became 
appreciated and efforts to develop replacement materials for PMMA took off. Silicone 
rubbers were identified as one candidate due to their higher oxygen permeability, in 
excess of 1000× that of PMMA. Unfortunately, the hydrophobicity and elasticity of the 
polymer causes it to stretch and de-wet the tear film during blinking, leading to binding 
of the lens to the cornea. Methods of surface treatment such as oxygen plasma and 
grafting to render the lenses hydrophilic are temporary due to the tendency of the highly 
mobile chains to reorient.  
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 Another class of materials known as rigid gas permeable polymers was developed 
by successive modification of PMMA to improve oxygen permeability. While the 
specific composition of RGP lenses vary, they are generally composed of tris(trimethyl-
siloxy)-methacryloxy-propylsilane (TRIS), a fluoroalkyl methacrylate, and methyl 
methacrylate. The hydrophilic co-monomers imbue hydrophobicity to the polymer while 
the siloxy and fluoralkyl methacrylates improve oxygen permeability. The resulting 
material is quite stiff but achieves oxygen permeability on the order of 100× PMMA, 
while maintaining superior wettability compared to silicone rubbers. 
Permeability of PDMS and Rigid Gas Permeable Materials 
 The permeability of clinically relevant RGP and silicone rubbers are indicated in 
Table 6.2 with comparisons made to air and water. 
Table 6.2: Permeability of common contact lens materials. 
Polymer System Permeability (Dk) Comment 
HDS 100 100 [174] 
MED4-4210 ~650 Measured 
Menicon Z 163 [175] 
Water 99 [165] 
Air 25000000 [176] 
  
Conventionally, permeability Dk is given in units of Barrer, where: 
1 barrer = 10!!"  cm!"#! ∙ cmcm! ∙ s ∙ cmHg 
Transmissibility Dk/t is given in units of Fatt, where: 
1 fatt = 10! barrercm = 1 barrer100µm = 10!!  cm!"#!cm! ∙ s ∙ cmHg 
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Measurement of Silicone Dk/t 
 To measure the permeability of silicone, MED4-4210 PDMS was cast into a 
uniform 120 µm film and placed in a custom apparatus that measures the oxygen 
permeability of membranes. The membrane seals a small compartment of known volume 
and cross-section that contains an oxygen probe. Oxygen gas is blown over the exterior 
surface of the membrane while the interior oxygen concentration of the compartment is 
monitored. From the resulting plot, the permeability of the MED-4210 membrane was 
computed to be 650 Barrer.  
Design of Gas Permeability Apparatus 
 Assume a well-mixed volume of gas (V) surrounded by impermeable 
walls/bottom and covered with a permeable membrane of given thickness (L) and surface 
area (A). From the ideal gas law: PV = NRT 
Differentiating with respect to time: dPdt V = dNdt RT 
From membrane permeation theory and conservation of mass: dNdt = −J ∙ A = − −D ∙ k ∙ P!"# − PL ∙ A = − DkL ∙ P− P!"# ∙ A 
Combining equations: dPdt V = − DkL ∙ P− P!"# ∙ A ∙ RT dPdt V = − DkL ∙ P− P!"# ∙ A ∙ RT 
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Solving the differential equation: 
P(t) = P! − P! ∙ e !!!!!"#$% +P!, where τ!"#$"%&'() =  !!"! !"# 
Verifying well-mixed condition for a membrane of permeability Dk: 
τ!"# = L!"#"!$%&!!D!!:!"# ≪ τ!"#$"%&'() 3.2mm !17.6mm!s = 0.58s ≪ 543mm
!Dk [barrer]0.12mm ∙ 184mm! ∙ 2476Jmol = 426886 sDk [barrer] Dk ≪ 736000 barrers  
Thus the setup is appropriate for characterizing virtually all known materials. 
 An embedded needle-type, fluorescence-based oxygen probe (FOXY-AL300 
from Ocean Optics, FL; refurbished by White Bear Photonics, MN) recorded oxygen 
concentration (Reader Model NEOFOXGT-NFG0739 from Ocean Optics, FL) within the 
apparatus volume during a step from atmosphere to nitrogen gas blowing over the 
exterior surface of the tested membrane. The resulting data was fit with an exponential 
equation in MATLAB using the nlinfit function of the form: f t = a ∙ e!∙! + c 
For calculation/conversion to permeability, the following formula is used: 
Dk [Barrer] = b s!! ∙ V cm! ∙ L [cm]A cm! ∙ 1R[cm! ∙ atm ∙ mol!!] ∙ T[K]∙ 22400 cm!"#!mol ∙ 176 atmcmHg ∙ 10!" 
Dk [Barrer] = b s!! ∙ V [cm!] ∙ L [cm]A cm! ∙ 182 [cm! ∙ atm ∙ mol!! ∙ K!!] ∙ 293[K]∙ 22400 cm!"#!mol ∙ 176 atmcmHg ∙ 10!" 
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Dk [Barrer] = b s!! ∙ V [cm!] ∙ L [cm]A cm! ∙ 1.23 ∙ 10!  cm!"#!cmHg ∙ cm!  
For calculation/conversion to transmissibility, the following formula is used: DkL [Fatt] = b s!! ∙ V [cm!]A cm! ∙ 1R[cm! ∙ atm ∙ mol!!] ∙ T[K]∙ 22400 cm!"#!mol ∙ 176 atmcmHg ∙ 10! DkL [Fatt] = b s!! ∙ V [cm!]A cm! ∙ 182 [cm! ∙ atm ∙ mol!! ∙ K!!] ∙ 293[K]∙ 22400 cm!"#!mol ∙ 176 atmcmHg ∙ 10! DkL [Fatt] = b s!! ∙ V [cm!]A cm! ∙ 1.23 ∙ 10!  cm!"#!cmHg ∙ cm!  
 
Table 6.3: Measurement and calculation of silicone oxygen transport properties 
Sample |b| Area Volume Thickness Dk/L [Fatt] Dk [Barrer] 
PDMS 0.00152 1.84cm2 0.543cm3 0.012cm 550 662 
 
Cavity-Style Design for Smart Lenses  
 Smart lenses look to integrate functionality beyond vision correction into the 
contact lens. However, most active components (e.g. sensors, LEDs, microchips) are 
based on silicon and metal, both gas impermeable materials, and so embedding them into 
lenses poses a challenge with respect to oxygen delivery. What is needed is a contact lens 
platform that enables easy encapsulation of active components without affecting the 
oxygen transmission of the overall lens. 
 In this work, a cavity style lens is developed that may act as such a platform. By 
bonding two lenses with slightly different curvatures together along their peripheral 
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edges, one can produce an internal cavity to house active components. The cavity may be 
filled with a highly-gas permeable filler material for structural reasons or to prevent 
accumulation of fluid. Two filler materials are considered in this work: PDMS, well 
known for its high oxygen permeability and hydrophobized Vycor, a new material 
developed in the MEMS lab with exceptional gas transport properties. This novel lens 
geometry and corresponding design considerations are outlined in the following section. 
In particular, the mechanism by which the composite lens overcomes oxygen 
transmissibility concerns is developed.  
 
Figure 6.6: Cavity style contact lens formed by bonding two lenses of different 
curvature along a complimentary peripheral edge. 
Simulations of Cavity-Style Lens Gas Transmissibility 
 To understand the design space, a 3D COMSOL model was made of such a 
composite contact lens with an inner 400 µm cavity, housing 24 GTLS (300 µm D x 2 
mm) as a relevant example. Top and bottom lens thicknesses, RGP material, and cavity 
filler material (e.g. air, hydrophobized Vycor, or PDMS) were varied and the resultant 
transmissibility of the lens were measured. Figure 6.7 depicts this geometry (note: 
corneal tissue was excluded from this modeling). The results are summarized in Table 6.4 
and are color-coded according to hyper, super, high, or medium gas transmissibility 
based on the standards set by [173]. 
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Table 6.4: Transmissibility of cavity style lens of various lens thickness and filler 
material. Hyper (green), Super (yellow), High (orange), and Medium (Red) 
transmissivity indicated. 
Lens Thickness 
[µm] 
RGP Material 
Dk [Barrer] 
Cavity Filler 
Material 
Transmissibility 
Dk/t [Fatt] 
50 163 Air 161 
50 163 Vycor 155 
50 100 Air 99 
50 100 Vycor 97 
50 163 PDMS 83 
100 163 Air 81 
100 163 Vycor 80 
50 100 PDMS 63 
100 163 PDMS 55 
150 163 Air 54 
150 163 Vycor 53 
100 100 Air 50 
100 100 Vycor 49 
150 163 PDMS 41 
100 100 PDMS 38 
150 100 Air 33 
150 100 Vycor 33 
150 100 PDMS 28 
 
 The analysis demonstrates that it is possible to design high transmissibility 
contact lenses suitable for overnight wear by utilizing a cavity-style design. Oxygen is 
able to shunt around the gas impermeable components within the lens, thereby mitigating 
their effect. For comparison, a similarly sized lens of solid Menicon Z would have an 
oxygen transmissibility of less than 33 Fatt, unsuitable for overnight use. 
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Experimental Validation of Cavity-Style Lens Approach 
 Using the RGP lenses from Chapter 4 and a similar setup and approach to section 
“Measurement of Silicone Dk/t”, the transmissibility of cavity style lens prototypes was 
carried out. The transmissibility of the top lens, bottom lens, an empty paired set of 
lenses, and a paired set of lenses containing a GTLS lighting system was measured and 
the results are summarized in Table 6.5.  
 
Table 6.5: Oxygen transmissibility of cavity-style contact lenses and related 
components. (*) Accounting for effect of setup on paired lenses. 
Sample |b|  
[s-1] 
Area 
[cm2] 
Volume 
[cm3] 
Thickness 
[cm] 
Dk/L  
[Fatt] 
Top Lens 0.0005618 0.341 0.0299 0.018 60 
Bottom Lens 0.000721 0.328 0.036 0.018 97 
Empty Pair 0.0004089 0.341 0.0299 0.096 44, 37* 
GTLS Pair 0.000282 0.341 0.0299 0.096 30, 26* 
PDMS 0.00470 0.00776 0.316 0.0534 0.012 
975 
1610 
PDMS + diX-A 0.000607 0.000635 0.316 0.0534 0.012 
126 
132 
 
 Briefly, the lens sat on top of an o-ring and was gently compressed against an 
acrylic plate, with a small hole for the oxygen probe, to form a sealed gas test volume. 
Oxygen was blown over the outside of the lens and the change in the interior oxygen 
concentration was measured. The volume of the gas compartment was measured by 
filling it with water and measuring the mass change of the system to account for slight 
variations in geometry due to different lens curvatures. The area of the lens interfacing 
with the gas compartment was calculated from the known diameter of the o-ring seal and 
the base curvature of the contact lens, which enable the spherical cap area to be 
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calculated. Oxygen profiles were fit with an exponential function and the rate constant b 
was extracted and used to calculate transmissibility based on the known geometry of the 
setup.   
 In the setup, due to the hollow cavity the entire bottom lens is exposed to oxygen, 
while only the indicated area of the top lens interfaces with the test volume. 
Consequently, the transmissibility of the lens is measured higher than reality. This is 
accurately predicted by scaling the transmissibility of the bottom lens by its relative 
exposed surface area compared to the top lens and then calculating the series 
transmissibility: 
Dkt !"#$%&'#$ = 1A!"##"$A!"# Dkt !"##"$ + 1Dkt !"#
!! = 10.5620.341 ∙ 97+ 160  !! = 44 
This is in agreement with what is measured by the setup. In reality, the series 
transmissibility of the paired lenses should be: 
Dkt !"#$%#!&'() = 1Dkt !"##"$ + 1Dkt !"#
!! = 197+ 160  !! = 37 
The measured values can then be corrected by scaling accordingly: 
Dkt !"##$!%$&,!"#$ = Dkt !"#$%#!&'(),!"#$%Dkt !"#$%&"',!"#$% ∙ Dkt !"#$%&"',!"#$ = 3744 ∙ 30 = 26 
Corrected values are indicated by (*) in Table 6.5. 
 Note that the lenses used in this experiment have a central thickness of 180 µm, 
which is quite thick, compared to what is technically achievable, and thus the absolute 
transmissibilities measured are relatively low compared to overnight wear lenses. 
  
139 
However, the relative performance of the cavity style lens concept can still be evaluated 
with the understanding from earlier simulations in Table 6.4 that transmissibility will 
scale nearly linearly with lens thickness. 
 The cavity-style lens filled with a GTLS lighting system is observed to have a 
transmissibility within 70% of the empty cavity-style lens, despite it containing gas 
impermeable components occupying >99% of the lens area over which transmissibility 
was measured. This result demonstrates that oxygen is able to transport around the 
impermeable components within the lens cavity, thereby mitigating their impact on 
overall lens transmissibility.  
 
Modeling Oxygen Profiles in Cornea 
 As a metric, transmissibility is useful in its simplicity. However, what ultimately 
matters is the oxygenation of the underlying corneal tissue. As lens geometries become 
more complex, including the encapsulation of impermeable components, it is important 
to have a more detailed picture of oxygen transport.  
 To this end, the 3D COMSOL model of the phototherapy contact lens was 
extended to include a corneal layer composed of epithelium, stroma, and endothelium 
(Figure 6.7). Standard Michaelis-Menten kinetics for oxygen consumption are utilized 
with tissue parameters collected from literature and summarized in Table 6.6. 
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Table 6.6: Parameters of oxygen transport in the cornea. (*) Indicates primary source 
in cases where references are daisy-chained. Where multiple independent sources were 
found for a given parameter, the one used in the simulations is indicated in bold. Note, 
Dk for corneal tissue is decomposed using kO2,water. 
Parameter Value [unit] Reference Comment 
DkO2,endothelium 5.3 [barrer] [170], [177]*  
DkO2,stroma 29.5 [barrer] [170], [177]*  
DkO2,epithelium 18.8 [barrer] [170], [177]*  
DkO2,tear 78 [barrer] [170]  
DkO2,water 99 [barrer] [165]  
DkO2,cornea 86 [barrer] [165]  
DkHDS100 100 [barrer] [174]  
DkMeniconZ 163 [barrer] [175]  
kO2,water 1.12 [mol/m3/atm] [165]  
kO2,water 1.09 [mol/m3/atm] [178]  
DO2,PDMS 3.4E-9 [m2/s] [179]  
kO2,PDMS 8 [mol/m3/atm] [179]  
DO2,Vycor 7.36E-8 [m2/s] Measured  
kO2,Vycor 9.22 [mol/m3/atm] [180]  
DO2,Air 2.2E-5 [m2/s] [181],[182]  
kO2,Air 8 [mol/m3/atm] Ideal Gas Law  
Ltear film 3 [µm] [170]  
Ltear film 150 to 350 [µm] [165]  
Lepithelium 50 [µm] [170], [165]  
Lepithelium 40 [µm] [163] Rabbit 
Lstroma 480 [µm] [170], [165]  
Lstroma 359 [µm] [163] Rabbit 
Lendothelium 1.5 [µm] [170], [165]  
Lendothelium 4 [µm] [163] Rabbit 
Lendothelium 5 [µm] [183] Human 
Popen eye 155 [mmHg] [170], [165]  
Pclosed eye 61.5 [mmHg] [170], [165], [184]*  
Paqueous humor 24 [mmHg] [170], [165]  
Paqueous humor 55 mean, 24-72 [mmHg] [164],	[185]*  
QO2, endothelium -2.13E-2 [mol/m3/s] [170], [171]  
QO2, endothelium -6.29E-2 [mol/m3/s] [163] Rabbit 
QO2, stroma -1.02E-3  [mol/m3/s] [170], [171], [163]*  
QO2, epithelium -1.16E-2  [mol/m3/s] [170], [171], [163]*  
QO2, corneal -4.69E-3 [mol/m3/s] [165]  
QO2, corneal -2.57E-3 [mol/m3/s] [186]  
QO2, corneal -2.68E-3 [mol/m3/s] [187]  
Tcornea, eye open, 25°C 32 [°C] [188]  
Tcornea, eye closed, 25°C 34 [°C] [188]  
Km 20 [mmHg] [189]  
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Figure 6.7: Model of composite contact lens on top of cornea used for simulations. 
Lens consists of an upper and lower lens of RGP (blue), filler material within the lens 
cavity (cyan), and GTLS (clear cylinder). Cornea consists of epithelium (grey), stroma 
(yellow), and endothelium (red, note: 10× thickness for visualization). Symmetry 
conditions on front and back face of model are applied to simplify computation. 
 The model allows for investigation of profile heterogeneity due to inclusion of 
impermeable components, edge effects, etc. Figure 6.8 compares three lenses: a 
monolithic PDMS lens and two cavity style lenses (50 µm top/bottom RGP lenses) with 
air and PDMS filler, respectively. Oxygenation is observed to be consistent over the 
contact lenses despite the inclusion of the impermeable GTLS, highlighting the 
effectiveness of cavity style designs.  The monolithic PDMS lens provides superior 
oxygenation of the cornea. 
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Figure 6.8: Slices of oxygen tension throughout contact on cornea COMSOL model 
for a monolithic PDMS lens and two cavity style lenses (50 µm top/bottom RGP lenses) 
with air and PDMS filler, respectively. 
 
Effect of Embedding Impermeable Components in Lenses 
 When an impermeable component is embedded into a contact lens it obstructs 
oxygen transmission, especially if its dimensions are at least comparable to the lens 
thickness. In these cases, the effective transmissibility is reduced to 
!"! ! = !"! !!"#$!!!"#$%&'$(!)!!"#$ , which can become significant for large or numerous 
components. 
 A strategy for overcoming this problem is to design a high permeability shell 
around the impermeable component to shunt oxygen. This can be accomplished by 
oversizing the cavity slightly to leave an air path or by encapsulating the component in a 
high permeability material like silicone. The relationship between component size, shape, 
shell thickness, and shell permeability are computed numerically. 
 Two geometries are considered and modeled in 2D: a rectangular (3 mm wide × 
300 µm thick) and cylindrical (300 µm diameter) obstruction. The lens is composed of a 
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top and bottom portion, each 50 µm thick. The lenses are separated by a 400 µm void 
space of filler. The obstruction has a 50 µm shell around it. The composition/permeability 
of the filler and shell material are varied to understand the implications on overall lens 
performance. 
Rectangular Obstruction in Lenses 
 A rectangular obstruction would include a silicon chip embedded in a contact lens 
and is therefore of interest. Figure 6.9 summarizes the simulation results for a rectangular 
obstruction as a function of shell and filler materials.  
 
Figure 6.9: Oxygen profiles of lenses containing a 3 mm wide × 300 µm thick 
rectangular obstruction (white) with symmetry about right edge indicated by dashed 
mirror line. Upper and lower lenses are RGP; filler as indicated: Vycor, PDMS, RGP; 
and shell as indicated: air, Vycor, PDMS, water. 
 The obstruction can be modeled as a reduction in the effective surface area of the 
lens by comparing transmissivity with and without the obstruction: 
𝐴!"#$%&'$(!) = 𝐴!"#$ 1− 𝐷𝑘𝑡 !𝐷𝑘𝑡  
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Note that the transmissivity of the unobstructed lens !"!  should be for a geometry with 
the minimum void width to enclose the obstruction, not the obstruction and shell. 
Otherwise, the metric biases towards the addition of a shell despite the fact that adding 
the shell can increase overall void width and hence the decrease the transmissivity of the 
rest of the lens that would otherwise have been higher.  
 To measure the effectiveness of the shell in shunting oxygen around the 
obstruction, a useful metric is to compare the effective obstruction area, Aobstruction, to the 
projected area of the obstruction, Aprojected. For Aobstruction/Aprojected < 1, the shell acts to 
reduce the obstruction; at Aobstruction/Aprojected = 0 the shell completely eliminates the 
obstruction; for Aobstruction/Aprojected < 0 the shell is shunting oxygen more effectively than 
transmission through the unobstructed lens, thereby increasing the effective surface area 
of the lens. Figure 6.10 plots this metric for the various lens combinations. 
 
Figure 6.10: Effect of shell permeability (air, Vycor, PDMS, water) on effective 
obstruction area for a rectangular object. 
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As can be observed, for relatively large obstructions (e.g. 3 mm width) it is necessary to 
include an air shell (50 µm) around the object in order to avoid reductions in 
transmissivity; smaller air shells could be utilized but achieving such tolerance at these 
scales becomes challenging.  
Cylindrical Obstruction in Lenses 
 Similarly, a cylindrical obstruction is considered as it models the inclusion of 
GTLS elements within the lens. Figure 6.11 summarizes the simulation results for a 
cylindrical obstruction as a function of shell and filler materials.  
 
Figure 6.11: Oxygen profiles of lenses containing a 300 µm diameter cylindrical 
obstruction (symmetry about right edge, dashed mirror line). Upper and lower lenses 
are RGP, filler as indicated (Vycor, PDMS, RGP), and shell as indicated (air, Vycor, 
PDMS, water). 
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 A similar analysis as performed in section “Rectangular Obstruction” can be done 
to measure the effectiveness of the shell in shunting oxygen around the cylindrical 
obstruction. Figure 6.12 plots this metric for the various lens combinations. Given the 
smaller dimensions of the obstruction, lower permeability shell material can be effective. 
 
Figure 6.12: Effect of shell permeability (air, Vycor, PDMS, water) on effective 
obstruction area of a cylindrical object. 
Min and Max Values of Transmissivity and Overall Lens Design Optimization 
 Lens design should be optimized to maximize lens oxygen transmissibility with 
possible constraints on minimum local transmissibility. The constraint is not well 
established in the literature as most lenses have a thick central region without 
obstructions and this is taken as the transmissibility of the lens. However, the 
encapsulation of impermeable components into the lens could cause underlying corneal 
oxygenation to be low, since lateral diffusion of oxygen is negligible over component 
length scales. This necessitates consideration of local transmissivity, which is taken as the 
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local flux through the bottom surface of the lens divided by the partial pressure difference 
across the lens, !"!  (𝑥) = 𝐽 𝑥 /∆𝑃.  
 While clinically acceptable levels of localized corneal hypoxia have not been 
characterized, the previous guidelines of corneal flux (6 µl/hr/cm2 [163]) or Michaelis-
Menten constant for corneal oxygen uptake (20 mmHg [189]) may be considered. The 
COMSOL simulations of rectangular obstructions are extended here to include 
underlying corneal tissue oxygenation (Figure 6.13), from which corneal flux is also 
calculated (Figure 6.14). Regions of the cornea below the 20 mmHg threshold are 
indicated by a contour line. 
 
Figure 6.13: Effect of rectangular obstruction in contact lens on corneal oxygenation. 
Shell and filler materials are indicated for the composite lens. White contour lines 
demarcate regions below Michaelis-Menten constant of cornea, Km = 20 mmHg. 
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Figure 6.14: Effect of rectangular obstruction in contact lens on corneal oxygen flux 
to underlying corneal tissue. Shell materials are indicated in the legend with filler 
materials of either PDMS (solid) or air (dashed). 
 Compared to the regular oxygen profile under homogenous contact lenses, where 
hypoxia increases through the tissue depth, an embedded obstruction can cause the most 
severe hypoxia to occur in the epithelium. This may exacerbate corneal edema since it 
increases the diffusional distance lactate must travel for clearance into the aqueous 
humor. Another consideration is that local corneal edema may change the profile of the 
cornea resulting in poor lens fitting. Lifting of the lens may result in a tear film forming 
underneath which further decreases the oxygen permeability of the other portions of the 
lens. Consideration of local oxygen transmissibility will be important in future contact 
lens designs featuring embedded components.  
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CHAPTER 7 – Fabrication Techniques 
 
Key Take-Aways 
 
• High resolution molds for casting PDMS parts can be fabricated utilizing a dry-
film photoresist process 
• Electrochemical etching provides a rapid means of producing high resolution 
metal parts 
 
Dry Film Photoresist Molding 
Need for High Resolution Molds 
 The rapid fabrication of high-resolution molds is of great utility in MEMS, 
especially for the casting of silicone parts (e.g. contact lenses, intraocular lenses, 
implants). Conventional approaches for mold making include CNC milling, lathing, and 
electrical discharge machining. However, these approaches are generally slow and 
expensive for high-resolution molds. An alternative method is to produce molds using 
negative photoresists (e.g. SU-8 epoxy), which involves the alternating steps of 
depositing a resist layer followed by UV exposure to pattern the layer [190]. For 
relatively thin molds, such as those used in microfluidics, this process is quite reliable, 
quick, and provides good resolution. However, for parts requiring relatively thick molds 
(i.e. >100-200 µm) or large molds, SU-8 can prove challenging due to its sensitivity to 
the processing parameters [191].  
 This need led to the initial development by Nicholas Scianmarello and Jun Park of 
an analogous photo-patterned negative photoresist process utilizing dry-film photoresist 
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instead. Dry-film photoresists generally consist of a photosensitive layer of negative 
resist sandwiched between a polyester film carrier layer and a polyethylene film 
protective layer [192]. Monomer, photo initiator, adhesion promoter, binder, and dye 
comprise the photosensitive layer. Exposure of the photosensitive layer to UV results in 
the production of free radicals via the photo initiator, which induces polymerization of 
the monomer. Unexposed regions can be removed with a developer that dissolves the 
monomer and binder. Dry-film is available in thickness from 1-150 µm and is typically 
laminated onto a substrate, providing a uniform thickness of resist, free of edge-bead. 
Sequential lamination and exposure of dry film layers followed by development allows 
for the facile production of high-resolution molds. 
 
Figure 7.1: High-resolution dry film photoresist mold for PDMS contact lens 
fabrication. 
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 Over the course of this thesis work, the dry film photoresist molding process has 
been used extensively and several optimizations to the process have been made, resulting 
in better mold fidelity and yield. The point of this chapter is to outline this optimized 
process and explain the rational behind it. 
Optimized Process for Dry Film Molds 
 A flat substrate (e.g. silicon wafer or glass slide) is thoroughly cleaned. A Piranha 
bath (3 H2SO4 : 1 H2O2, 120 °C, >10 min) followed by an extensive rinse in DI water is 
generally advised, although rinsing with acetone, IPA, DI water may be sufficient. The 
substrate should be dried prior to use under nitrogen.  
 A laminator (Eagle 35 from GBC, IL) was used in this process along with WBR 
2000 Series dry film photoresist of 120 µm thickness (WBR2120 from DuPont, USA) 
[193]. The dry film is installed on the laminator such that the polyester carrier film is 
peeled away, leaving only the polyethylene layer and resist layer going over the heated 
roller with the resist layer facing outwards. The roller temperature should be set to 95°C, 
the pressure lever set in the 3rd position, and the speed set to 1.  
 The substrate is placed on a carrier sheet to help pull it through the laminator as 
well as to prevent the dry-film from laminating itself to the bottom roller. Lint-free 
cleanroom paper or waste polyester sheeting from previous runs works well. It is 
recommended that an initial layer of dry film photoresist is applied to the wafer, trimmed 
with a fresh razor blade around the edge of the substrate, and exposed (260-520 
mJ/cm2/120 µm), excluding a small peripheral border, to provide strong adhesion to the 
substrate as well as provide an ideal surface for the bonding of small features on 
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subsequent layers. If this is not done, such features are liable to release from the substrate 
during the final development step.  
 Additional layers of dry film resist are laminated similarly, making sure to 
remove the protective polyethylene film between successive laminations. The desired 
thickness of the layer is achieved through multiple laminations prior to exposure.  
 When constructing a mold composed of multiple layers, there are two approaches 
each with strengths and drawbacks. In the first approach, all lamination and exposure 
steps are done sequentially without intermittent soft baking as is recommended by the 
manufacturer (65 °C, 20 min) to improve adhesion to the substrate. The rationale is that 
during soft baking there is contraction of the resist layer, which induces a tensile stress in 
the resist. Repeated lamination and soft baking causes this stress to add with each layer, 
leading to significant wafer bowing and increased risk of delamination. Another 
consideration is the 20 min dwell time significantly slows down the process. One of the 
drawbacks of this approach is that the resist has not contracted prior to exposure so the 
fidelity between mask and mold geometry is not perfect. In most cases, the slight 
difference is acceptable due either to the fact that all parts are similarly scaled, that the 
elasticity of the PDMS cast in the molds can accommodate slight mismatches in 
geometry, or that the contraction of PDMS during curing (e.g. to 98% of designed linear 
dimensions in Sylguard 184) is more significant. For a cleaned substrate, it is generally 
unnecessary to perform a soft bake and the adhesion between successive layers of 
photoresist is sufficiently strong; however, if one is having adhesion problems to the 
substrate itself, performing a soft bake after the initial resist layer is laminated may 
alleviate these problems.  
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Figure 7.2: Optimization of soft baking conditions for dry film photoresist. (Left) Edge-
to-edge mirror flat surface achieved after soft bake with PE film removed and carrier 
border remaining. (Middle) Waves appear in the resist film if PE film is left on during 
soft baking. (Right) Contraction of photoresist film occurs if carrier border is removed 
prior to soft bake. 
 In the second approach, the dry film is soft baked (65 °C, 20 min) after each (set 
of) lamination(s). If this is done, it is critical to remove the protective polyethylene film 
before baking otherwise differential thermal expansion between the polyethylene and the 
photoresist layer will compromise flatness. The advantage of this approach is that the 
film has constricted prior to exposure so that the fidelity of the mold and mask is optimal; 
however, the multiple soft bakes required slow down the process. Additionally, the 
removal of the polyethylene film now introduces the risk of resist adhesion to the mask 
glass during exposure. The user can either reapply the removed polyethylene layer or pre-
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coat the mask with >1 µm of Parylene (e.g. C). Pre-coating masks with Parylene results 
in a superior top surface finish of the layer compared to reapplying polyethylene, which 
tends to imprint texture as observed in Figure 7.3.  
 
Figure 7.3: Considerations for exposure. (Left) Adhesion of photoresist to glass mask 
during exposure can lead to delamination of mold. (Middle) Re-application of PE film 
prevents adhesion but imprints film surface. (Right) Coating mask with Parylene 
prevents adhesion and maintains a smooth top surface. 
 For molds composed of multiple layers, it is necessary to perform alignment with 
marks on the photoresist. Unfortunately, the contrast between exposed and unexposed dry 
film is very subtle and the transparency of thick dry film is low making the process of 
alignment difficult or impossible. If alignment is needed, it is recommended that a piece 
of polyethylene film be placed over the alignment marks of the bottom layer prior to 
lamination of the next layer, locally preventing adhesion. Then with a razor blade, the 
overlaying dry film can be cut and peeled away to reveal the alignment pattern, as shown 
in Figure 7.4. If needed, a drop of developer can be placed on the alignment mark to 
locally develop it to improve contrast during the alignment process. 
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Figure 7.4: Removal of overlaying dry film resist ensures that alignment marks are 
visible. 
 Once the lamination and exposure of the various layers is complete, the mold 
should be post-exposure baked to complete polymerization of exposed regions (85 °C, 25 
min) and allowed to cool gradually to room temperature. Development of the dry film 
photoresist is carried out in a solution of 1 part AZ 340 to 4 parts DI-water under 
agitation. It is convenient to carry this out in a cylindrical dish with a stir bar (~300 rpm 
is sufficient) and wafer holder. Place the wafer in a wafer holder so that the dry film 
photoresist side is facing down and is high enough that it will not contact the stir bar. Tilt 
the dish to ensure there are no air bubbles under the wafer. Development takes 
approximately 5 min per layer. Development can be accelerated by running the wafer 
under DI-water once the unexposed dry film photoresist has turned milky in color. This 
reduces the amount of time that the wafer is in developer and hence reduces the 
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likelihood of delamination. Since delamination occurs due to developer attack at the dry 
film resist and substrate interface, it is recommended that an unexposed periphery be left 
on the bottom most layer to act as a sacrificial region, preventing infiltration of 
developer. Alternatively, a specialized dish can be used that seals against the mold to 
contain the developer directly over regions to be developed and away from the peripheral 
edge of the dry film resist and substrate. Either approach practically eliminates the mold 
delamination, which is otherwise a significant cause of low yield.  
 Once development is complete, the mold should be thoroughly rinsed in DI-water, 
spin dried, and allowed to equilibrate at room temperature and humidity. This is 
necessary to prevent warping and delamination from occurring during subsequent 
exposure to vacuum if Parylene coating is carried out as a mold release layer for PDMS. 
A 5-10 µm coating of Parylene is sufficient to allow the mold to be reused several times.  
 Dry film photoresist molds coated with Parylene can be used to cast PDMS parts. 
The PDMS is prepared according to the manufacturer’s instructions and degassed under 
vacuum. It is then poured into the mold and squeegeed to achieve a relatively flat surface. 
The PDMS-filled mold can then be degassed a second time to ensure infiltration of 
PDMS into small features of the mold. A smooth surface is finally achieved by 
squeegeeing with a fresh razor blade (at an approximately 45° angle) over the mold 
surface. This is particularly effective because it cleanly removes PDMS from the 
peripheral edge of the molds, eliminating the need to manually remove flash after curing. 
Dry film photoresist molds can withstand temperatures of up to 120 °C allowing them to 
be used for rapid thermal curing of PDMS.  
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Electrochemical Etching  
Stainless Steel 
 The production of fine metal structures can be accomplished utilizing a 
galvanically-enhanced etching process, known as electrochemical etching. The advantage 
of the process is that relatively mild etchant can be used (e.g. saline) and the etching 
speed can be accelerated. The substrate to be etched is patterned with a protective resist 
and connected to the anode of a DC power supply while an electrode of similar material 
to that being etched acts as the cathode. An electrolyte solution, composed either of ions 
of the metal to be etched or otherwise, completes the circuit. The application of electrical 
potential extracts electrons from the metal to be etched, producing soluble ions that can 
dissolve away into the electrolyte solution (Table 7.1).  
Table 7.1: Standard electrode potentials of major components of stainless steel. 
𝐹𝑒!! + 2𝑒! !!.!!! 𝐹𝑒 
𝐶𝑟!! + 3𝑒! !!.!"! 𝐶𝑟 
𝑁𝑖!! + 2𝑒! !!.!"! 𝑁𝑖 
 
 A custom setup was assembled composed of a DC power supply (TP343A from 
Power Designs, NY), alligator-to-banana leads, stainless steel cathode, substrate anode, 
etching container, and brine (electrolyte). The metal to be etched (e.g. 304 stainless steel, 
0.001” thick, #63045 by Trinity Brand Industries, IL) was adhered to a substrate wafer 
(e.g. with a thin film of photoresist or with copper tape) and patterned with AZ 1518 
photoresist (2.5 µm thick). The wafer was then installed into a container that seals up 
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against the wafer to form a reservoir for the electrolyte while allowing external access to 
the metal substrate for connection to the anode lead.  
 
Figure 7.5: Electrochemical etching setup comprised of DC power supply, stainless 
steel cathode, substrate anode, and etching container. 
 The power supply was operated at 5-10 V and the etching process was controlled 
manually by inserting/removing the cathode. Due to the evolution of chlorine and 
hydrogen gas during the process, it was carried out in a fume hood. Progression of the 
etching was monitored using a microscope. 
 
Figure 7.6: Etched stainless steel reflectors on copper backing. 
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Copper Etching 
 Copper traces can be easily formed through a chemical etching process. Traces 
were etched from copper shim (Alloy 110 Annealed Temper, 0.001” thick, CUX-1 by 
Lyon Industries, IL) according to an established recipe, utilizing AZ 1518 positive 
photoresist as a mask [194]. The etchant solution was composed of 70 mL hydrochloric 
acid (12.1 M) and 30 mL hydrogen peroxide (30%) in 900 mL deionized water and 
achieves an etch rate of ~1 µm/min at room temperature under mild agitation. 
 
Flexible Copper-on-Parylene Circuit Boards 
 Techniques for flexible circuits continue to be developed to accommodate 
requirements in non-planar applications such as wearable electronics [195]. Many 
approaches are based on lamination of copper to a thin, flexible polymer substrate such as 
polyimide or polyester via an adhesive. For biomedical applications, such polymers pose 
biocompatibility concerns, adhesives can undergo degradation, and substrates remain 
fairly stiff and lack transparency. Parylene, as a highly biocompatible, 
temperature/chemical resistant, and CVD polymer, has emerged as a candidate for 
flexible circuit applications. The typical processing strategy is to deposit a layer of 
Parylene onto a substrate coated with a release agent and then use photolithography, 
metal evaporation, and electroplating to produce traces on the Parylene, followed by a 
sealing layer of Parylene [196]. For certain applications this is suitable; however, it often 
requires a fairly thick film of Parylene (8-10 µm) in order to successfully peel from the 
substrate without tearing [197]. It also requires the multiple steps of metal evaporation 
and electroplating to achieve thick traces. 
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 An alternative processing strategy was developed that simplifies the fabrication of 
flexible Parylene circuit boards and allows for significantly thinner Parylene substrate 
while allowing thick copper traces. In this approach, a copper sheet (0.001”, 25.4 µm 
thick) was cleaned (acetone, isopropyl alcohol, deionized water) and then a release was 
applied to one side (2% Micro-90 in DI-water from VWR, PA) and allowed to dry. The 
sheet was then coated with 2.5 µm Parylene C (DPX-C from Specialty Coating Systems, 
IN; manufactured by Galentis, IT). Subsequently, the Parylene was peeled off the side 
with release, rinsed with deionized water, and dried under nitrogen. Photoresist was 
applied to the exposed copper face via spin coating (AZ 1518, 2000 rpm) to 
approximately 2.5 µm and soft baked (30 min, 100 °C). Photomasks of the traces were 
exposed under UV (80 s; 405 nm: 4.12 mW/cm2, 365 nm: 1.63 mW/cm2) on a contact 
aligner (MA-56 from Karl Suss, DE). The photoresist was then developed (1 part AZ 
340, 4 parts deionized water, 60 s). The copper was etched (as above) through to the 
Parylene backing to produce the traces. Photoresist was stripped by rinsing with acetone, 
IPA, and deionized water. 
 
Figure 7.7: Copper on Parylene flexible circuit board fabrication. (Left) Photoresist 
patterned and developed on exposed copper, (Middle) midway through copper etching, 
(Right) Completed traces after stripping photoresist. 
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 Through such a process, flexible copper traces can easily be produced on a thin 
Parylene substrate. Given that it is a subtractive process, one may need to account for 
undercutting of the photoresist and scale feature widths according to the thickness of the 
copper substrate. 
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